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Abstract 
Lymphatic filariasis (LF) and onchocerciasis are significant global public health issues with 
more than 900 million individuals at risk and over 60 million people currently living with 
symptomatic manifestations caused by filarial diseases. Current drug treatments 
(albendazole, diethylcarbamazine citrate, ivermectin), which form the mass drug 
administration (MDA) of the World Health Organisation (WHO), only have a microfilaricidal 
properties and have a partial or ineffective efficacy against adult worms. The WHO has 
recognised that its target of achieving LF elimination by 2020 is not currently attainable 
through current MDA and has highlighted the importance of finding alternative drug 
regiments. Due to the importance of Wolbachia, an essential mutualistic intracellular 
bacterium, in the survival of filarial nematodes, anti-Wolbachia therapy has been validated 
as a safe macrofilaricidal treatment for LF and onchocerciasis. The A-WOL consortium was 
established with the goals of refining existing (repurposed) anti-Wolbachia antibiotics, as 
well as developing new drugs in a course of 7 days or less. Autophagy was chosen as a 
potential target in anti-Wolbachia drug efficacy due to previous research highlighting its role 
in the regulation of Wolbachia populations. In this study, we investigated the role of 
autophagy in the mode-of-action and efficacy of the portfolio of anti-Wolbachia drugs. This 
research has identified a range of concentrations for two autophagy inhibitors, wortmannin 
and l-asparagine, that suppressed autophagy and did not negatively impact cell growth, 
viability and toxicity in mosquito C6/36 cells and nematodes. By testing autophagic activity, 
this work has demonstrated a consistent increase in autophagy in four broad-spectrum anti-
Wolbachia antibiotics from different classes (doxycycline, rifampicin, moxifloxacin and 
sparfloxacin) exposed to two different insect cell lines (C6/36 and SF9 cells) and in B. malayi 
microfilariae (mf). This activation was also observed for selected-candidates from the A-
WOL consortium (TylAMacTM, AWZ1066S and fusidic acid). Antibiotic-induced autophagy 
was observed in the absence of Wolbachia, indicating its effect independent of the bacteria. 
In this work, the activation of autophagy was not observed in mammalian cells indicating 
that autophagy activation by anti-Wolbachia drugs is restricted to insect cells and 
nematodes. Through concentration-dependency testing of anti-Wolbachia antibiotics, this 
study has demonstrated that only concentrations that induced autophagy resulted in 
effective Wolbachia depletion (of >90%), the empirical threshold of delivering the desired 
macrofilaricidal activity. In this work, the contribution of autophagy in the efficacy of anti-
Wolbachia drugs and their ability to reduce bacterial viability was demonstrated in B. malayi 
mf and adult worms when autophagy was inhibited during anti-Wolbachia drug exposure. 
Moreover, a partial role for autophagy was observed in the continued decline in Wolbachia 
post-drug exposure. The findings of this research could be used in developing high-
throughput screening of additional drug libraries and in the lead optimisation of existing 
'hits' identified by the A-WOL consortium. Autophagy can become an important target for 
anti-Wolbachia drug research and provide future solutions in drug therapy. The outcomes of 
the study may help future work in improving the understanding of selective autophagy and 
the development of treatments against filarial diseases and other infectious diseases.  
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Chapter 1 Introduction  
1.1 Human filarial diseases: Epidemiology and causative agents 
1.1.1 Lymphatic filariasis (overview) 
Lymphatic filariasis (LF) is caused by parasitic filarial nematodes Wuchereria bancrofti, 
Brugia malayi, and Brugia timori (1). All three nematodes belong to the family of 
Onchocercidae and under the subfamily of Onchocercinae (2). The vast majority (over 90%) 
of human cases are caused by W. bancrofti, with most of the remaining cases of LF caused 
by B. malayi (1). LF caused by Brugia species (spp.) occurs predominantly in Asia (3). 
According to the World Health Organisation (WHO), LF is endemic in 72 countries 
worldwide, with 52 of them requiring preventive drug therapy for their populations (4). 
From a global perspective (see Figure 1.1), more than 880 million individuals are at risk of 
contracting LF, resulting in an estimated annual economic burden of over 1 billion USD for 
endemic countries (1, 5). LF is considered to be a significant global public health issue, 
particularly in tropical countries, where in 2000 an estimated 120 million cases were 
infected. Global burden estimates in 2018 (6) now account for 64.6 million cases as a result 
of the impact of the Global Programme for the Elimination of LF. Moreover, approximately 
40 million individuals are currently living with symptomatic manifestations caused by the 
disease, including disability and disfigurement (1, 7). 
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Figure 1. 1 Geographic distribution of lymphatic filariasis - 2018. 
Figure source: (8). 
 
While infections with W. bancrofti are exclusive to human hosts, Brugia spp. may naturally 
infect primates and carnivores (9). Transmission of LF requires mosquito vectors from the 
Anopheles, Aedes, Culex, Mansonia and Coquillettidia genera (9). For W. bancrofti there is 
evidence to suggest that transmission via Culex species generally occurs in urban settings, 
while rural transmission mainly occurs with Anopheles as vectors (1). 
The life cycle of W. bancrofti is presented in Figure 1.2. The mosquito vector transmits the 
third stage filarial larvae (L3) as it feeds on a human host. Within the human host, the larvae 
continue to mature into adult worms and may survive for approximately ten years in the 
lymphatic system. Female adult worms release sheathed microfilariae (mf) into the blood of 
the host, thereby continuing the life cycle via subsequent blood feeding by mosquito 
vectors. Within the mosquito, mf start to exsheath in the midgut and haemocoel and later 
migrate towards the thoracic muscles and develop into the first larval stage (L1). Moulting 
of L1 occurs producing the second larval stage (L2), which moult again to produce infective 
L3. The L3 larvae migrate towards the head and the proboscis of the mosquito and the cycle 
is repeated when the infected mosquito initiates a blood feed on a human host (2, 10).  
Figure has been removed due to third party copyrighted material. 
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LF in the human host can present with acute, as well as serious chronic clinical 
manifestations. Despite the fact that the majority of LF cases are asymptomatic, 
approximately 40% of these individuals may present with subclinical evidence of impaired 
kidney function, such as haematuria, and all infected individuals present with (5). 
Furthermore, asymptomatic individuals are the principal sub-clinical lymphatic damage 
contributors to ongoing transmission of the nematode due to the presence of the mf in their 
blood (asymptomatic microfilaraemia) (11). Acute LF illness is generally characterised by the 
presence of fever and can be divided into two distinct syndromes: acute filarial lymphangitis 
(AFL) and acute dermatolymphangioadenitis (ADLA). AFL occurs when an adult worm dies 
resulting in inflammation and lymphangitis, while ADLA arises from secondary bacterial 
infections that cause additional lymphangitis and cellulitis. Acute illness can further develop 
into chronic LF, particularly in repeated acute episodes of the disease. Individuals suffering 
from chronic LF generally present with lymphoedema, commonly referred to as 
elephantiasis, affecting the extremities, as well as the breasts and male sexual organs. It is 
worth noting that the presentation of hydrocoele in males is restricted to infection with W. 
bancrofti, due to the absence of this particular symptom in chronic LF caused by B. malayi 
(1, 11). The symptoms associated with chronic LF may result in lifelong disfigurement, which 
can cause social stigma and socioeconomic disadvantages, on the individual and the 
community, as well as a negative impact on their mental health status (1).  
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Figure 1. 2 The life cycle of Wuchereria bancrofti.  
Figure source: (10). 
 
 
 
Figure has been removed due to third party copyrighted material. 
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1.1.2 Onchocerciasis (overview) 
While the experiments in thesis have focused on B. malayi, it is important to discuss the 
causative parasite of onchocerciasis, Onchocerca volvulus, due to its significance as a human 
filarial disease and its relevance to anti-Wolbachia treatment (12). Onchocerciasis is of 
important public health relevance in the African continent (see Figure 1.3), which accounts 
for the vast majority (over 99%) of global cases. The remainder of cases occur in certain 
parts of South America, as well as in Yemen in the Middle East (13). O. volvulus is 
transmitted to a human host by the Simulium genus of blackflies that naturally occur near 
fast flowing rivers in endemic areas, hence the term “river blindness” is used to describe the 
disease (14). According to a recent estimate by the WHO, around 21 million people were 
infected with onchocerciasis in 2017, with approximately 70% of them presenting with 
dermatological conditions and 5% suffering from visual impairment due to the parasite (13).  
 
 
Figure 1. 3 Geographic distribution of onchocerciasis – 2018 
Figure source: (15). 
 
 
Figure has been removed due to third party copyrighted material. 
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The life cycle for O. volvulus in the human host and infected blackflies is presented in Figure 
1.4. When the L3 larvae enters the human host from an infected blackfly bite, they migrate 
to the subcutaneous tissue where they continue to develop to adult worms (16). This results 
in the formation of nodules, referred to as onchocercomas, which occur in subcutaneous 
sites and in deeper tissues (9). Adult female worms remain in the nodules for up to 15 years, 
where they produce millions of mf for approximately 9-11 years, which migrate to the skin 
for transmission to the blackfly vector (9, 16). 
Severe itching is the commonest symptom in onchocerciasis infection. This occurs due to mf 
death, resulting in an inflammatory response from the human host (13). Moreover, dermal 
onchocerciasis may cause depigmentation (commonly named leopard skin) and lichenified 
onchodermatitis. One of the most important symptoms of onchocerciasis is the occurrence 
of ocular lesions caused by the migration of mf to the eye, potentially leading to optical 
atrophy and blindness (11, 13). Hence, onchocerciasis carries a huge socioeconomic burden 
due to the risk of visual impairment or blindness and the physical, psychological and social 
impact of dermatological symptoms (12). 
15 
 
 
Figure 1. 4 The life cycle of Onchocerca volvulus.  
Figure source: (16). 
 
 
 
Figure has been removed due to third party copyrighted material. 
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1.2 Current treatments for filarial diseases 
In 2000, the WHO established its Global Programme to Eliminate Lymphatic Filariasis 
(GPELF) with the goal of preventing the transmission of LF and eliminating it as a global 
public health problem by 2020 (17, 18). The focus of the GPELF includes 1) preventive 
treatment through annual mass drug administration (MDA) (Table 1.1) in endemic areas 
using double combinations of three donated anthelminthic drugs; albendazole, 
diethylcarbamazine citrate (DEC) and ivermectin, and 2) morbidity management and 
disability prevention in patients with clinical disease (hydrocoele and lymphoedema) (1). 
The aim of MDA is to block transmission of infection by suppression of circulating 
microfilaraemia. All three agents used in MDA (albendazole, DEC and ivermectin) exhibit 
microfilaricidal or transient embryogenesis blocking properties, although they have only a 
partial efficacy or are ineffective against adult worms. Hence, suppression of transmission 
requires prolonged repeated annual doses, which may last for several years to cover the 
reproductive life-span of the adult worms (17). A total effective coverage for MDA of at least 
65% of the population at risk is required for adequate control of LF in endemic areas (18).  
 
Anthelminthic Annual Dose Combination Administration 
Albendazole 400 mg (twice/year) N/A 
Regions co-endemic 
with loiasis 
Ivermectin 200 mcg/kg Albendazole 400 mg 
Regions with 
onchocerciasis 
infections 
Diethylcarbamazine 
citrate (DEC) 
6 mg/kg Albendazole 400 mg 
Regions with no 
onchocerciasis 
infections 
Table 1. 1 WHO recommendations for MDA of lymphatic filariasis in endemic areas.  
Data source: (1). 
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Since the start of the GPELF, approximately 900 million individuals have received more than 
7 billion administrations of MDA in 68 endemic countries (1). Despite this, only 20 out of a 
total of 72 countries have effectively reached the recommended WHO targets for LF 
elimination and no longer require MDA. Furthermore, more than 40% of endemic countries 
have not implemented adequate MDA coverage based on the WHO recommendations (17). 
The situation appears to be more complicated in the African region, where MDA coverage is 
often less than 60% and several endemic countries (South Sudan, Gabon and Equatorial 
Guinea) have not started MDA (18). 
It is important to note that the three agents used for MDA are not eligible for use in the 
entire population. For example, ivermectin and DEC are contraindicated during pregnancy, 
and albendazole cannot be administered in the first trimester. Moreover, children below 2 
years cannot receive DEC or two annual doses of albendazole. All three agents are 
contraindicated in children that are less than 90 cm in height and in the presence of severe 
illness (17). As MDA requires annual administration, the potential of long-term non-
compliance has to be considered. Additionally, political, cultural and social acceptance 
change over time. Many of the countries that are considered endemic with LF are also 
developing nations and face numerous economic burdens, as well as the potential of 
conflict, famine and natural disasters. In the case of ivermectin, the emergence of drug 
resistance has been reported for O. volvulus (19, 20). All these factors can negatively impact 
on MDA and LF elimination (17). 
In its recent guidelines on eliminating LF, the WHO has recognised that its previous target of 
achieving LF elimination by 2020 is not currently attainable, due to the previously 
mentioned issues and the multiple annual rounds required for MDA (17). In the same 
report, the WHO highlighted the importance of finding alternative drug regiments. One 
example that has been recommended is administering ivermectin, DEC and albendazole 
together, referred to as IDA, which received approval by the WHO in four countries in 2018 
(18). 
Due to the numerous limitations and issues associated with current MDA guidelines and 
available anthelminthic drugs, there is a need to develop and administer new agents for 
treating filarial diseases. This is also important due to the fact that current anti-filarial drugs 
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are not effective against adult worms and a macrofilaricidal drug treatment would provide 
many benefits towards the elimination of LF and onchocerciasis. One example of 
macrofilaricidal therapy has come from targeting Wolbachia, an essential intracellular 
bacterium with a mutualistic association with the filarial nematodes causing LF and 
onchocerciasis. 
 
1.3 Wolbachia: filarial symbiosis and importance in potential treatment 
Wolbachia are intracellular gram-negative bacteria with an approximate size of 0.2-4µm, 
that reside in vacuoles derived from its host (21). Wolbachia belong to alphaproteobacteria 
of the order Rickettsiales, under the Anaplasmatacea family. Currently, Wolbachia pipientis 
is the only recognised species within the Wolbachia genus (21-23). However, differences 
exist in Wolbachia supergroups (A to Q) in different host organisms, which will be discussed 
below (23). Hertig and Wolbach first discovered Wolbachia in the mosquito Culex pipiens 
(24). Wolbachia are now known to be widespread in other insects, where it is estimated up 
to 65% of species host the bacterium, as well as other arthropods, including certain types of 
spiders, mites and crustacea (25-27). 
Since the 1970s, scientists have observed intracellular bacteria within filarial nematodes (26, 
28-30). While earlier studies concluded they were a form of Rickettsia-like species, it was 
later confirmed that these intracellular bacteria were in fact Wolbachia (26, 31-33). 
Wolbachia are present in all life stages of filarial nematodes of humans, with the exception 
of Loa loa, the causative agent of loiasis (22, 34). Filarial nematodes responsible for 
onchocerciasis and LF contain Wolbachia from supergroups C and D, respectively (23, 35). 
Supergroup F of Wolbachia is also relevant to human filarial diseases as it is present in 
Mansonella ozzardi, the causative agent of mansonellosis (23, 36). In contrast, Wolbachia 
supergroups A and B are associated with arthropods (23). 
From an evolutionary perspective, it is not fully understood how Wolbachia first infected 
Onchocercidae, the family that comprises numerous filarial nematodes, including the 
causative agents of LF and onchocerciasis (22, 37). Wolbachia may have been transmitted 
from arthropods to filarial nematodes (or the opposite) approximately 100 million years ago 
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through a single event (26, 35). Following this event, filarial nematodes were infected with 
Wolbachia vertically from female adult worms to their offspring. However, recent analysis 
of supergroup F has suggested the possibility of horizontal transmission, due to its presence 
in both insects and nematodes (23, 26, 35). The exact reason for the lack of Wolbachia in 
certain Onchocercidae nematodes is not known, although research has suggested that their 
ancestors may have been previously infected but have lost the bacteria. This theory was 
proposed due to the presence of genes acquired through lateral gene transfer with 
homology to Wolbachia in the host genome of nematodes that lack the bacteria, for 
example Acanthocheilonema viteae, Onchocerca flexuosa and Loa loa (22, 35, 38).  
The complex relationship between filarial nematodes and Wolbachia is described as an 
obligate mutualistic symbiosis, due to the inability of nematodes to mature, reproduce, and 
obtain essential nutrients for survival without the presence of these bacteria (26, 37). Much 
of our understanding of the basis for this relationship has been revealed through 
comparative genomics of B. malayi and its Wolbachia symbiont (wBm) (39, 40). One 
biochemical pathway provided by the endosymbiont is haem biosynthesis, which is crucial 
for filarial nematodes viability and motility and other processes involved in their maturity 
and energy metabolism (23, 40-43). Nematodes cannot synthesise haem in the absence of 
Wolbachia due to essential haem biosynthetic genes that are only present in the bacteria 
(22, 40-43). Similarly, synthesis of riboflavin and flavin adenine dinucleotide (FAD), are also 
derived from Wolbachia (22, 23, 40, 41). Conversely, there is evidence that Wolbachia also 
benefit from the filarial hosts, for example they provide essential amino acids needed for 
bacterial growth, as well as biotin, ubiquinone and coenzyme A, that the bacteria cannot 
synthesise alone (23, 44-46).  
Wolbachia are located in the lateral cords of both male and female adult worms. In adult 
females, Wolbachia can be found throughout the reproductive system, including the ovaries 
and oocytes and developing embryos in the uterus (26). The reproductive system of adult 
male filarial nematodes is devoid of Wolbachia (47, 48). Antibiotic treatment results in a 
block of embryogenesis, indicating a critical role of the bacteria in embryo development 
(49).  
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Wolbachia also plays a crucial role in larval development. When the L3 larvae enters the 
mammalian host, Wolbachia populations dramatically expands and continues to growth 
throughout fourth-stage larval (L4) development (49). Antibiotic treatment of developing 
larvae leads to an arrested development at the early L4 stage. The consequence of 
Wolbachia removal following antibiotic treatment leads to extensive apoptosis in the adult 
germline and somatic cells of larvae and embryos (50). 
Wolbachia can drive inflammatory responses that contribute to symptomatic presentations 
in onchocerciasis and LF. One example of this is observed in onchocerciasis infection of the 
cornea, where Wolbachia from mf are detected by Toll-like receptors (TLR2 and TLR6), 
resulting in inflammation and corneal oedema due to localised neutrophil recruitment and 
activation (12, 22). There is evidence to suggest that the adverse reactions following the 
administration of anti-filarial drugs DEC and/or ivermectin are linked to Wolbachia. These 
adverse reactions, include fever, neurological symptoms and enlarged lymph nodes, and are 
associated with the release of Wolbachia following nematode death, where the human 
host’s innate and acquired immune system are activated through a neutrophil mediated 
response (9, 12). The severity of these adverse reactions appears to be linked to Wolbachia 
load in the patient’s blood following anti-filarial treatment (9). Landmann et al. (47) have 
established that even viable adult worms may release Wolbachia through their 
secretory/excretory canal and initiate an immune response in the human host. The 
molecular drivers of Wolbachia mediated inflammation are derived from bacteria 
lipoproteins and principally the Peptidoglycan Associated Lipoprotein, PAL (51).  
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1.4 Anti-Wolbachia treatment: current situation and future potential 
Due to the importance of Wolbachia in the survival of filarial nematodes, and the previously 
mentioned limitations of drugs used in MDA, anti-Wolbachia therapy has been validated as 
a safe macrofilaricidal treatment for LF and onchocerciasis (52, 53). 
Doxycycline and rifampicin as anti-Wolbachia agents: 
One of the first drugs that has been used for its anti-Wolbachia properties is doxycycline. 
Since its discovery in 1967, doxycycline, a derivative of tetracycline, has been widely used as 
a broad spectrum anti-bacterial drug and prophylaxis treatment for malaria (11, 54). The 
mechanism of action of doxycycline as a bacteriostatic agent is achieved through its 
targeting of the 30s ribosomal subunit in Wolbachia leading to inhibition of protein 
synthesis by blocking aminoacyl-tRNA attachment to ribosomes (22). In 1999, Hoerauf et al. 
(55) described the infertility and growth inhibiting effect of tetracycline on rodent filarial 
nematodes (Litomosoides sigmodontis) to be linked with Wolbachia. The same study also 
conducted experiments on filarial species Acanthocheilonema viteae, which lack Wolbachia 
and is unaffected by tetracycline treatment (55). Other research groups in the late 1990s 
have also described similar anti-Wolbachia properties using tetracycline against Dirofilaria 
immitis and Brugia pahangi (56). In terms of early in vitro studies on causative agents of 
human LF, B. malayi treated with doxycycline and tetracycline reduced Wolbachia load, 
leading to impairment of essential processes, including mf release and embryogenesis (57, 
58).  
Due to its importance in treating infections of Mycobacterium tuberculosis and leprosy, 
rifampicin is included in the WHO “model list of essential medicines” (59). The mechanism 
of action of rifampicin is achieved by disrupting nucleic acid production through its blocking 
of RNA polymerase (22, 60). Rifampicin is widely recognised to have potent anti-Wolbachia 
properties (61-64). Numerous in vitro (57, 58, 60, 63) and in vivo (61, 62) studies have 
demonstrated the ability of rifampicin to decrease Wolbachia load in filarial nematodes, 
including the causative agents of LF and onchocerciasis.  
Following administration of anti-Wolbachia agents, adult worms slowly die after 
approximately 12 months and 18-27 months, for LF and onchocerciasis, respectively (65). 
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The anti-Wolbachia activity of rifampicin have been shown to be more potent than 
doxycycline (61). However, this observation was not replicated in human subjects when 
treated with the standard dose of rifampicin (61, 66, 67). Turner et al. (61) have shown this 
to be due to the pharmacokinetics of rifampicin, and PK/PD modelling and empirical studies 
in pre-clinical models (64) suggest higher doses of the drug would be required to achieve 
macrofilaricidal activity.  
Human clinical trials using anti-Wolbachia drugs: 
Optimisation of doxycycline regimens targeting Wolbachia have been tested in clinical trials. 
Initial trials on LF using doxycycline alone at 200mg per day, showed a sustained 
amicrofilaraemia, as well as potent macrofilaricidal properties with treatment periods for 6 
or 8 weeks (68, 69). In a double-blind randomised control trial conducted by Supali et al. 
(70) on patients infected with B. malayi administered with doxycycline alone at 100mg per 
day for 6 weeks, recorded a 77% reduction in prevalence of LF after a year post-treatment. 
More recent trials have observed a complete elimination of adult worms after 18 months, 
following administration of doxycycline for 4 weeks (200mg/day) (67). In terms of 
onchocerciasis infections, successful macrofilaricidal effect and disruption of embryogenesis 
following treatment with doxycycline alone (100mg/day) for 5 weeks was achieved when 
patients were examined two years post-treatment (71).  
Trials of a 3-week course of doxycycline produced only partial macrofilaricidal activity, 
although blockage of embryogenesis and reduced adverse events to subsequent antifilarial 
drugs remained intact (72). However, another study on bancroftian filariasis produced a 
macrofilaricidal effect and a significant reduction of hydrocoele when combining 
doxycycline (for 3 weeks) and DEC (after 4 months) (73). Other human trials on LF (68, 70) 
and onchocerciasis (74, 75) have produced the desired results when combining doxycycline 
with other drugs used in MDA, although these required longer treatment with doxycycline 
for 6 continuous weeks. 
Rifampicin is another anti-Wolbachia antibiotic that has been examined in human clinical 
trials, however it did not exhibit the desired macrofilaricidal activity when administered 
alone. In onchocerciasis patients treated with rifampicin (at 10mg/kg/day) for 2 or 4 weeks, 
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Specht et al. (66) did not observe macrofilaricidal properties for both treatment periods, 
despite higher mf clearance and reduction in embryogenesis in the longer treatment period. 
Furthermore, the same study observed higher clearance of mf and more prominent 
impairment embryogenesis in 6-week treatment of doxycycline compared to rifampicin 
treatment for 2 or 4 weeks. A single clinical trial was found that combined both doxycycline 
(200mg/day) and rifampicin (10mg/kg/day) for 2 weeks and their effect was compared to 
doxycycline treatment at the same dose in a 4-week period. While macrofilaricidal activities 
were observed when combining both anti-Wolbachia drugs, this combination was not as 
potent as doxycycline alone for 4 weeks in eliminating adult worms (67). 
A recent study by Aljayyoussi et al. (64) predicted through pharmacokinetic-
pharmacodynamic (PK/PD) modelling that a higher dose of rifampicin (35mg/kg) may be 
required to produce a better macrofilaricidal outcome. In vivo studies on mice and gerbils 
infected with B. malayi testing this higher dose of rifampicin have been successful in 
producing a macrofilaricidal effect following a 7-day treatment combined with albendazole 
(61). 
While other anti-Wolbachia agents have been examined in clinical trial on LF and 
onchocerciasis infected patients, the results of these did not provide the desired outcomes 
compared to doxycycline for 4 weeks. A newly repurposed agent, minocycline, has shown 
promise in onchocerciasis patients. Klarmann-Schulz et al. (76) have found that minocycline 
(at 200mg/day) for 3 weeks was more effective than doxycycline (200mg/day) in the same 
timeframe, however, it was not as effective as doxycycline for 4 weeks from a 
macrofilaricidal perspective. 
Anti-Wolbachia consortium (A-WOL): 
In 2007, the A-WOL consortium was established, through funding by the Bill and Melinda 
Gates Foundation, with the goals of refining existing (repurposed) anti-Wolbachia 
antibiotics, as well as developing new agents (52, 77). As the current anti-Wolbachia 
standard regimen of doxycycline for 4 to 6 weeks is a fairly long treatment period, the A-
WOL consortium has targeted shorter oral treatment duration of ≤ 7 days (52, 78). Due to 
the length of current treatments, the risk of non-compliance and other individual barriers in 
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endemic areas must be considered. Additionally, despite its relative safety in adults, 
doxycycline is contraindicated in pregnancy, during breastfeeding and in children below the 
age of 8 years old (11, 52). Hence, new drugs should benefit these groups (79). 
In order to achieve its objectives, the A-WOL consortium focuses on four different 
approaches: 
A) Target identification: researchers in the A-WOL consortium identify important aspects 
associated with Wolbachia survival that could be used as potential targets for treatment 
(79). Examples of these include many of the previously mentioned metabolic pathways that 
provide the nematode with essential nutrients, such as haem (Wolbachia aminolevulinic 
acid dehydratase (ALAD), wALAD) and lipoproteins (Wolbachia prolipoprotein signal 
peptidase II, LspA) biosynthesis (52, 79).  
B) A-WOL assay development: the A-WOL screening funnel utilises cell-based high content 
screening assay (Operetta) to determine suitable drug hits that are effective against 
Wolbachia at 7 days or less (79, 80). At the time of writing, over 2 million chemical agents 
have been assessed for their anti-Wolbachia properties (81). Selected hits are tested on mf 
in vitro and larval and adult stages of B. malayi in vivo (79). 
C) A-WOL library screening: drugs are selected from an extensive series of focused and 
diversity libraries, developed with the help of collaborators in the pharmaceutical industry 
(52). 
D) Clinical field trials: these trials focused on optimising existing drugs with anti-Wolbachia 
properties to test the shortest regimen to obtain adequate macrofilaricidal activity (77).  
Three newly identified (or repurposed) drug candidates have been selected by the A-WOL 
consortium through achieving potent anti-Wolbachia activity in a course of 7 days or less: 
TylAMacTM, AWZ1066S and fusidic acid. The first drug TylAMacTM (ABBV-4083), a tylosin A 
analogue, was successfully tested in vivo in animals infected with B. malayi, Litomosoides 
sigmodontis and Onchocerca ochengi and demonstrated over 90% Wolbachia clearance 
following 1-week of treatment. Toxicology assessment provided a suitable safety profile 
(81). In comparison to doxycycline or minocycline for 3-4 weeks, TylAMacTM treatment for a 
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duration of 1 week showed higher efficacy. Currently, TylAMacTM has completed phase I 
trials and is progressing to phase II trials in Ghana. 
The second pre-clinical candidate, AWZ1066S, synthesised from 
thienopyrimidine/quinazoline scaffold, is a highly potent macrofilaricidal with a high degree 
of specificity to Wolbachia (82). Through in vitro and in vivo experimentation, AWZ1066S 
has been shown to have higher anti-Wolbachia properties than doxycycline in B. malayi. 
Furthermore, it can also achieve its anti-Wolbachia properties through shorter treatment 
periods (1-day drug exposure) compared to doxycycline, rifampicin, moxifloxacin and 
minocycline in a time-kill assay. AWZ1066S, is currently undergoing pre-clinical development 
and lead optimisation studies (82).  
Lastly, fusidic acid, a narrower spectrum antibiotic that principally targets gram-positive 
bacteria (83, 84), with utility in children and pregnancy (85), has been highlighted as a 
potential macrofilaricidal agent. In vitro and in vivo experiments have shown significant 
reduction of Wolbachia in B. malayi L3 and adult worms in animal models, for 14 and 7 days 
of treatment, respectively. PK/PD modelling has predicted promising outcomes for shorter 
regimens in human trials (86).  
 
1.5 Autophagy: types and regulation 
The rationale for studying the role of autophagy in anti-Wolbachia drug efficacy was driven 
by a study highlighting its role in the regulation of Wolbachia populations. The study by 
Voronin et al. (87) demonstrated that activating autophagy by chemical or genetic 
approaches reduced Wolbachia loads to the same magnitude as antibiotics. This stimulated 
us to investigate the role of autophagy in the mode-of-action and efficacy of the portfolio of 
anti-Wolbachia drugs. 
In this section, we will start by describing the concept of autophagy, along with the different 
types and regulatory processes involved with this pathway. 
From a general standpoint, autophagy can be defined as “the major intracellular 
degradation system by which cytoplasmic materials are delivered to and degraded in the 
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lysosome” (88). The process serves a crucial role in various cellular mechanisms, including 
homeostasis in response to stress stimuli and quality control of proteins and organelles (89). 
Autophagy may occur at low levels in the absence of stress and external stimuli, which is 
referred to as basal autophagy (90). It is believed that basal autophagy regulates the 
removal of damaged organelles and proteins in most types of cells under normal 
circumstances to maintain cellular homeostasis (91).  
Autophagy occurs in all eukaryotic cells and can be divided broadly into three distinct types: 
macroautophagy, microautophagy and chaperone-mediated autophagy (92, 93). Prior to 
discussing macroautophagy (the form of autophagy we have examined in my thesis), we will 
briefly describe the other two types of autophagy. Microautophagy occurs when lysosomes 
directly engulf small cytoplasmic material via invaginations on the lysosomal membrane (93, 
94). The second type of autophagy, chaperone-mediated autophagy, has only been 
observed in mammalian cells and involves specific targeting of cytosolic substrates that 
carry KFERQ-like pentapeptides (88, 93). This targeting is achieved through chaperone 
proteins in the cytoplasm, including heat shock cognate 70 (Hsc70) and other cochaperones, 
which transport the substrate to receptors on the lysosome called lysosomal-associated 
membrane protein 2A (LAMP2A), forming a multimeric complex (88, 93). Following the 
delivery of the substrate to the lumen of the lysosome for degradation, the LAMP2A reverts 
back to its monomeric form for subsequent substrate transportation (88, 93). Hence, 
chaperone-mediated autophagy does not result in structural changes to the lysosomal 
membrane (94). It is worth mentioning that this type of autophagy is absent in organisms 
that lack the LAMP2A homolog, for example Drosophila (95). 
Macroautophagy is the most widely studied type of autophagy and the process examined in 
the experimental approaches used in this thesis. In contrast to the other two types of 
autophagy, macroautophagy requires the presence of specific double membraned vesicles 
called autophagosomes. The general pathway for macroautophagy is presented in Figure 
1.3. This pathway is regulated by a series of autophagy-related (Atg) proteins and other non-
autophagy-related proteins (96). Activation of the macroautophagy pathway can occur 
through various cellular stress conditions, for example microorganism infections, oxidative 
stress, endoplasmic reticulum (ER) stress and nutritional depletion of amino acids, growth 
factors and energy (88). These stress conditions result in autophagy induction through the 
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inhibition of target of rapamycin (TOR). There are two classes of TOR, both of which are 
involved in the macroautophagy pathway: TORC1 and TORC2, where the former is more 
sensitive to rapamycin (97). The inhibition of TOR causes the activation of Atg1-Atg13-
Atg17-Atg31-Atg29 complex, which initiates the formation of the pre-autophagosome 
structure (PAS) (88, 93). It is still unknown if the formation of PAS occurs from the ER, 
although there is evidence that the mitochondria, plasma membrane and Golgi apparatus 
may play a role in their formation (88).  
The formation of phagophores from PAS occurs through two steps: i) nucleation of the 
vesicles, followed by ii) vesicle elongation. This formation takes place in close proximity of 
the cytoplasmic material that initiated autophagy in order to completely engulf it at a later 
stage. Nucleation is mediated by phosphatidylinositol 3-phostphate (PI3P), which is 
generated by phosphatidylinositol 3-phostphate kinase class 3 (PI3KC3) complex. The 
PI3KC3 complex contains Atg6 (mammalian: BECN1), an important autophagy marker, as 
well as vacuolar protein sorting 34 (Vps34), Vps15 and Atg14 (90, 93). 
Following nucleation, phagophores expand through a process called elongation. This is 
achieved by two ubiquitin-like conjugation systems in yeast and mammalian cells: Atg12-
Atg5-Atg16 related to phagophores; and Atg8- phosphatidylethanolamine (PE) (mammalian: 
LC3-PE) related to both phagophores and autophagosomes (98). The formation of the 
Atg12-Atg5-Atg16 complex involves two enzymes, Atg7 (E1 enzyme) and Atg10 (E2 
conjugating enzyme) (93, 99). The second system requires Atg12-Atg5, which performs as an 
E3 ligase to form the Atg8-PE (LC3-PE) complex. Prior to the formation of this complex, Atg4 
processes Atg8, which is later transferred to Atg7 (E1 enzyme) and Atg3 (E2-like enzyme), 
thereby forming Atg8-PE (93). Atg8 (LC3) is an important autophagy marker that we have 
used in the experimentation in this thesis and is described in more detail in Chapter 2 (99). 
LC3-I indicates the processed form of LC3, while LC3-II refers to the conjugated form of LC3 
with PE (93). In addition to LC3, there are several forms of Atg8-like proteins in mammalian 
cells, including γ-aminobutyric type A (GABAA)-receptor associated protein (GABARAP). 
There is evidence to suggest that Atg9 may play a role in both yeast and mammalian cells in 
the elongation process in macroautophagy by further developing the phagophore 
membrane, although its mechanism is not completely understood (93). At the end of 
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elongation process, the autophagosome formation is complete and the target material is 
engulfed within its structure. 
Mature autophagosomes reach the lysosomes via microtubules and fuse to form 
autophagolysosomes. While the fusion process in macroautophagy is not fully understood, 
there are several proteins that may influence the fusion. Examples of these include Rab7, as 
well as N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) components 
in yeast, Drosophila and mammalians (93, 95, 100). Moreover, there is evidence that LAMP-
2 may be involved in the fusion process in mammalian cells (99). Following the fusion 
process, a variety of acid hydrolases, including Atg15, Rab2 (in Drosophila and mammalians), 
and cathepsin B, D and L, will initiate the degradation of the engulfed material (95, 99). The 
degraded material is released and could provide the cell with amino acids for reuse (92). The 
exportation of recycled amino acids from the degraded autophagolysosomes to the cytosol 
is mediated by Atg22 and lysosomal amino acid transporter 1 (LYAAT-1), in yeast and 
mammalians, respectively (92).   
Macroautophagy can be regulated either dependently or independently of mTOR. If 
macroautophagy is regulated through mTOR, it follows the same pathway described above 
from inhibition of mTOR (or activation of mTOR in the case of autophagy suppression) and 
until lysosomal degradation (100). There is evidence that mTORC1 regulates autophagy in 
nutrient and growth factor depletion, while mTORC2 activates the Protein kinase B (Akt) 
pathway, resulting in the activation of mTORC1 (93, 97). On the other hand, cAMP-
dependent protein kinase A (PKA) may activate autophagy independently of mTORC1. PKA 
can be influenced by nutrients, for example glucose, causing an upregulation of PKA and 
inhibition of autophagy. Furthermore, PKA can directly activate mTORC1, or indirectly 
through inhibition of AMP-activated protein kinase (AMPK) (93). Manipulation of the 
autophagy pathway can be achieved experimentally, through chemical or genetic 
approaches, and the literature covering the inhibition and activation of autophagy is 
described in detail in Chapter 2 and Chapter 3.  
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Figure 1. 5 Steps for the macroautophagy pathway.   
The pathway is regulated through a series of autophagy-related (Atg) proteins (abbreviated as ATG for mammalian proteins) and other non-autophagy-
related proteins. Green and grey boxes represent proteins in yeast and mammalian autophagy, respectively. Yellow boxes indicate shared proteins between 
yeast and mammalian cells.  
Data source: modified from (92, 93). 
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Despite the fact that macroautophagy can engulf cytoplasmic materials for degradation in a 
non-selective manner, such as that observed in starvation, it can also achieve this by 
selective engulfing specific targets (93). An example of this is mitophagy, where damaged 
mitochondria are specifically targeted for degradation through the autophagic pathway. 
This occurs in response to ROS generation caused by mitochondrial damage, where 
deficiency of this type of autophagy can result in neurodegenerative conditions and 
pathological disorders associated with ageing (101, 102). Other types of selective autophagy 
with specific targets include lipophagy (targets lipid droplets), aggrephagy (protein 
aggregates), pexophagy (peroxisomes), reticulophagy (ER) and ferritinophagy (ferritin) (101).  
One of the most important types of selective macroautophagy is xenophagy, where 
intracellular microorganisms are specifically targeted for degradation as a host immune 
response against infections (101). This is achieved by selective autophagy adaptors, referred 
to as sequestosome-1 like receptors (SLRs), targeting ubiquitinated effectors present in 
intracellular bacteria. Bacterial components are detected through pathogen recognition 
receptors (PRR), for example Toll-like receptors. The most important SLRs are Nuclear dot 
protein 52 (NDP52), TAX1 binding protein 1 (TAX1BP1), optineurin (OPTN), as well as p62 
(mammalian: sequestosome-1), which was used extensively in the experimentation of our 
research and will be discussed in detail in Chapter 2 (103). The previously mentioned SLRs 
also play a role in host inflammatory responses. To achieve their selective autophagic 
properties, SLRs have the same three specific binding sites, these are: the ubiquitin-binding 
domain, LC3 interacting region, and multimerisation domain (103). An example of 
autophagy induced by bacteria is observed in Mycobacterium tuberculosis, where the 
bacteria is marked by ubiquitination, which enables its binding to the autophagic adaptors 
NDP52 and p62. In Salmonella infection, PRRs recognise bacterial effectors resulting in their 
ubiquitination and subsequently detection by p62 and OPTN (103). Conversely, bacteria, 
viruses and parasites may induce or suppress host autophagy for their own survival and 
growth (104). This concept of pathogen manipulated autophagy will be discussed in further 
detail in Chapter 2 and Chapter 3.  
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There is evidence that autophagy is involved in the regulation of Wolbachia populations in 
filarial nematodes (87, 105). While Wolbachia and the filarial nematode host share a mutual 
symbiotic relationship (as previously described in Section 1.4), Wolbachia may still be 
considered a foreign “pathogen” by the host immune system (105). Voronin et al. (87) have 
examined this relationship by chemically and genetically inducing and suppressing 
autophagy, which resulted in a decrease and increase of Wolbachia load respectively, in 
mosquito cell C6/36 infected with Wolbachia (C6/36Wp) as well as filarial nematodes of B. 
malayi . In this experiment the primary focus was on autophagy activation, which was 
achieved chemically using rapamycin, a known autophagy promoter, and genetically 
through gene silencing of TOR in B. malayi adult worms (bmTOR). Voronin et al. (87) 
evaluated the activation of autophagy by observing an increase in mature autophagosomes 
and autophagolysosomes in female adult worms. Additionally, the presence of degraded 
Wolbachia was observed within autophagolysosomes. Wolbachia elimination was also 
confirmed by an increase of apoptotic structures and impaired embryogenesis. 
Furthermore, the researchers described the observed bacterial elimination of Wolbachia 
from nematode autophagic activation to have a similar level as doxycycline treatment and 
carries a future potential in antibiotic treatment against filarial diseases (87, 105). Despite 
this, the mechanism of how Wolbachia harness or evade nematode host autophagy is still 
not understood.  
While Voronin et al. (87) have examined the chemical inhibition of autophagy to have the 
opposite effect of autophagy activation by increasing Wolbachia load, this was only 
observed in mosquito cell line C6/36Wp. Hence, the impact of chemically inhibiting 
autophagy and its effect on Wolbachia populations in other cell lines and organisms, 
including B. malayi, is unknown. Moreover, cell/organism viability and toxicity of chemical 
inhibition of autophagy was not addressed. Despite the fact that autophagy inhibition was 
observed to increase Wolbachia number, this relationship was not examined further in the 
presence or absence of antibiotics with activity against Wolbachia. As anti-Wolbachia 
antibiotics are essential in the treatment of filarial diseases, the potential of understanding 
the role autophagy when combined with these drugs could further enhance current 
treatment regimen.  
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1.6. Project Aims: 
This project will examine the role of autophagy in anti-Wolbachia therapy of antibiotics for 
treatment of lymphatic filariasis. The main aim of this thesis is to examine the role of 
autophagy in the anti-Wolbachia activity of diverse classes of antibiotics in different 
experimental conditions. This will be achieved experimentally through the following 
objectives:  
1. Screening for optimum chemical autophagy inhibitors in mosquito cell line C6/36Wp. 
2. Monitoring and measuring antibiotics-induced autophagy in different cell lines and 
nematodes. 
3. Examining the contribution of autophagy in the activity of anti-Wolbachia drugs with 
different modes of action, during exposure and post-drug exposure to antibiotics. 
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Chapter 2  Screening for optimum chemical autophagy inhibitors 
2.1 Chapter overview 
This chapter of the thesis will present and discuss the experimentation performed in order 
to determine suitable chemical autophagy inhibitors for the Aedes albopictus C6/36 cell line. 
It will start by presenting a brief literature review the concept of autophagy inhibition, 
previous studies conducted on different autophagy inhibitors (both chemical and genetic) 
and the methodology followed in monitoring autophagy inhibition. The concept of 
autophagy as a cellular process has previously been covered in detail (Chapter 1). 
In order to examine the role of autophagy in antibacterial activity of selected antibiotics 
against Wolbachia, it is necessary to suppress autophagy in the presence of these antibiotics 
using autophagy inhibitors. The rationale of this is to determine the impact of suppressing 
autophagy on anti-Wolbachia activity to eliminate the symbiotic bacteria.  
Four different experiments were done in this chapter using four pre-selected chemical 
autophagy inhibitors, namely:  3-methyladenine (3-ma), 2-(4-morpholinyl)-8-phenylchromo 
(ly294002), wortmannin and l-asparagine. These chemical inhibitors, which target different 
stages of the autophagy pathway, were evaluated in Wolbachia-infected mosquito cell line 
(C6/36Wp).  
 
2.2 Background 
2.2.1 Naturally occurring autophagy inhibition  
Specific biological conditions can either activate or inactivate autophagy. For example, 
health conditions such as heart diseases and acute pancreatitis have been found to activate 
autophagy, whereas inflammatory bowel conditions, neurodegenerative diseases and some 
types of cancer may suppress the pathway. Additionally, certain infectious diseases can alter 
the autophagy process, in which pathogens can manipulate the pathway for the benefit of 
their survival and replication (106). Mycobacterium tuberculosis has been found to indirectly 
influence autophagy by inactivating the JUN N-terminal kinase (JNK), in turn preventing the 
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generation of reactive oxygen species (ROS) resulting in autophagy inhibition. This process is 
mediated by the mycobacterial enhanced intracellular survival protein (Eis) and its absence 
has been found to activate autophagy by increasing autophagosome production (107). A 
second example of an organism indirectly influencing autophagy is Salmonella typhimurium. 
In the initial hour of infection S. typhimurium activates autophagy, it then inhibits the 
process over the next four hours by normalising amino acid levels, leading to the activation 
of the mechanistic target of rapamycin (mTOR) causing the suppression of autophagy (108). 
As previously mentioned in Chapter 1, the inactivation of mTOR is a crucial step in the 
initiation of autophagy (107).  
In certain circumstances, microorganisms can directly inhibit the autophagy pathway. For 
example, Legionella pneumophila can inhibit autophagy through targeting the C-terminal 
region of the lipidated form of the microtubule associated protein 1 light chain 3 (LC3) 
mediated by RavZ effector protein, thereby disabling the binding of LC3 to the membranes 
of pre-autophagosomal structures and preventing their maturity (109, 110). There is also 
evidence suggesting that Shigella flexneri may directly inhibit autophagy related genes (110, 
111). Other microorganisms, such as Staphylococcus aureus (112), Anaplasma 
phagocytophilum (113) and Coxiella burnetii (114, 115), can influence the autophagy 
pathway to their own benefit. In these microorganisms, this is achieved by replicating within 
the autophagic vacuoles (107, 110). 
2.2.2 Autophagy inhibitors: chemical and genetic 
From a broad perspective, autophagy inhibitors can be classified into two categories: 
chemical and genetic. Chemical autophagy inhibitors are compounds that can act on 
different stages of the autophagy pathway and comprise a broad range of chemical agents. 
Genetic autophagy inhibitors are genes (whether experimentally modified or naturally 
occurring) that are directly or indirectly involved in the autophagy pathway.  
In the literature, genetic inhibition of autophagy has been achieved in using a gene silencing 
RNA interference technique by knocking down regulatory genes involved in autophagy 
pathway. The most commonly targeted genes include: Atg3, Atg5, Beclin1, Atg7, Atg9, 
Atg16L1, Focal adhesion kinase family interacting protein of 200 kD (FIP200) and Activating 
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molecule in Beclin 1-regulated autophagy protein 1 (Ambra1). One disadvantage of genetic 
inhibition is that many of these genes and other autophagy related genes are multi-
functional and can be involved in other signalling pathways (106). 
Experimental suppression of the autophagy pathway can be accomplished with the use of 
chemical compounds with a known inhibitory effect on the process. These chemical 
inhibitors are widely discussed in the literature and target different stages of the autophagy 
cascade. One group of widely used chemical inhibitors act on phosphatidylinositol 3-kinases 
(PI3ks). These enzymes act on the phosphorylation of the 3-hydroxyl group 
phosphatidylinositol (PI) located on the inositol ring of phospholipids (116). While there are 
three different classes of PI3ks, only two (class I and III) are known to be associated with 
autophagy. Class I PI3ks have been found to inhibit autophagy through the activation of 
beclin1 and protein kinase B mediated by the phosphorylation of PI 4,5-biphosphate to 
phosphatidylinositol 3,4,5-triphosphate (PI(3,4,5)P3) (116, 117). Conversely, class III PI3ks 
activate autophagy and primarily act on stimulating the biogenesis of autophagosomes by 
the production of phosphatidylinositol triphosphate (PI3P). This in turn will recruit other 
autophagic components for the elongation process of the pre-autophagosome vesicles to 
form complete autophagosomes (117, 118). Hence, chemical autophagy inhibitors that act 
on PI3ks should ideally target class III of this pathway as the inhibition of this class will 
prevent the formation of autophagosomes (117, 118).  
Three of the chemical inhibitors used in the experiments in this chapter, 3-ma, ly294002 and 
wortmannin, have been identified in the literature as PI3ks inhibitors, mainly acting on class 
III (119-121). Although 3-ma was the first of these to be discovered and one of the most 
commonly used inhibitors, it has recently been identified to have a dual function in acting 
on both class I and III PI3ks when using nutrient rich medium over an extended period of 
time (116-118). There is also evidence to suggest that class I PI3ks are inhibited by 
wortmannin and ly294002. However, in the case of wortmannin the inhibition of class I is 
short-acting and does not persist as in the case with 3-ma (117). With regards to ly294002, it 
appears to exhibit a link with calcium stores when inhibiting class I PI3ks, thereby increasing 
the generation of intracellular calcium levels (118).  
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Certain types of autophagy inhibitors act at a later stage of the autophagy cascade, for 
example preventing the delivery of mature autophagosomes to lysosomes. Examples of 
these include nocodazole and vinblastine, which alter microtubules to prevent the fusion of 
autophagosomes with lysosomes (106, 122, 123). Erythro-9-[3-2-hydroxynonyl] adenine 
(EHNA) also blocks the delivery of autophagosomes to lysosomes, although this is achieved 
by inactivating dynein ATPase (122). Autophagy inhibition can also occur by directly altering 
lysosomal pH levels, which prevents their fusion with mature autophagosomes. Two 
commonly used autophagy inhibitors that target lysosomes in this manner include 
bafilomycin A1 (a vacuolar ATPase inhibitor) and chloroquine (an alkaliser) (118, 124).  
L-asparagine, an amino acid that has been examined in this chapter as a potential 
autophagy inhibitor, has a long history as a chemical inhibitor selectively blocking the 
delivery as well as the fusion of autophagosomes with lysosomes (123, 125, 126). There is 
evidence in the literature that different amino acids can play a role as autophagy inhibitors, 
and this may differ depending on the selected amino acid (127).  
In situations where autophagy is highly activated, the degradation of the components of the 
autophagolysosomes results in the release of excessive amino acids. There is evidence to 
suggest that this amino acid influx will promote protein phosphorylation through mTOR 
class 1  (mTORC1) activation or by an mTOR independent manner, both of which affect the 
Unc-51-like kinase 1 (ULK1) complex (128, 129). As the ULK1 complex is inhibited, this 
facilitates the binding of beclin1 with bcl2 leading to sequestration of beclin1-UVRAG/Atg6 
complex, thus resulting in the inhibition of autophagy (128). For the mTOR independent 
mechanism, inhibition can be achieved by the suppression of AMP-activated protein kinase 
(AMPK), causing an increase in ATP production by the release of 2-oxoglutarate. Other 
methods of AMPK inhibition involve phosphorylation of ribosomal protein S6 (8). It is 
important to note that inhibition of autophagy with amino acids is not fully understood, 
therefore the possibility of different actions on different cell types cannot be ruled out.  
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Figure 2. 1 Target sites of selected autophagy inhibitors in the autophagy pathway.  
3-ma, ly294002 and wortmannin act at an early stage of the autophagy pathway by inhibiting 
PI3Ks class III, inhibiting autophagosome formation. L-asparagine inhibits a later stage, by blocking 
the delivery of autophagosomes to fuse with lysosomes thereby inhibiting autophagic 
degradation. Rapamycin inactivates mTOR class I, hence activating autophagy.  
 
2.2.3 Available methods and assays to measure and monitor autophagy 
Several experimental methods that have been developed to qualitatively and quantitively 
measure autophagic influx and inhibition. The first method focuses on monitoring the 
morphological features of autophagic vacuoles, such as autophagosomes and 
autophagolysosomes, as well as other cellular structures, including endoplasmic reticulum 
and mitochondria, using transmission electron microscopy (130, 131).  
One of the most commonly used methods for studying autophagy is by performing 
immunofluorescence (IF) staining techniques to monitor autophagic activity and visualise 
intracellular pathogen (in xenophagy) or mitochondria (in the case of mitophagy) (types of 
autophagy previously mentioned in Chapter 1). These IF techniques can be performed using 
fluorescence microscopy, laser scanning confocal microscopy and flow cytometry. 
Fluorescent labelled antibodies are selected based on their ability to target specific markers 
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and cellular components involved in the autophagy cascade (131, 132). In both Chapter 2 
and 3 of this thesis, laser scanning confocal microscopy was used to monitor autophagy 
inhibition and activation of specific targeted markers.  
Flow cytometry can be utilised as a quantitative approach by measuring fluorescent 
intensity or the location of “live” individual cells within the autophagy cascade. Although 
flow cytometry analysis is considered faster and requires less cell material than confocal 
microscopy, its use is mainly with cells in suspension (133). While preparing adherent cells in 
suspension can be achieved, this can induce cellular stress, which in turn activates 
autophagy and may influence experimental outcomes. Also, a second limitation of using this 
approach is that flow cytometry can only evaluate the total LC3 expression in cells, rather 
than identifying its isoforms separately (131).  
An example of an autophagy marker that was targeted in the experimentation performed in 
this chapter is LC3B using confocal microscopy, a mammalian homologue of the Atg8a 
protein previously described in Chapter 1, which will be referred to as LC3B in this thesis. 
Within the autophagy pathway, LC3 plays an important role in inducing autophagic 
elongation and promoting autophagosome growth when autophagy is activated. While 
there are three different types of LC3 (LC3A, LC3B and LC3C) only the LC3B/Atg8a 
component is associated with an increase in size or number of autophagosomes  (93, 99, 
130). LC3B is recruited by Atg7, the E1 ubiquitin activating enzyme, which is activated by 
Atg12, Atg5 and Atg16 complex. A cysteine protease known as Atg4 cleaves the C terminal 
of LC3 to produce the cytosolic form LC3B-I, which in turn will be transported by Atg3 to an 
E2 like ubiquitin transporter. This will be followed by lipid conjugation of 
phosphatidylethanolamine (PE) to the carboxyl terminal glycine of the cytosolic form 
generating the active membrane form LC3B-II (94, 98, 134-137). While other members of 
the LC3 family can be targeted in a similar manner, for example γ-aminobutyric type A 
(GABAA)-receptor associated protein (GABARAP), little is known about them and they are 
not widely used as LC3B-II (94, 137). 
A second commonly used marker is p62, which was also used as part of the experimentation 
for screening a suitable autophagy inhibitor in this chapter. As previously mentioned in 
Chapter 1, p62 is a human homologue of sequestosome 1 (SQSTM1) and Ref(2)p in 
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Drosophila species, which will be referred to as p62 in this thesis (138-140). P62 plays an 
important role as an adaptor in the selective autophagy pathway (141). This is achieved 
through two interactive domains present in the p62 gene. The first of these is ubiquitin 
binding domain (UBA), which facilitates the specific binding of p62 to other ubiquitinated 
proteins in the cytoplasm, including bacterial ubiquitin  (141). The second domain is referred 
to as Phox/Bem 1p (BP1), which allows the accumulation of p62 genes resulting in a polymer 
structure, thereby stabilising its binding to selected targets (138).  
P62 may interact with the previously discussed LC3 protein through what is referred to as 
the LC3 interacting region (LIR) (138, 142). Hence, in the case of xenophagy, pathogens will 
be recognised and targeted for autophagic degradation through LIR (143). For detection 
purposes, levels of p62 will be low in circumstances of induced autophagy due to high 
degradation levels of targeted material, as well as p62 degradation. On the other hand, 
when autophagy is suppressed, an increase in p62 levels is observed (138). 
In addition to p62, other autophagy markers have recently gained prominence in the 
literature for selective autophagy. These include neighbour of Brca1 gene (NBR1), nuclear 
dot protein 52 (NDP52) and optineurin (OPTN) (143). These three selective autophagy 
adaptors share similar structural characteristics to p62, as they all have the UBA and LIR, 
which aid in targeting ubiquitinated material and attachment to LC3 on autophagosomal 
membranes (143-145). Despite the similarity between p62 and NBR1, one study has found 
they operate independently and can selectively target cargo for degradation in the absence 
of the other (146). It has been reported in the literature that NDP52 has an additional role in 
ensuring complete ubiquitinated microbial degradation autophagosome maturation (145).  
Other autophagy proteins can also be used as markers using immunofluorescence staining 
and other experimental methods. Examples of these markers include Atg4, Atg5, Atg12 and 
beclin1 (130). However, their lack of specificity for xenophagy is not ideal for the 
experimental requirements in this thesis. (130). 
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Figure 2. 2 The location of autophagic markers (LC3B-I, LC3B-II and p62) in the autophagy 
pathway.  
LC3B-I/Atg8a-I is located in the cytoplasm and LC3B-II/Atg8a-II lipid conjugated form is 
located on the autophagosomal membrane. P62 is attached to both the ubiquitinated 
targeted pathogen and LC3B-II.  
 
Immunoblotting analysis has an important role in monitoring autophagic flux. Many of the 
protein markers previously mentioned in the IF techniques, including LC3B and p62 used in 
this thesis, can also be used in measuring autophagy using western blot. One important 
difference with the use of LC3B in western blot is that it detects both of its isoforms (LC3B-I 
and LC3B-II), while most of the available antibodies used in IF techniques only detect LC3B-
II. The protein LC3B has two isoforms: a cytosolic form LC3B-I, and a membrane form LC3B-II 
(98, 137, 147). This feature of detecting both isoforms of LC3B presents an added advantage 
over IF techniques, which measure the conversion of LC3B-I to LC3B-II. However, there are 
limitations to assessing this conversion, since expression of LC3B-I and LC3B-II varies in 
different cell lines and therefore need experimental validation (130).  
An additional method used for measuring autophagy activity is by using transcriptome 
analysis. Autophagy related genes can be specifically targeted for deletion or silencing and 
can be quantified through measuring mRNA transcripts of selected genes using quantitative 
polymerase chain reaction (qPCR) (130-132).  
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2.2.4 Experimental justification 
In this chapter, four chemical autophagy inhibitors were tested: 3-ma, ly294002, 
wortmannin and l-asparagine. These inhibitors and their concentrations were pre-selected 
based on their known role in inhibiting autophagy in vitro. 3-ma, ly294002 and wortmannin 
are known to affect an early step of autophagy by inhibiting class III PI3k enzymes thereby 
blocking autophagosome formation (116-118, 148). L-asparagine, has a later stage inhibitory 
effect in the autophagy process, in which it blocks the delivery of autophagosomes to 
lysosomes (123, 125, 129).  
The first set of experiments in this chapter were performed to determine whether the 
selected chemical autophagy inhibitors affected cell viability/cytotoxicity. Different 
concentrations and incubation times were used for each chemical inhibitor on the mosquito 
cell line C6/36 using the high content imaging system (Operetta).  
The second set of experiments were conducted to determine the overall autophagic 
inhibitory ability of the four chemical inhibitors, as well as the optimum concentration to 
achieve this. Two widely used markers for selective autophagy, p62 and LC3B, were selected 
as autophagy markers using immunofluorescence staining technique (confocal microscopy) 
and immunoblotting assay (western blot).  
All experiments in this chapter were conducted on mosquito cell line C6/36Wp, a validated 
in vitro model developed by the A-WOL consortium for anti-Wolbachia drug screening. The 
use of this particular insect cell-based model was considered for carrying out a high 
throughput screening for suitable autophagy inhibiters based on its previous optimisation 
by the A-WOL consortium using Operetta (52). Due to the technical and economic issues 
related to the use of B. malayi nematodes, primary screening of autophagy inhibitors was 
carried on C6/36Wp cells and the suitable inhibitors in terms of favourable outcomes of 
viability and toxicity will be further tested on nematodes (Chapter 4). 
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2.3 Materials and methods 
For more details on the materials used in the experimentation performed in this chapter, 
please refer to the Appendix B section of this thesis (Table B.1).  
2.3.1 In vitro culture of the mosquito cell line C6/36 infected with Wolbachia 
In the experiments performed in this chapter, the Wolbachia infected mosquito cell line, 
Aedes albopictus clone (C6/36Wp) was used. C6/36 cells were retrieved from a 
cryopreserved culture vial (with a cell density of 4 x 106 cells/ml) stored at Liverpool School 
of Tropical Medicine (LSTM), United Kingdom (UK). These cells were originally purchased 
from European Collection of Authenticated Cell Cultures (ECACC) (clone C6/36, 89051705) 
and transfected by Dr Kelly Johnston (Department of Tropical Disease Biology, LSTM, UK). 
Cells were infected with Wolbachia pipientis wAlbB strain derived from Aa23 cells using the 
procedure and methodology described by O’Neill et al. (149) and Turner et al. (150) and 
cryopreserved and stored in liquid nitrogen. 
Leibovits-15 (L-15) (Gibco, Thermo Fisher Scientific) medium used in C6/36Wp cell culture 
was supplemented with 20% heat inactivated hyclone fetal bovine serum (FBS) (Thermo 
Fisher Scientific), 2% tryptone phosphate broth (Sigma Aldrich) and 1% non-essential amino 
acids (Sigma Aldrich), all were filtered using 1 L filter with 0.22 µM pores. 
Immediately after thawing, L-15 medium lowered to room temperature was used to wash 
the C6/36Wp cells. Cells were centrifuged at 400 g (gravitational force) for 5 minutes to 
pellet them. The obtained pellet was resuspended in 13 ml media, cultured in a closed cap 
75- cm2 tissue culture flask (Nunc™, Thermo Fisher Scientific) and incubated at 26˚C. 
C6/36Wp cells were sub-cultured and kept at a dilution of 1:4 (split ratio) every 7 days to 
reach confluency of approximately 80%. Under sterile conditions, cells were detached using 
cell scrapers (Nunc, Thermo Fisher Scientific), and resuspended in fresh media.  
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2.3.2 High content screening imaging system: Operetta/harmony software for 
C6/36Wp cells – Growth dynamics 
Cell based screening assay was optimised following the protocol described by Clare et al. 
(80) using Operetta (PerkinElmer). All Operetta assays in this chapter were done on 
C6/36Wp at a confluency level of ~80% at day 7 of culture. 
The Operetta assays were carried out using 384-well Cell Carrier plate (PerkinElmer) at a 
density of 2000 cells/well with 100 µl final volume diluted in L-15 medium. Attached cells 
were dislodged using sterile cell scrapers in spent media. Total viable cell count was 
calculated using an automated cell counter (Biorad). 10 µl of cell suspension and 0.4% 
trypan blue (Sigma Aldrich) were mixed and added to a cell counter slide (Biorad) for the 
total number of live cells per ml.   
C6/36Wp cells were incubated with different autophagy inhibitors at different 
concentrations, as follows:  3-ma (between 1 to 5 mM), ly294002 (between 1-20 µM), 
wortmannin (between 1-20 µM), and l-asparagine (between 1-20 mM), along with 1% 
Dimethyl sulfoxide (DMSO) treated cells as a vehicle control, for 8 days at 26◦C. All chemical 
autophagy inhibitors and DMSO were purchased from Sigma Aldrich.  
All concentrations of the four tested autophagy inhibitors were prepared in DMSO for a 
working stock and diluted in culture medium with four biological repeats for each 
concentration. On day 0, 2, 4, 6 and 8, cells were stained for 30 minutes with Syto11 (Life 
Technologies, Thermo Fisher Scientific), a nucleic acid green fluorescent stain to visualise 
cell nuclei and Wolbachia at 2 µl/ml and imaged using Operetta/Harmony software (with 
objective lens at 60x and fluorescein filter).  
Harmony software was used to analyse the cell images of each well (5 fields and 4 stacks) to 
calculate the total number of cells during the 8-day period of treatment with autophagy 
inhibitors. Autophagy inhibitor concentrations were considered to have an impact on cell 
growth when we observed a reduction of 50% compared to control groups with no 
treatment.  
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2.3.3 High content screening imaging system: Operetta/Harmony software for 
C6/36Wp cells – Cell viability and cytotoxicity  
The viability of C6/36Wp cells in the presence of autophagy inhibitors was determined using 
Live/Dead Viability/Cytotoxicity kit (Life Technologies, Thermo Fisher Scientific). This kit 
contained Calcein AM for staining live cells (green fluorescent) and Ethidium homodimer-1 
for staining dead nuclei (red fluorescent), diluted at 2 µM and 4 µM respectively. The 
dilution was prepared as per manufacturer guidelines. The cells were counterstained with 
Hoechst 34442 (Life Technologies, Thermo Fisher Scientific) at 2 µg/ml to visualise the 
nuclei. Saponin (Sigma Aldrich) treated cells were used as a positive control for this 
experiment, in which 0.1% saponin was added to cells for a duration of 10 minutes.  
Using Operetta under bright field, the following channels were utilised: i) fluorescin for 
calcein AM, ii) DSred for ethidium homodimer-1 and iii) Hoechst for Hoechst 34442. 
Harmony software was used to analyse the cell images in each well (8 fields and 6 stacks per 
well) to calculate the total number of live and dead cells during the 8-day period of 
treatment with autophagy inhibitors.  
 
2.3.4 Immunofluorescence staining assay: Confocal laser scanning microscopy and 
fluorometric assay: 
C6/36Wp cells were treated for 7 days with the four autophagy inhibitors at different 
concentrations: 3-ma (at 1 mM), ly294002 (at 1 µM), wortmannin (at 1, 5, 10 and 20 µM) 
and l-asparagine (at 1, 5, 10 and 20 mM). In this experiment, DMSO was used as a vehicle 
control.  
A known autophagy activator, rapamycin at 5 µM (Sigma Aldrich), was used as positive 
control. Additionally, rapamycin at 5 µM was also added to all tested concentrations of 
autophagy inhibitors to examine if the tested inhibitors can continue to suppress autophagy 
in rapamycin-induced autophagy groups.  
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Confocal laser scanning microscopy: 
Microscopic localisation of two autophagy markers; LC3B-II and p62 was performed in cells 
treated with the four autophagy inhibitors. The expression of these markers and 
interpretation within the autophagic pathway are presented in Figure 2.3. 
 
 
Figure 2. 3 Interpreting the expression of autophagic markers LC3B and p62 in the autophagy 
pathway.  
Basal levels of autophagy represent naturally occurring autophagy. In autophagy activation 
(as seen with rapamycin, a known autophagy activator), expression of LC3B is increased (due 
to autophagosomes formation) and p62 levels decreased (due to autophagic degradation). 
Differences occur in terms of autophagy inhibition. For early inhibition (for example 
measuring autophagy using wortmannin), LC3B expression levels will decrease and p62 will 
increase in level due to inhibition of autophagosomes formation and autophagic degradation, 
respectively. Conversely, in late autophagy inhibition (as seen with l-asparagine), both 
markers will increase in level, due to autophagosomes accumulation (for LC3B) and blocking 
autophagic degradation (p62).  
Data source: modified from (106). 
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50,000 cells were seeded in 2 ml L-15 media using shell vial tubes (Thermo Fisher Scientific) 
for confocal analysis. After cell suspensions were incubated between 14-16 hours at 26◦C to 
allow cell attachment to the cover slips, the culture media was removed and replaced with 
prepared autophagy inhibitors diluted in L-15 media at the desired concentrations and 
cultured for 7 days in the incubator at 26◦C. Media was removed and cells were fixed and 
permeabilised using 4% formaldehyde (Pierce, Thermo Fisher Scientific) diluted in 
phosphate-buffered saline (PBS) (Sigma Aldrich) containing Triton x100 (PBS-T) (Sigma 
Aldrich) for 30 minutes. Cells were then washed 3 times to remove excess fixative solution 
with PBS and blocked with 1% bovine serum albumin (BSA) (Sigma Aldrich) diluted in PBS for 
15 minutes. 
It is important to note that the LC3B-II and p62 markers were used separately in the 
immunofluorescence staining assay to avoid species mismatch. The primary antibodies used 
in this experiment, rabbit anti-LC3B-II (Invitrogen, Thermo Fisher Scientific) and rabbit anti-
p62 (Cell Signaling), were diluted in 1% BSA blocking buffer at 1:400 and cells were 
incubated overnight at 4◦C. Next, fluorescence-labelled secondary antibodies diluted at 
1:500, goat anti-rabbit Fluorescein isothiocyanate Ds grade (FITC) (Invitrogen, Thermo Fisher 
Scientific) used to target LC3B-II and goat anti-rabbit tetramethylrhodamine (TRITC) (Sigma 
Aldrich) used to target p62, were added to cells for one hour at room temperature.  
Cells were washed three times with PBS following each antibody incubation to remove 
unbound antibodies. Cover slips of each vial were removed and mounted on a microscopic 
slide with 4′,6-diamidino-2-phenylindole (DAPI) mounting medium (Vectashield, Vector 
Laboratories) to view under confocal laser scanning microscope (Zeiss LSM 880) at 63x 
magnification using Z-stack 3D images. Fixed cells on slides were imaged and analysed 
across three different areas, in which each cell per area was selected using a graphic 
software (Zen software) to measure mean fluorescence intensity. 
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Fluorometric assay: 
Quantitative analysis of fluorescence expression of autophagy markers was measured using 
fluorometric assay. Cells were seeded in 200 µl L-15 media of a 96-well plate, which were 
black walled with clear flat-bottom (PerkinElmer). Following the same protocol mentioned 
above for confocal immunostaining assay, at day 7 the intensity of LC3B-II-FITC and p62-
TRITC fluorescence was measured at an excitation of 490 and 557, and emission of 525 and 
576 for FITC and TRITC respectively, using Varioskan plate reader (Thermo Fisher Scientific). 
Wells without cells were also measured to exclude fluorescence background readings.  
 
2.3.5 Western blot analysis 
C6/36Wp cells were seeded into T-25 flasks (Thermo Fisher Scientific) at a density of 1x106 
cells per 5 ml L-15 media. Different concentrations were used for the three autophagy 
inhibitors: for ly294002 at 1 µM, wortmannin 1-20 µM and l-asparagine 1-20 mM. Additional 
treatment groups consisting of C6/36Wp cells treated with the three autophagy inhibitors 
(using the same concentrations mentioned above) combined with rapamycin were analysed 
using western blot. DMSO treated cells were used as a vehicle control and rapamycin as an 
autophagy inducer. All treatment groups were incubated at 26◦C for 7 days. 
At the end of treatment, cells were washed with cold PBS and lysed using 100 µl RIPA lysis 
buffer (Thermo Fisher Scientific) with an added protease inhibitor mix (GE Healthcare) at 10 
µl/ml for 5 minutes and centrifuged to pellet the cell debris. The prepared whole cell lysates 
were used for protein measurements (in µg/µl), in which the total protein concentration of 
each sample was estimated using bicinchoninic acid protein assay kit (Pierce, Thermo Fisher 
Scientific). 
Equal protein concentrations of 50 µg/40 µl were diluted in NuPAGE LDS sample loading 
buffer (Thermo Fisher Scientific) and loaded into gels along with 5 µl of molecular weight 
marker PageRuler Prestained Protein Ladder - 10 to 180 kDa, (Thermo Fisher Scientific). All 
lysates were reduced using NuPAGE reducing agent (Thermo Fisher Scientific) and heated at 
70◦C for 10 minutes before loading into gels. Loaded proteins were then separated using 
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sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) in a precast of 
NuPAGE 6-12% Bis Tris Bolt plus polyacrylamide gel (Thermo Fisher Scientific) at a voltage of 
130 v for 1 hour with NuPAGE MES running buffer (Thermo Fisher Scientific) containing 
NuPAGE antioxidant reagent (Thermo Fisher Scientific).  
Proteins were then transferred into a nitrocellulose membrane with a pore size of 0.22 µM 
(Amersham, GE Healthcare). In a Mini Trans-Blot Electrophoretic Transfer Cell (Biorad), a 
gel-blot sandwich was assembled into a gel holder cassette and placed into the transfer cell 
and processed at 200 mA for 1 hour using Tris Glycine transfer buffer containing 20% 
methanol (self-prepared: see Appendix B Table B.2 for components). All components of the 
gel-blot sandwich including filter papers and filter pads were equilibrated by submerging 
them into the same transfer buffer for 10 minutes before transferring the blot. Transferred 
proteins were checked with Ponceau S staining (self-prepared: see Appendix B Table B.2 for 
components) to confirm transfer quality and an equal amount of loading volumes. 
Membrane blots were blocked using 5% BSA diluted in Tris buffered saline with 0.1% Tween 
20 (TBS-T) (Sigma Aldrich) for 2 hours with gentle agitation. All primary antibodies were 
added to the membranes as indicated in Table 2.1 and left overnight at 4◦C with gentle 
agitation (~30rpm). Following this step, blots were washed three times with PBS-T, with 
each wash cycle lasting 5 minutes, to remove unbound primary antibodies. Secondary 
antibodies were then added to the membranes as presented in Table 2.1 and left for 1 hour 
at room temperature.  
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Primary antibody Secondary Antibody (HRP conjugated) 
Target Species Dilution 
Blocking 
buffer 
Supplier Target Species Dilution 
Blocking 
buffer 
Supplier 
LC3B Rabbit 1:1000 
5% non-
fat milk in 
TBS-T 
Novus 
Anti-
rabbit 
Goat 1:5000 
5% non-
fat milk 
in TBS-T 
Cell 
Signaling 
P62 Rabbit 1:1000 
5% BSA in 
TBS-T 
Cell 
Signaling 
Anti-
rabbit 
Monkey 1:10000 TBS-T 
GE 
Healthcare 
Beta 
actin 
Mouse 1:1000 
5% BSA in 
TBS-T 
Cell 
Signaling 
Anti-
mouse 
Rabbit 1:20000 TBS-T 
Sigma 
Aldrich 
Table 2. 1 Primary antibodies and secondary antibodies used in western blot analysis, along 
with their target, species, dilution, and type of blocking buffer.  
 
Excess secondary antibodies were removed by washing the membranes again with PBS-T x3 
for 10 minutes. SuperSignal Chemilluminscent substrate HRP system (Pierce, Thermo Fisher 
Scientific), was added to the membranes for 5 minutes, and then exposed to x-ray CL 
Xposure films (Thermo Fisher Scientific) and imaged using Photons Developer Instrument. 
For blots where the primary antibodies were of similar species (see Table 2.1), primary and 
secondary antibodies were stripped off using Restore Plus Western Blot Stripping Buffer 
(Thermo Fisher Scientific) for 15 minutes and washed 3 times with washing buffer TBS-T.  
 
2.3.6 Statistical analysis  
Statistical analysis for this chapter was performed for continuous variables in cell growth 
dynamic and confocal immunofluorescence assay using independent sample Student’s t-
test. One-way analysis of variance (ANOVA) was used for continuous variables with two or 
more independent variables for viability/cytotoxicity experiment. Statistical significance was 
at p ≤ 0.05. GraphPad Prism version 7 was used for all sections of the statistical analysis in 
this chapter. 
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2.4 Results 
The results section for this chapter is divided into four parts, where each section represents 
the different set of experiments conducted to determine an optimum autophagy inhibitor in 
C6/36Wp cells.  
2.4.1 Cell growth dynamic of mosquito cell line C6/36Wp  
The findings for total C6/36Wp cell number using the Operetta high throughput imaging 
system are presented in Figure 2.4, obtained at different time points during the 8-day 
treatment period with the four autophagy inhibitors at a range of concentrations. Each 
treatment group had four biological repeats, and the values presented as mean total cell 
count per group. The measured values for the percentage reduction in total number of cells 
for each treatment group are presented in the Appendix A (Table A1). 
Each individual graph in Figure 2.4 presents the total number of C6/36Wp cells for different 
autophagy inhibitors: 3-ma (1-5 mM), ly294002 (1-20 µM), wortmannin (1-20 µM) and l-
asparagine (1-20 mM). The cut-off for autophagy inhibitor effect on cell growth was taken at 
a 50% reduction of total cells compared to the control (DMSO treated cells) at day 8. This 
cut-off point was based on the threshold used previously for A-WOL drug screening (151). It 
should be noted that prior to day 4 of treatment, all autophagy inhibitors at all 
concentrations appeared similar in terms of cell growth effect.  
For 3-ma (Figure 2.4 A) only the lowest concentration at 1 mM did not affect cell growth by 
more than 50%. This was also observed for ly294002, although the initially selected range of 
concentrations warranted further evaluation, which presented a suitable range between 1-2 
µM (Figure 2.4 B and C). However, it is important to note that for ly294002 at 2 µM there 
was noticeable variability measured at day 8 (Figure 2.4 C).  
In the case of wortmannin and l-asparagine (Figure 2.4 D and E), all the initially selected 
concentrations were suitable and did not hinder cell growth by more than 50%.  
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Figure 2. 4 C6/36Wp cell growth dynamics for autophagy inhibitors at different concentrations.  
C6/36Wp cells infected with wAlbB were treated with four autophagy inhibitors for 8 days. Total 
number of cells/well were measured every two days (at day 0, 2, 4, 6 and 8) using Operetta. 
Graphs (mean with SD) represent the total number of cells/well in four biological repeats for 
every treatment group. Suitability of autophagy inhibitor concentration was considered if its 
effect on cell proliferation was less than 50% reduction compared to control (DMSO treated 
cells). 
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2.4.2 Cell viability and cytotoxicity 
In the second experiment, viability of cells was assessed on C6/36Wp cells treated with the 
selected autophagy inhibitors (3-ma, ly294002, wortmannin and l-asparagine) at different 
concentrations for 8 days using the Operetta/Harmony high throughput imaging. This 
experiment was performed as a confirmatory step for the previous experiment (section 
2.4.1), in which four chemical autophagy inhibitors were tested to determine their effect on 
reducing cell growth at 50% compared to a control.  
Live cells were differentiated from dead with the use of two viability stains as mentioned in 
the method section 2.3.3. For all autophagy inhibitors, the same concentrations were used 
as experiment 2.4.1. The findings for cell viability and cytotoxicity are presented in Figure 
2.5.  
As in the previous experiment, there was a significant difference between 3-ma at 1 mM 
and all the other concentrations tested in terms of cell cytotoxicity. Moreover, there was a 
significant difference recorded between DMSO treated cells (control) and 3-ma at 1 mM, 
indicating a toxic effect even at the lowest concentration tested for this inhibitor.  
In the case of ly294002, only the lowest concentration tested (1 µM) did not appear to have 
a toxic effect compared to the control. As expected, the effect on cell viability was 
concentration-dependent, where an increase in the concentration of ly294002 significantly 
increased cell toxicity compared to the control.   
For both wortmannin and l-asparagine, all the tested concentrations presented a similar 
picture and did not appear to have a significant effect on cell toxicity/viability even at the 
highest concentration, as indicated in Figure 2.5. 
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Figure 2. 5 C6/36Wp cell viability/cytotoxicity for autophagy inhibitors at different 
concentrations. 
C6/36Wp cells were treated with four autophagy inhibitors for 8 days. Total number of viable 
cells were stained with calcein AM and measured at day 8 using Operetta. Saponin was used 
as a control, expressing the presence of dead cells. Graphs (mean with SD) represent total 
viable cell count/well in four biological repeats for every treatment group. Cell 
viability/cytotoxicity was assessed by comparing with DMSO control using one-way ANOVA 
Dunnett’s test, where statistical significance was p ≤ 0.05. For p-value * = 0.01 to 0.05, ** = 
0.01 to 0.001, *** = 0.001 to 0.0001, and **** ≤ 0.0001.
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2.4.3 Immunofluorescence staining assay 
Based on the results obtained from the experiments on cell growth dynamic and cell 
viability/cytotoxicity (section 2.4.1 and 2.4.2), we selected suitable concentrations for the 
four autophagy inhibitors, and these were assessed using an immunofluorescence staining 
method at day 7 of treatment. Therefore, autophagy inhibitor concentrations that were 
deemed non-toxic and were evaluated for their autophagic inhibitory effect. These findings 
are presented in Figures 2.6-2.11, using two autophagy markers: LC3B-II (conjugated with 
FITC - green fluorescent puncta) and p62 (conjugated with TRITC - red fluorescent puncta), 
and cell nuclei (DAPI - blue fluorescent). It should be noted that for all PI3ks inhibitors (3-
ma, ly294002 and wortmannin), inhibition of autophagy will present a decrease in LC3B-II 
green fluorescence expression indicating a blocking of autophagosome formation. Whereas, 
for l-asparagine inhibition of autophagy will present as an increase in green fluorescence 
intensity due to its late stage inhibition in the autophagy cascade indicating the 
accumulation of autophagosomes. While for p62, an increase of red fluorescence indicated 
a suppression of autophagy degradation for all inhibitors.  
As previously described in the methods section, rapamycin was used a positive control for 
autophagy activation. The optimum concentration of rapamycin at 5 µM was determined 
through a separate cell growth dynamic and cell viability/cytotoxicity analysis. This is 
presented in Appendix A (Figure A1). 
Autophagy inhibitor: 3-ma 
While 3-ma was observed to be toxic even at the lowest tested concentration, it did not 
affect cell growth by more than 50% following an 8-day treatment. Due to this inconsistent 
finding we tested the inhibitory effect of 3-ma at 1 mM for 7 days. As presented in Figure 
2.6, 3-ma at 1 mM did not significantly reduce LC3B-II (Figure 2.6 A and B) or increase p62 
(Figure 2.6 C and D) compared to the DMSO control, indicating this concentration as not 
adequate for autophagy suppression. The addition of 3-ma to rapamycin-induced autophagy 
cells decreased LC3B-II fluorescence intensity when compared to rapamycin treated cells 
alone. This indicates that 3-ma at 1 mM suppressed autophagy effectively only in cells with 
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rapamycin-induced autophagy. This was further confirmed by the higher fluorescence 
intensity of p62 in rapamycin and 3-ma treated cells compared to rapamycin alone.  
Autophagy inhibitor: Ly294002 
In the case of ly294002 (Figure 2.7), only one concentration (1 µM) was observed to be 
suitable in terms of its lack of toxicity to carry out immunofluorescence staining analysis. 
However, ly294002 at 1 µM was not found to be an effective autophagy inhibitor at this 
concentration. Additionally, ly294002 combined with rapamycin was found to be ineffective 
when compared to rapamycin alone. 
Autophagy inhibitor: wortmannin 
For both wortmannin and l-asparagine, the findings in cell growth and cell 
viability/cytotoxicity presented a wide range of suitable concentrations to be tested. For 
wortmannin, apart from the lowest concentration tested at 1 µM, all concentrations 
presented a statistically significant difference compared to the control with a lower 
expression of LC3B-II (Figure 2.8) and a higher expression of p62 (Figure 2.9). This 
observation indicates that autophagy inhibition has occurred by the blocking of 
autophagosome biogenesis and p62 degradation.  As expected, wortmannin combined with 
rapamycin significantly suppressed autophagy compared to the high LC3B-II fluorescence 
signal observed with rapamycin alone. The suppression of autophagy by wortmannin at the 
tested concentrations in rapamycin-induced autophagy cells measured by p62 fluorescence 
level was significant only at 10 µM and 20 µM compared to rapamycin alone.  
Autophagy inhibitor: L-asparagine 
For the four tested concentrations for l-asparagine, only the highest two concentrations (10 
and 20 mM) achieved a statistically significant differences compared to the control. As 
previously mentioned, this was expressed differently compared to the other tested 
autophagy inhibitors due to the late stage autophagy inhibition of l-asparagine. Therefore, 
both LC3B-II (Figure 2.10) and p62 (Figure 2.11) expression increased for l-asparagine at 10 
mM and 20 mM compared to the control, indicating the suppression of autophagosomes 
fusion with lysosomes. Interestingly, the combination of rapamycin with l-asparagine 
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treated cells did not present any significant differences in LC3B-II expression compared to 
rapamycin-induced autophagy treated cells. However, as with all other tested autophagy 
inhibitors, combining rapamycin with l-asparagine at the desired concentrations significantly 
increased p62 levels compared to l-asparagine alone.  
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Figure 2. 6 Immunofluorescence staining for C6/36Wp cells treated with 3-ma.   
Infected C6/36 cells with wAlbB were treated with autophagy inhibitor 3-ma at 1 mM, rapamycin at 5 µM (positive control), a combination of 3-
ma and rapamycin and DMSO treated cells (vehicle control representing basal autophagy) for 7 days. Graphs (mean with SD) represent B) LC3BII 
or D) p62 fluorescence intensity in nine biological repeats per treatment group. Cells were fixed, permeabilized and incubated with primary and 
secondary antibodies. DAPI was used to counterstain cell nuclei (blue fluorescence). Autophagy inhibition is shown by a decrease in green 
puncta (decrease in LC3B-II) and an increase in red puncta (increase in p62). Scale bars in A are 50 µm and in C are 10 µm. 
Statistical significance tested using Student’s t-test, statistical significance was at p ≤ 0.05. For p-value * = 0.01 to 0.05, ** = 0.01 to 0.001, *** = 
0.001 to 0.0001, and **** ≤ 0.0001. 
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Figure 2. 7 Immunofluorescence staining for C6/36Wp cells treated with ly294002.  
Infected C6/36 cells with wAlbB were treated with autophagy inhibitor ly294002 at 1 µM, rapamycin at 5 µM (positive control), a combination of 
ly294002 and rapamycin and DMSO treated cells (vehicle control representing basal autophagy) for 7 days. Graphs (mean with SD) represent B) 
LC3BII or D) p62 fluorescence intensity in nine biological repeats per treatment group. Cells were fixed, permeabilized and incubated with 
primary and secondary antibodies. DAPI was used to counterstain cell nuclei (blue fluorescence). Autophagy inhibition is shown by a decrease in 
green puncta (decrease in LC3B-II) and an increase in red puncta (increase in p62). Scale bars in A are 50 µm and in C are 10 µm.  
Statistical significance tested using Student’s t-test, statistical significance was at p ≤ 0.05. For p-value * = 0.01 to 0.05, ** = 0.01 to 0.001, *** = 
0.001 to 0.0001, and **** ≤ 0.0001.
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Figure 2. 8 LC3B-II Immunofluorescence staining for C6/36Wp cells 
treated with wortmannin.   
Infected C6/36 cells with wAlbB were treated with autophagy inhibitor 
wortmannin at 1-20 µM, rapamycin at 5 µM (positive control), a 
combination of wortmannin and rapamycin and DMSO treated cells 
(vehicle control representing basal autophagy) for 7 days. Graph (mean 
with SD) represents LC3BII fluorescence intensity in nine biological 
repeats per treatment group. Cells were fixed, permeabilized and 
incubated with primary and secondary antibodies. DAPI was used to 
counterstain cell nuclei (blue fluorescence). Autophagy inhibition is shown 
by a decrease in green puncta (decrease in LC3B-II due to suppression of 
autophagosomal formation). Scale bars in A are 50 µm. 
Statistical significance tested using Student’s t-test, statistical significance 
was at p ≤ 0.05. For p-value * = 0.01 to 0.05, ** = 0.01 to 0.001, *** = 
0.001 to 0.0001, and **** ≤ 0.0001.  
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Figure 2. 9 P62 Immunofluorescence staining for C6/36Wp cells treated 
with wortmannin.  
Infected C6/36 cells with wAlbB were treated with autophagy inhibitor 
wortmannin at 1-20 µM, rapamycin at 5 µM (positive control), a 
combination of wortmannin and rapamycin and DMSO treated cells 
(vehicle control representing basal autophagy) for 7 days. Graph (mean 
with SD) represents p62 fluorescence intensity in nine biological repeats 
per treatment group. Cells were fixed, permeabilized and incubated with 
primary and secondary antibodies. DAPI was used to counterstain cell 
nuclei (blue fluorescence). Autophagy inhibition is shown by an increase in 
red puncta (increase in p62 due to the suppression of its autophagic 
degradation). Scale bars in A are 10 µm. 
Statistical significance tested using Student’s t-test, statistical significance 
was at p ≤ 0.05. For p-value * = 0.01 to 0.05, ** = 0.01 to 0.001, *** = 
0.001 to 0.0001, and **** ≤ 0.0001.  
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Figure 2. 10 LC3B-II Immunofluorescence staining for C6/36Wp cells 
treated with l-asparagine.  
Infected C6/36 cells with wAlbB were treated with autophagy inhibitor l-
asparagine at 1-20 mM, rapamycin at 5 µM (positive control), a 
combination of l-asparagine and rapamycin and DMSO treated cells 
(vehicle control representing basal autophagy) for 7 days. Graph (mean 
with SD) represents LC3BII fluorescence intensity in nine biological 
repeats per treatment group. Cells were fixed, permeabilized and 
incubated with primary and secondary antibodies. DAPI was used to 
counterstain cell nuclei (blue fluorescence). Autophagy suppression with a 
late autophagy inhibitor is presented by an increase in green puncta 
(increase in LC3B-II due to blocking the fusion of autophagosomes with 
lysosomes causing autophagosome accumulation). Scale bars in A are 50 
µm. 
Statistical significance tested using Student’s t-test, statistical significance 
was at p ≤ 0.05. For p-value * = 0.01 to 0.05, ** = 0.01 to 0.001, *** = 
0.001 to 0.0001, and **** ≤ 0.0001. 
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Figure 2. 11 P62 Immunofluorescence staining for C6/36Wp cells treated 
with l-asparagine.  
Infected C6/36 cells with wAlbB were treated with autophagy inhibitor l-
asparagine at 1-20 mM, rapamycin at 5 µM (positive control), a 
combination of l-asparagine and rapamycin and DMSO treated cells 
(vehicle control representing basal autophagy) for 7 days. Graph (mean 
with SD) represents p62 fluorescence intensity in nine biological repeats 
per treatment group. Cells were fixed, permeabilized and incubated with 
primary and secondary antibodies. DAPI was used to counterstain cell 
nuclei (blue fluorescence). Autophagy inhibition is shown by an increase in 
red puncta (increase in p62 due to the suppression of its autophagic 
degradation). Scale bars in A are 10 µm. 
Statistical significance tested using Student’s t-test, statistical significance 
was at p ≤ 0.05. For p-value * = 0.01 to 0.05, ** = 0.01 to 0.001, *** = 
0.001 to 0.0001, and **** ≤ 0.0001. 
 
69 
 
2.4.4 Western blot  
Three autophagy inhibitors (ly294002 at 1 µM, wortmannin at 1-20 µM and l-asparagine at 
1-20 mM) were assessed in lysed C6/36Wp mosquito cell line using western blot analysis as 
a confirmatory step to validate the observations in the immunofluorescence staining 
method (section 2.4.3). 3-ma was not examined using western blot due its toxic effect in the 
viability/cytotoxicity experiment (section 2.4.2).  
The results for the inhibitory activity of the chemical inhibitors using western blot are 
presented in Figure 2.12 using autophagy markers LC3B (Figure 2.12 A) and p62 (Figure 2.12 
B). For the full gel of the antibody blotting membrane in this experiment please refer to 
Appendix A (Figure A2). In both immunoblots, DMSO used as a vehicle control, represented 
the basal level of autophagy in C6/36Wp cells. LC3B antibody was expressed in the 
immunoblot in two bands: LC3B-I at a protein molecular weight ~ 16 kDa and LC3B-II at ~14 
kDa. Unlike LC3B-I, the second form LC3B-II is conjugated with lipids and theoretically 
should have a higher molecular weight, although it has been found to migrate at an 
apparent lower protein size due to its higher mobility during gel electrophoresis (130, 134). 
As the conversion of LC3B-I to LC3B-II indicates the occurrence of autophagic activity, the 
band intensity of LC3B-II expresses autophagosomal formation (136). The expression of 
LC3B-I was stable throughout the treatment groups (Figure 2.12) and its expression was not 
used to indicate autophagic activity, this was previously noted in other studies (147, 152-
154). 
P62 was represented by a single protein band at ~80 kDa. Previous studies on insect cells 
have found p62 to exhibit a similar molecular weight using western blot (98, 140, 155, 156). 
As shown in both blots, Beta-actin of a molecular size at ~ 40 kDa was used as a loading 
control to ensure that an equal amount of protein concentration was loaded per lane.  
In a similar manner to the immunofluorescence staining experiment, rapamycin was used as 
a positive control and this is presented alone and combined with the three autophagy 
inhibitors. Due to rapamycin’s autophagic promoting role, the expression of LC3B-II was 
more prominent (due to autophagosome production), while p62 appeared faint in the blot 
(representing higher autophagic degradation).  
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In the case of ly249002, the reduced band of LC3B-II was similar in intensity to the DMSO 
control. This suggests that at this concentration of 1 µM only basal autophagy is exhibited 
and there appeared to be no inhibitory effect by ly294002. Similarly, this was also observed 
for p62 degradation. As expected, combining ly294002 at 1 µM with rapamycin did not 
reduce autophagy activity showing no observable decrease in fluorescence intensity of 
LC3B-II compared to rapamycin and a reduced band of p62 expression appeared in the 
combination group.  
At all tested concentrations of wortmannin, there were no observed bands for LC3B-II 
indicating its autophagic inhibitory role by blocking autophagosome generation. For p62, 
the lower concentration of wortmannin tested at 1 µM showed no difference from the 
control and there appeared to be a concentration-dependent increase of intensity with 
increasing concentrations of wortmannin. The findings in the rapamycin and wortmannin 
groups point to a similar conclusion, where autophagy was suppressed by a lower and 
higher expression of LC3B-II and p62, respectively.   
For a late-stage autophagy inhibitor such as l-asparagine, the expression of LC3B-II should 
increase in autophagy inhibition, suggesting the blocking of autophagosomes transforming 
to autophagolysosomes (157). As shown in Figure 2.12 A, there appeared to be a gradually 
increase in intensity of the LC3B-II band with increasing concentrations of l-asparagine. It is 
important to note that compared to the control, there appeared to be no noticeable 
difference between the reduced intensity of the LC3B-II band at concentrations 1 mM and 5 
mM for l-asparagine. Similar findings were also observed when immunoblotting p62 in l-
asparagine, where only at 10 and 20 mM l-asparagine appeared to have an inhibitory role 
compared to the control. L-asparagine when combined with rapamycin did not present a 
noticeable difference in LC3B-II expression compared to rapamycin alone. Conversely, p62 
expression was increased when l-asparagine was combined with rapamycin compared to 
rapamycin alone.  
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Figure 2. 12 Detection of LC3B and p62 expression for autophagy inhibitors in C6/36Wp cells 
using Western blot.  
C6/36 mosquito cells infected with Wolbachia wAlbB were treated with: DMSO – vehicle 
control (lane 1), Ly294002 at 1 µM (lane 2), wortmannin from 1-20 µM (lane 3-6), and l-
asparagine from 1-20 mM (lane 7-10) for 7 days. A combination of rapamycin with Ly294002 
(lane 11), wortmannin (lane 12-15) and l-asparagine (lane 16-19) and rapamycin alone - 
positive control (lane 20) were also analysed. Reduced protein extracts of cells were loaded 
at 50 µg/40 µl per lane into 4-12% bis tris SDS-PAGE gels. Separated proteins were 
transferred into nitrocellulose membrane, blocked with 5% BSA-TBST and incubated with 
primary and secondary antibodies. 
Western blot protein expression is presented in A) for rabbit anti-LC3B (LC3B-I at 16 kDa and 
LC3B-II at 14 kDa) and B) rabbit anti-p62 (at 80 kDa). A reference protein; mouse anti-beta 
actin was used as a control with a size of approximately 40 kDa. In autophagy inhibition: A) 
LC3B-II intensity decreased (for early autophagy inhibitors) and increased (for late autophagy 
inhibitor, l-asparagine) B) p62 intensity increased.  
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2.5 Discussion 
The series of experiments performed in this chapter have successfully achieved their role in 
determining suitable concentrations of pre-selected chemical autophagy inhibitors by 
examining their suitability and inhibitory profile in mosquito cell line C6/36Wp. 
Furthermore, it has presented a methodology to determine optimum concentrations of 
autophagy inhibitors in C6/36Wp cells based on their impact on cell viability/cytotoxicity, as 
well as their impact on cell growth.  
For the four tested autophagy inhibitors, the experiments conducted on C6/36Wp cells for 
cell growth effect and cell viability/cytotoxicity have produced consistent findings. The 
results have shown that 3-ma is not a suitable option for inhibiting autophagy in C6/36 cells. 
3-ma has been shown to have a significant toxic effect over the 8-day culture period, even 
at the lowest tested concentration of 1 mM. While 3-ma did not impact cell growth over 
shorter treatment periods, this observation requires further experimentation and validation 
in other insect cells. Most of the previous research on 3-ma as an autophagy inhibitor was 
conducted on mammalian cells (116, 119, 158-161). However, concerns have been 
proposed with the use of 3-ma due to its effect on cell proliferation and other signalling 
pathways, including apoptosis, even within the commonly used concentrations for 
autophagy inhibition (162-166). Additionally, there is evidence to suggest that 3-ma has a 
dual role in the autophagy cascade, as it may inhibit and activate autophagy (117). Two of 
the conditions highlighted in the literature for 3-ma to promote autophagy were culturing 
cells in full nutrient medium and long experimentation time. In the same study, 3-ma did 
not activate autophagy in starved cells and culturing for less than 9 hours (117). 
In this research, the results of immunofluorescence staining for autophagy protein markers 
LC3B-II and p62 for C6/36Wp cells treated with 3-ma at 1 mM (lowest concentration tested) 
did not inhibit autophagy. This indicates that a higher concentration of 3-ma would have 
been needed to suppress autophagy in C6/36 cells. Previous studies using 3-ma on C6/36 
cell line (in both Wolbachia infected and uninfected cells) observed an effective 
concentration for autophagy inhibition at 5 mM, however this concentration was found to 
have a toxic effect in our study (87). Experiments performed on non-insect cells have found 
an optimum inhibitory concentration for 3-ma to be between 5-10 mM (127, 167, 168). 
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Therefore, further research is needed to enhance our understanding on using 3-ma on 
insect cells considering the findings of our study.  
The results for ly294002 showed a lack of toxicity at 1 µM, while all the higher 
concentrations tested were toxic. This was further confirmed through analysing its effect on 
cell growth, where the same concentration at 1 µM did not hinder cell proliferation. 
However, ly294002 treated cells at 1 µM failed to achieve a significant autophagy inhibitory 
effect when analysed by immunofluorescence staining and western blot. Previous studies on 
ly294002 as an autophagy inhibitor have been mainly conducted on mammalian cells, with 
concentrations ranging between 1-100 µM (116, 121, 134, 169, 170). A single study has 
suggested that the autophagic effect of ly294002 was concentration-dependent and it was 
found to cause cell cycle arrest at 25 µM in mouse embryo fibroblast cells (171). This 
suggests that the concentration of ly294002 may operate differently according to the type 
of cells, both in terms of toxicity and inhibitory effect on autophagy. Recent studies have 
shown that ly294002 may not be suitable as a PI3Ks inhibitor as it can also inhibit mTOR 
through an ATP binding site, thereby activating autophagy (172). To conclude, based on our 
experimentation ly294002 was not a suitable chemical to evaluate autophagy on C6/36Wp 
cells. 
Based on our results, both wortmannin and l-asparagine have been observed to be suitable 
autophagy inhibitors in C6/36 cells in terms of their lack of toxicity in all tested 
concentrations. Additionally, we were able to determine a suitable range of concentrations 
for both chemical compounds that successfully inhibited autophagy (wortmannin= 5-20 µM, 
l-asparagine= 10-20 mM).  
In the case of wortmannin, the concentrations tested in our study were between 1-20 µM, 
and this range was higher than most of the previous research on wortmannin as an 
autophagy inhibitor, where concentrations ranged between 10 nM-1 µM (116, 120, 148, 
161, 170, 173, 174). With regards to C6/36 cells, wortmannin has been previously used to 
inhibit autophagy at 10 µM and this was within the suitable concentration observed in our 
study (87). While little is known about the suitable upper limit of wortmannin concentration 
in insect cells, one study on Hela cells has suggested that 50 µM may induce cell death 
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(162). In conclusion, from the findings of this study wortmannin between 5-20 µM has been 
observed to be a suitable autophagy inhibitor for C6/36Wp cells.  
From the results of this chapter, while l-asparagine has been found to be non-toxic in all 
tested concentrations, autophagy inhibition was only achieved between 10-20 mM. Other 
studies have also achieved successful autophagy suppression at similar concentrations using 
rat hepatocytes (123, 125). Moreover, previous research conducted on other amino acids 
(for example histidine, leucine and glutamine) acting as autophagy inhibitors, whether 
combined or alone, have also recorded their inhibitory effect through lysosomal dysfunction 
in higher concentrations (125, 175-177).  
In this study, we used rapamycin as a control for autophagy activation, alone or combined 
with different autophagy inhibitors. The use of rapamycin is well documented as a promoter 
of autophagy and has been used in previous studies to assess autophagy inhibitors, 
including 3-ma and wortmannin (178-181). Voronin et al. (87) used rapamycin at 5 µM to 
activate autophagy in both B. malayi worms and C6/36 mosquito cells (infected and 
uninfected with Wolbachia). In addition, the same study assessed autophagy promotion 
through nutrient starvation, where serum deprivation in C6/36Wp cells activated 
autophagy. The potential of using other means of autophagic induction are described in 
more detail in Chapter 3.  
An observation worth mentioning in our immunofluorescence experiment using LC3B-II for 
the inhibitory effect of l-asparagine when combined with rapamycin was that it did not 
provide a statistically significant result compared to rapamycin alone. Previous research has 
also found that levels of LC3B-II when analysing late stage autophagy inhibitors have 
presented similar findings to our observations (147). A proposed cause of this is due to the 
lack of generation of autophagosomes and autophagic degradation was inhibited by l-
asparagine (a late stage autophagy inhibitor) (147). Conversely, the use of p62 in our study 
provided a more conclusive and expected result for l-asparagine combined with rapamycin.  
While there are gaps in the current knowledge of the role of amino acids (such as l-
asparagine) in the autophagy inhibition cascade, it has been found that rapamycin and 
amino acids influence mTORC1 in opposite directions. Meijer et al. (128) have proposed that 
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in addition to disrupting the delivery of autophagosomes to fuse with lysosomes, amino 
acids may also activate mTORC1.  
The use of more than one method in this research to measure autophagic inhibition is the 
optimum approach and has been recommended in the literature. While there is no “gold 
standard” method to measure autophagic activity, the two methods used in this research, 
immunofluorescence and western blot, have been widely proposed as suitable and valid 
methods (98, 106, 133, 152).  
There are two important points worth mentioning with regards to the protein markers 
(LC3B and p62) used for western blot in our study. First, in our interpretation of LC3B in 
western blot, only LC3B-II was used to analyse autophagic inhibition (blocking 
autophagasomal formation) while LC3B-I remained unchanged in all treatment groups. 
Previous studies have also commented on the unreliable role of LC3B-I in measuring 
autophagic activity in certain conditions or cell types (132, 147). Second, while p62 in 
mammalian cells has a protein molecular weight of 62 kDa, it has been observed to have a 
higher molecular weight in insect cells at 80-100 kDa (98, 154, 156). This correlates with our 
findings for the bands obtained in western blot for p62, which were observed at ~80 kDa.  
An important limitation in our western blot experiments is that we were unable to quantify 
band intensity (densitometry). This was due to the occurrence of two bands expressed by 
the LC3B antibody, which were close in terms of their molecular weight on the SDS-PAGE 
gels (131). Therefore, attempting to quantify these bands using ImageJ software may 
present inaccurate results. 
In conclusion, we were able to determine two autophagy inhibitors, wortmannin and l-
asparagine, that have successfully inhibited autophagy in C6/36Wp cells without affecting 
cell viability and growth. In the upcoming chapters both wortmannin and l-asparagine will 
be used for their autophagic inhibitory roles in order to study the main aim and objectives 
of our research.  
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Chapter 3 Monitoring and measuring antibiotic-induced autophagy 
3.1 Chapter overview: 
In this chapter I will present a series of experiments to examine autophagic induction by 
different classes of antibiotics on various cell lines (both insect and mammalian cells) and B. 
malayi. The chapter will start with a brief background section of the previous literature 
involving autophagy activation, through chemical, metabolic and physiological methods. 
This will be followed by a literature review of studies examining antibiotic-induced 
autophagy. As previously noted, autophagy as a concept was covered in detail in Chapter 1, 
while the chemical inhibition of autophagy was discussed in Chapter 2 of this thesis.  
Four sets of experiments are presented in this chapter. In the first group of experiments, 
autophagy activation was monitored using eight different antibiotics from five diverse 
classes (doxycycline, rifampicin, moxifloxacin, sparfloxacin, levofloxacin, ciprofloxacin, 
amoxicillin and streptomycin) in four different cell lines and nematodes: Aedes albopictus 
C6/36 cells (and C6/36Wp), Spodoptera frugiperda (SF9) cells, Brugia malayi microfilariae, 
Human monocytic leukaemia (THP-1) cells and Madin-Darby Canine Kidney (MDCK) cells. In 
the second set of experiments, three highly specific anti-Wolbachia agents recently 
prioritised by the A-WOL consortium (TylAMacTM, AWZ1066S and fusidic acid) were tested 
in C6/36 cells for their autophagy activation. The third and fourth group of experiments 
examined autophagic induction of the same eight antibiotics mentioned above to 
investigate concentration-dependency and the timeframe for activation. 
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3.2 Background 
3.2.1 Autophagy induction: environmental, physiological, and chemical  
Numerous factors ranging from environmental, physiological, and chemical sources may 
influence and induce autophagy in different cells and tissues. This upregulation can be 
measured using the same experimental techniques described in Chapter 2 for monitoring 
and measuring autophagy inhibition.   
Basal autophagy has been observed to naturally occur at low levels in almost all species, 
including humans, and has been widely described in the literature. There is evidence to 
suggest that basal autophagy may provide a benefit to organisms through maintaining their 
internal homeostatic environment (106, 182, 183). An example of how this might be 
achieved is through its regulation of accumulated damaged proteins and eliminating 
dysfunctional cellular organelles (91, 184-186). In Drosophila species, basal autophagy can 
play a role in targeting damaged mitochondria to ensure the survival of the organism (187). 
Starvation and nutrient depletion 
Modification of environmental and physiological conditions can influence the induction of 
autophagy in various organisms. These environmental and physiological stimuli can be 
intracellular or extracellular in their origin (99, 188). One of the commonest stress stimuli 
that can induce macroautophagy is starvation, which can occur naturally or be achieved 
experimentally by energy or nutrient withdrawal (189). Examples of essential nutrients and 
elements that have been observed to induce autophagy when depleted include amino acids, 
nitrogen, growth factors, glucose, carbon, oxygen and sulphate (92, 190-192). Experiments 
have observed that depletion of amino acids result in the highest starvation-induced 
autophagy (88, 193, 194). Autophagy induction through nutrient starvation mostly occurs 
through an mTORC1 dependent manner, but can also occur independently of mTOR for 
certain nutrients, such as amino acids (92, 195-197).  
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Environmental stimuli: Oxidative stress, hypoxia, acidic pH 
A second example of a stimuli that can activate autophagy is reactive oxygen species (ROS) 
formation. These are molecules that contain a reduced form of oxygen, such as peroxide 
compounds, superoxide and hydroxyl radicals (198). ROS are mainly generated 
intracellularly by mitochondria through certain conditions which include nutrient deficiency, 
resulting in an increase ATP consumption and hence ROS formation (199). Due to their link 
to mitochondria, it is believed that chronic damage to these organelles could potentially 
lead to an increase in ROS formation. This is referred to as mitophagy (200, 201). A lesser 
studied method of ROS formation, specifically superoxide production, is generated by 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 2 (NOX2), occurring on the 
surface of macrophages and neutrophils following microbial infection. When autophagy is 
induced in this manner it is referred to as xenophagy (198, 202, 203).  
Hypoxia is recognised as an important stimulus for autophagic induction, which can occur to 
due ROS accumulation (199). This can be achieved through ATP reduction in hypoxic 
conditions, in turn increasing AMP-activated protein kinase (AMPK), thereby inactivating 
mTORC1 and inducing autophagy. Hypoxia can also influence autophagic induction by 
activating hypoxia induced factor-1 alpha (HIF-1a). Activation of HIF-1a results in the 
inhibition of mTORC1 by the inhibitory effect of hypoxia responsive genes on Ras homolog 
enriched in brain (Rheb) guanosine triphosphate enzymes (GTPase), hence inducing 
autophagy (92, 99, 189, 204). Hypoxic conditions can also occur due to the presence of 
certain types of cancer, which could potentially lead to an increase in autophagic activity. In 
the presence of hypoxia, cancer cells could hijack the autophagy cascade in order to provide 
essential nutrients for tumour growth (205-208). 
A final environmental factor that can influence autophagy induction is the occurrence of 
acidic pH conditions. Despite the evidence documenting the role of a low pH to be linked 
with other autophagy inducers, such as hypoxia, nutrient starvation and ROS, recent 
evidence has shown that acidic pH alone may induce autophagy (209-211). This was 
observed experimentally in osteoblastic cells, where acidic media directly promoted 
autophagy in the absence of other environmental stimuli (209). Moreover, exposing 
melanoma cells to acidic media induced autophagy in an mTOR dependent manner (210). 
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Autophagy induction by microorganisms 
While certain microorganisms can inhibit autophagy, as previously discussed in Chapter 2, 
there are also several that can induce autophagy within a host. From a general perspective, 
intracellular bacteria may induce autophagy in order to seize nutrients from host cells 
produced through autophagy to ensure their own survival (104, 188). One example of this is 
observed in Anaplasma phagocytophilum, which can promote autophagosome formation by 
secreting the Anaplasma translocated substrate 1 (Ats-1) effector, resulting in an increase in 
autophagic influx (188, 212). Certain bacteria may also form intracellular vacuoles that 
accumulate autophagy specific markers, thereby promoting autophagy (188). Examples of 
such vacuole forming bacteria include Yersinia species, such as Y. pseudotubeculosis and Y. 
pestis, Coxiella burnetii, Brucella abortus and Legionella pneumophila (188, 213-219).  
In the case of Staphylococcus aureus infection, there is evidence to suggest that toxins 
secreted by the bacteria may increase autophagic activity by influencing Atg5 and possibly 
participating in the completion of autophagosomes (188, 220, 221). Similarly, in parasitic 
infections, for example Toxoplasma gondii, autophagy can be induced through activating 
Atg5 in human cell lines (222).  
With regards to viral infections, both RNA and DNA viruses have been found to upregulate 
the autophagic pathway. For instance the RNA viruses; poliovirus, dengue virus, coronavirus 
and rhinovirus and the DNA virus, Epstein-Barr virus, have been shown to influence 
autophagic induction in order to promote viral replication (223-225). .  
Previous studies on Wolbachia have shown the induction of autophagic activity in Brugia 
malayi wBm, Aedes albopictus wAlbB and Drosophila melanogaster wMelPop (87), which is 
particularly upregulated during rapid population expansion and is a key regulator of 
Wolbachia populations. In arthropods, Le Clec'h et al. (226) observed that horizontal 
transfer of Wolbachia from Armadillidium vulgare transfected into another host, Porcellio d. 
dilatatus, can activate autophagy in the new host. This activation of autophagy resulted in 
disrupting the central nervous system of the new host.  
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Chemical inducers of autophagy 
Chemical inducers may activate autophagy through inhibiting mTOR. An example of this is 
Torin1, which is defined as a “selective ATP-competitive small molecule mTOR inhibitor” 
(227). Torin1 affects both mTORC1 and mTORC2 (227, 228). A more recent discovery is that 
of Torin2, that has been shown to have similar but more efficient pharmacological 
properties than Torin1, as well as having an additional function of inhibiting 
phosphatidylinositol 3-kinases (PI3Ks). Hence, Torin2 produces a stronger autophagic 
induction than its predecessor (100).  
Certain chemicals can induce autophagy by specifically inhibiting mTORC1 and not mTORC2, 
for example rottlerin, amiodarone and niclosamide. In the case of rottlerin, the inhibition of 
mTORC1 is achieved through the presence of tuberous sclerosis complex 2 (TSC2), while this 
has not been observed for the other two chemicals (229, 230).  
Lithium, a chemical used therapeutically to treat bipolar disorder, is described in the 
literature as an mTOR-independent inducer of autophagy (231, 232). It activates autophagy 
by reducing inositol levels through the blocking of inositol monophosphatase (IMPase). 
Similar observations were also documented in other psychotropic drugs, such as sodium 
valproate and carbamazepine, where the former was found to decrease inositol 1,4,5-
trisphosphate (IP3) in addition to its effect on inositol (229, 233).  
Several agents belonging to L-type calcium channel blockers, including loperamide and 
verapamil, are presented in the literature as autophagy inducers. This induction is achieved 
by their ability in decreasing intracellular calcium concentrations thereby inhibiting calpains, 
a form of cysteine proteases specific to calcium (229, 234). 
Other chemicals that have proven autophagic inducing properties include minoxidil, 
resveratrol, spermidine and trehalose (100). 
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Antibiotic-induced autophagy 
Two antibiotics used in the treatment of Mycobacteria tuberculosis, isoniazid and 
pyrazinamide, were found to induce autophagy in macrophages infected with the bacteria. 
The proposed mechanism of this induction was believed to have occurred through the 
involvement of ROS production, as well as increase in calcium levels and AMPK activation 
(235). In a second study another anti-TB drug, rifampicin also activated autophagy by 
targeting mitochondria and initiating their degradation (236). Additionally, rifampin was also 
observed to initiate ROS accumulation in M. tuberculosis, an important inducer of 
autophagy (237).  
With regards to the tetracycline class of antibiotics, three have been identified as possible 
autophagy inducers. The first of these to be recognised was tigecycline, which upregulated 
autophagy in an mTOR dependent manner in human gastric cancer cells (238). Similar 
autophagic inducing characteristics were also observed for minocycline, which enhances 
autophagy in a number of cell types, including cardiomyocytes (239), neurons (240) and 
vascular endothelial cells (241), but can also suppress autophagy in other systems (242, 
243). Another tetracycline antibiotic, doxycycline, which was used in the experiments 
conducted in this chapter, was found in a previous study to induce autophagy, possibly 
through its known effect on mitochondria and ROS formation (244). Both doxycycline and 
minocycline cause mTOR inhibition in hepatocyte cell lines, which may contribute to 
tetracycline-induced hepatoxicity adverse effects (245).   
Several other antibacterial agents have been described as potential autophagy inducers, 
including ohmyunsamycin, which activates autophagy by influencing AMPK pathway (246).  
Rapamycin 
One of the commonest used autophagy inducers is the macrolide and immunosuppressant 
agent rapamycin, sometimes referred to as sirolimus. Rapamycin acts by inhibiting mTORC1 
through binding with FK506-binding protein 12 kDa (FKBP12), leading to the stability of 
regulatory associated protein of mTOR (Raptor) (100, 118, 227, 229). While rapamycin 
mainly inhibits mTORC1, there is evidence that prolonged exposure may also inhibit 
mTORC2 in certain cell lines (247). Due to its widespread use and autophagy inducing 
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characteristics in many different cell lines, rapamycin was selected as an autophagy inducing 
control (positive control) in the experimentation performed in this chapter (87, 178, 180, 
181).  
An analogue of rapamycin, CCI-779 (or temsirolimus), has shown to have a similar 
autophagic inducing effect. CCI-779 has gained prominence recently due to its potential use 
in the treatment of solid tumours (118, 248). Interestingly, while CCI-779 operates in the 
same manner as rapamycin by inhibiting mTORC1, it has been observed that in higher 
concentrations it may induce autophagy independently of FKBP12 (248). Recent studies 
have examined safer approaches in delivering rapamycin, referred to as small molecule 
enhancers of rapamycin (SMERs) in an mTOR-independent manner. SMERs possibly achieve 
their autophagic inducing role through Atg5. (118, 229, 249).  
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3.2.2 Experimental justification  
For the experiments in this chapter of the thesis, eight antibacterial antibiotics were pre-
selected: doxycycline, rifampicin, moxifloxacin, sparfloxacin, levofloxacin, ciprofloxacin, 
amoxicillin, and streptomycin. The choice of the four anti-Wolbachia drugs (doxycycline, 
rifampicin, moxifloxacin, and sparfloxacin) was based on their known role in eliminating 
Wolbachia (26, 67, 250-253). The remaining four antibiotics were pre-selected from 
different classes due to them not exhibiting efficacy against Wolbachia (55, 250, 252, 253). 
Rapamycin and wortmannin were used as controls in the experiments of this chapter due to 
their known effects in different cell lines as autophagy inducer and autophagy inhibitor, 
respectively (254-257).  
In the first group of experiments, the eight previously mentioned antibiotics were examined 
in terms of their autophagy inducing effects on different insect and mammalian cell lines 
and the filarial nematode, B. malayi. All antibiotics were tested at 5 µM (the gold standard 
set by A-WOL consortium for the concentration of doxycycline in vitro testing) in all cell lines 
and nematodes. These group of experiments were performed using immunoblotting assay 
(western blot) and confocal microscopy (for C6/36 and C6/36Wp cells only). To further 
confirm our findings, concentrations of 1 µM and 10 µM of the eight antibiotics tested were 
assessed for autophagy activation in C6/36 and C6/36Wp cells using western blot assay. 
The second group of experiments were performed on uninfected and infected mosquito cell 
line C6/36 with Wolbachia (wAlbB) treated with three anti-Wolbachia agents that have 
recently been candidate-selected by the A-WOL consortium: TylAMacTM (a newly discovered 
tylosin analogue), AWZ1066S ( a newly synthesised thienopyrimidine/quinazoline anti-
Wolbachia agent), and fusidic acid (a repurposed antibiotic) (81, 82, 86). Autophagy 
activation for these agents was assessed using immunoblotting assay (western blot).  
The third and fourth set of experiments were conducted on infected mosquito cell line 
C6/36Wp with Wolbachia (wAlbB), treated with the same eight pre-selected antibiotics 
(mentioned above) at different concentrations and time-points. The rationale of testing on 
different concentrations and time-points of antibiotics was to determine the effect it may 
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have on measurable autophagic activity (measured using confocal microscopy and western 
blot) as well as on Wolbachia load (quantified by qPCR).  
In this chapter, we have monitored autophagic activity using two widely used autophagic 
markers (LC3B and p62). Previous research has recommended the use of more than one 
marker when examining autophagic influx (106, 131, 133). 
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3.3 Materials and methods: 
For more details on the materials used in the experiments conducted in this chapter please 
refer to the Appendix B Table B.1 section of this thesis.  
3.3.1 In vitro culture of cell lines and nematodes 
i) Wolbachia-free mosquito cell line C6/36:  
Mosquito cells (Aedes albopictus clone) were purchased from European Collection of 
Authenticated Cell Cultures (ECACC) (clone C6/36, 89051705). 
For the maintenance of Wolbachia-free C6/36 cells, the same preparation and cell sub-
culture procedures were followed as previously described in Chapter 2.3.1. 
ii) Mosquito cell line C6/36Wp cells with wAlbB:  
The materials and preparation used for mosquito cell line C6/36Wp infected with wAlbB 
were the same as previously described in Chapter 2.3.1.  
iii) Brugia malayi microfilariae (mf):  
B. malayi life cycle is maintained at Liverpool School of Tropical Medicine (LSTM), UK and 
were originally obtained from TRS Laboratories, United States (US).  The mf stage of the 
parasite was extracted from the peritoneal cavity of gerbils, this was performed by Mr 
Andrew Steven and Mr John Archer, Department of Tropical Disease Biology at LSTM, UK 
following the same protocol and procedure as described by Griffiths et al. (258). Mf worms 
were cleaned and filtered using PD-10 Desalting columns (GE Healthcare) using RPMI 1640 
culture media (Gibco, Thermo Fisher Scientific) containing 2 mM L-glutamine, 25 mM HEPES, 
100 U/ml penicillin-streptomycin (Thermo Fisher Scientific) and 2.5 mg/ml amphotericin B 
(Thermo Fisher Scientific) at 37◦C.  
After filtration, mf were centrifuged at 400 g for 5 minutes to form a pellet. The pellets were 
resuspended in fresh RPMI 1640 culture media supplemented with L-glutamine, HEPES and 
antibiotics (as mentioned above), and 10% FBS (Thermo Fisher Scientific), which will be 
referred to as RPMI media in this chapter. Mf were counted using light microscopy, where 
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an average of three readings were taking per 10 µl of 1 ml media containing mf. 10,000 mf 
(for western blot) were cultured in 200 µl media containing antibiotics at the desired 
concentrations per well of 96-well plate with a clear flat-bottom (Thermo Fisher Scientific) 
and incubated at 37◦C in 5% CO2.  
iv) Spodoptera frugiperda derived cell line (SF9): 
Cryopreserved Spodoptera frugiperda (known as the fall armyworm) SF9 cells (Gibco® Sf9, 
Thermo Fisher Scientific) were obtained from Dr. Abdulwahab Khashab, Tropical Disease 
Biology Department, LSTM, UK. SF9 cells were defrosted and diluted in SF-900 II media 
(Gibco®, Thermo Fisher Scientific), centrifuged at 400 g for 5 minutes and resuspended in 13 
ml Sf-900 II media and cultured in a 75- cm2 flask (Thermo Fisher Scientific) at 2.3 x106 
cells/ml.  
The culture media used to maintain SF9 cells was supplemented with 20% FBS, 1% non-
essential amino acids (Sigma Aldrich) and 2% Tryptone phosphate broth (Sigma Aldrich) and 
flasks were incubated at 26◦C. Cells were sub-cultured weekly using cell scrapers (Nunc, 
Thermo Fisher Scientific) at a split ratio of 1:4.  
v) Human monocytic leukaemia cell line (THP-1): 
Cryopreserved THP-1 cells were provided by Professor Giancarlo Biagini’s group, with the 
help of Dr Shaun Pennington and Mr. Julio Furlong-Silva, Tropical Disease Biology 
Department at LSTM, UK. Cryopreserved cells were dissolved in a water bath at 37◦C, 
washed with RPMI 1640 media (2 mM L-glutamine, 10% FBS, 5% penicillin-streptomycin and 
amphotericin B) and centrifuged at 400 g for 5 minutes to form a pellet. Pellets were 
resuspended in media, cultured at 3 x105 cells/ml in suspension (vertical positioned) in a 75-
cm2 flask at 37◦C with 5% CO2. Cells were sub-cultured twice a week by removing 10 ml cell 
suspension and replacing it with fresh culture media. 
vi) Madine-Darby canine kidney epithelial cells (MDCK): 
Cryopreserved MDCK epithelial cells (ECACC) were supplied by Ms. Amy Marriott, Tropical 
Disease Biology Department at LSTM, UK. Cryopreservation media was removed by 
centrifugation of cells at 400 g for 5 minutes in Eagle’s Minimum Essential Medium (EMEM) 
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media (Sigma Aldrich) supplemented with 10% FBS, 5% penicillin-streptomycin and 
amphotericin B. Cells were cultured at 1 x105 in 75-cm2 flasks and incubated at 37◦C in 5% 
CO2. A split ratio of 1:4 was performed when cells reached a confluency of approximately 
80%.  
When MDCK cells were ready to sub-culture, they were washed once while cells were 
adhered at room temperature with phosphate-buffered saline (PBS) (Sigma Aldrich). After 
washing, 10 ml of trypsin/EDTA (Sigma Aldrich) was added to culture flasks for 5 minutes for 
cell detachment followed by the addition of an equal amount of fresh media in order to 
neutralise the trypsin/EDTA solution. Collected cells were later centrifuged and supernatant 
was removed and replaced with fresh media.  
 
3.3.2 Western blot analysis 
The western blot protocol followed for all tested cells and nematodes in this experiment 
was previously described in Chapter 2.3.5. Any differences for the experimentation in this 
chapter are mentioned below. 
As in Chapter 2, we used two autophagic protein markers for immunoblotting assay to 
monitor autophagic activation: LC3B and p62. The method in which these two markers are 
expressed and their interpretation within the autophagic cascade is presented in Figure 3.1. 
Three controls were used for western blot analysis: DMSO (as a vehicle control), rapamycin 
at 5 µM (as a positive control for autophagy activation) and wortmannin at 10 µM (as a 
negative control for autophagy inhibition). All three compounds were purchased from Sigma 
Aldrich.  
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Protein sample preparation for different cell line/nematodes: 
i) Insect cell lines: Mosquito cell line C6/36 cells (C6/36Wp and Wolbachia-free) and SF9 
cells  
Following the same protocol mentioned in Chapter 2.3.5, cells were treated for three days 
with the following antibiotics at two different concentrations (1 and 10 µM for C6/36 cells - 
infected or uninfected with wAlbB) and at one concentration (5 µM for SF9 cells): 
doxycycline, rifampicin, moxifloxacin, sparfloxacin, levofloxacin, ciprofloxacin, amoxicillin 
and streptomycin (all from Sigma Aldrich). 
All antibiotics and chemical agents used in this experiment were dissolved in DMSO. Protein 
expression of two autophagy markers LC3B (rabbit antibody from Novus) and p62 (rabbit 
antibody from Cell Signaling) diluted at 1:1000 in 5% non-fat milk/TBS-T and 5% BSA/TBS-T, 
respectively. Secondary antibodies conjugated with horseradish peroxidase (HRP) (goat anti-
rabbit from Cell Signaling diluted at 1:5000 in 5% non-fat milk in TBS-T blocking buffer for 
LC3B, and monkey anti-rabbit from GE Healthcare diluted at 1:10,000 in PBS-T for p62) were 
added and measured against beta actin (loading control) (Cell Signaling). 
Pre-clinical candidates and re-purposed antibiotic from the A-WOL consortium 
Three drugs identified by the A-WOL consortium were also tested for their autophagy 
activation using mosquito cells C6/36 (infected and uninfected with wAlbB) for three days at 
their pre-determined 10x EC50 concentrations (concentrations that demonstrated 50% of 
the maximal response of drugs) in mosquito cells and nematodes against Wolbachia: 
TylAMacTM (at 7 nM), AWZ1066S (at 2390 nM) and Fusidic acid (at 2890 nM). 
ii) B. malayi mf larval worms 
The same treatment groups for the eight antibiotics mentioned above for insect cells were 
tested in mf at one concentration (5 µM) for three days. 
Microfilariae (mf) were collected and filtered using PD-10 columns. 10,000 mf/well were 
cultured in flat-bottom 96-well plate in 200 µl RPMI 1640 media. At day 3, mf were pooled 
out of a total of 4 wells to yield the adequate amount of protein required for 
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immunoblotting assay. All worms were lysed with 50 µl Tissue Extraction Reagent 
(Invitrogen, Thermo Fisher Scientific). Tissue lysates were homogenised using a Pellet pestle 
motor (Kimble) and incubated for 5 minutes. All lysates were centrifuged at 13,000 g for 2 
minutes, and supernatant were transferred to new tubes. Following this step, the rest of the 
western blot procedure is as described in Chapter 2.3.5.  
The primary antibodies used for B. malayi worms were rabbit antibodies against LC3B and 
p62 (both from Cell Signaling) at a dilution of 1:1000 in 5% BSA in TBS-T and secondary 
monkey anti-rabbit conjugated with HRP (from GE Healthcare) diluted at 1:10,000 in PBS. 
iii) Mammalian cell lines: THP-1 cells and MDCK cells 
The same treatment groups for the eight antibiotics mentioned above for insect cells were 
tested at one concentration (5 µM) for two different time-points: day 3 and day 7 of 
treatment.  
THP-1 cells were mixed manually prior to centrifugation at 400 g for 5 minutes. MDCK cells 
were detached using trypsin/EDTA solution in 25-cm2 flasks prior to centrifugation. For both 
mammalian cells, the same primary and secondary antibodies as mf were used.  
 
3.3.3 Immunofluorescence staining assay – Confocal laser scanning microscopy  
For this experiment’s C6/36 cell preparation, fixation/permeabilisation, primary and 
secondary antibody incubation/staining and slide mounting, the same procedure as that 
described in Chapter 2.3.4 was followed for the confocal microscopy.  
C6/36 mosquito cells infected or uninfected with Wolbachia (wAlbB) were treated for 3 days 
with eight antibiotics at a range of selected concentrations: between 0.125-20 µM for 
rifampicin, moxifloxacin, sparfloxacin, levofloxacin, ciprofloxacin, amoxicillin and 
streptomycin and between 0.125-10 µM for doxycycline (previously determined to be toxic 
at 20 µM in C6/36Wp cells by A-WOL consortium). The range of concentrations for all 
antibiotics was selected where the upper limit did not exceed toxic concentrations in C6/36 
cells, previously determined by members in the A-WOL consortium (unpublished data). 
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Starting from the highest concentration, 6 concentrations were titrated for each antibiotic, 
in order to determine the impact of concentration response on Wolbachia reduction and 
autophagy activation.  
DMSO (as a vehicle control), rapamycin at 5 µM (positive control for autophagy activation) 
and wortmannin at 10 µM (negative control for autophagy inhibition) were used as controls 
for this experiment. All compounds were purchased from Sigma Aldrich and diluted in 
DMSO.  
As in Section 3.3.2 for western blot, the same two autophagic markers were used for the 
confocal microscopy in this chapter: LC3B and p62 (both primary antibodies are generated 
in rabbit). For the expression of these markers and interpretation within the autophagic 
pathway please refer to Figure 2.3. In addition to autophagic antibodies, Wolbachia was 
stained with nucleic acid stain, syto11 and cell nuclei were counter-stained with DAPI. This 
was also used to confirm Wolbachia absence from uninfected C6/36 cells.  
Quantification analysis for autophagy marker expression was determined by measuring the 
number of LC3B-II (Invitrogen) and p62 (Cell Signaling) puncta formation per cell. The total 
number of puncta/cell was then graphed and expressed as percentages, where an increase 
and decrease in percentage indicated autophagic activity for LC3B-II and p62 puncta, 
respectively. Using confocal microscopy/Zen software (Zeiss LSM 880), LC3B-II and p62 
positive cells (representing autophagic marker presentation) were quantified across 3 
different sections of the slides and compared to the DMSO control. Each area covered a 
minimum of ≥ 50 cells as a threshold for further analysis.  
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3.3.4 Quantitative polymerase chain reaction (qPCR) - C6/36 cells: 
C6/36 cells were prepared as described in Section 3.3.1. In a 96-well plate, C6/36 cells 
(uninfected and infected with wAlbB) were seeded at 10,000 cells/ml for a total volume of 
200 µl Leibovits-15 (L-15) media.  
For antibiotic treatment prior to qPCR analysis, two methods were performed depending on 
the experimental variable, as described below: 
i)  Concentration -based antibiotics experiment  
C6/36Wp cells were exposed to pre-selected antibiotics for 3 days at different 
concentrations: Between 0.125-10 µM for doxycycline, and between 0.125-20 µM for 
rifampicin, moxifloxacin, sparfloxacin, levofloxacin, ciprofloxacin, amoxicillin and 
streptomycin. DMSO was used as a vehicle control, while rapamycin at 5 µM (autophagy 
activator) and wortmannin at 10 µM (autophagy inhibitor) were used in this experiment to 
monitor the effect of autophagy activation or inhibition on Wolbachia titre. For every tested 
concentration in each compound, three biological repeats were performed. All compounds 
were diluted in DMSO.  
ii) Time-course experiment 
C6/36Wp were treated with the following antibiotics: doxycycline, rifampicin, moxifloxacin, 
sparfloxacin, levofloxacin, ciprofloxacin, amoxicillin and streptomycin at 5 µM for different 
time-points: Day 0, 1, 3, 5 and 7. DMSO (vehicle control), rapamycin at 5 µM (autophagy 
activator) and wortmannin at 10 µM (autophagy inhibitor) were used along the control. For 
every tested time-point for each compound, three biological repeats were performed. 
At day 0, 1, 3, 5 and 7 samples were taken for DNA extraction and assessed for their 
Wolbachia titre using qPCR.  
iii) Wolbachia detection in C6/36 and SF9 cells 
qPCR technique was used to confirm the absence of Wolbachia in both insect cells: C6/36 
and SF9 cells used in the experiments of this chapter. For SF9 cells, 10,000 cells/ml were 
seeded in a 96-well plate for a total volume of 200 µl SF9-II media.  
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DNA lysis and extraction – C6/36 cells 
Using QIAmp mini DNA kit (Qiagen) to extract genomic DNA from cultured cells, the media 
was removed from 96-well plates and placed into 1.5 ml microtubes. 35 µl Proteinase K and 
100 µl ATL tissue lysis buffer (supplemented with kit) were added to all microtubes and 
incubated overnight in a water bath set at 56◦C. On the following day, microtubes were 
removed and 200 µl AL lysis buffer (supplemented with kit) was added. Next, all tubes were 
placed back in the water bath at 70◦C for 10 minutes to allow for adequate cell lysis. 200 µl 
absolute ethanol (Sigma Aldrich) was added to tubes and incubated for 5 minutes at room 
temperature for DNA precipitation. All cell lysates were transferred to mini spin columns 
(provided by the DNA kit) and centrifuged at 5000 g for 1 minute. Following centrifugation, 
two washing steps were performed by adding 500 µl of AW1 followed by 500 µl of AW2 
washing buffer (supplemented with kit). 100 µl AE elution buffer (supplemented with kit) 
was added into each mini spin column. Columns were centrifuged at 13,000 g for 5 minutes 
and purified eluted DNA was collected and stored at -20◦C for qPCR analysis. 
qPCR Analysis: 
Extracted DNA was amplified using specific primers against the 16s rRNA Wolbachia gene 
normalised to Aedes albopictus 18s rRNA gene (forward and reverse primers sequence were 
designed by Integrated DNA Technologies (UK) see Appendix B Table B.3). In a total volume 
of 10 µl per reaction, a master mix was added into tested wells of the 384 well-plate 
(Biorad). In each reaction well, the master mix (8 µl) contained the following: 5 µl Ssofast 
EvaGreen Supermix (Biorad), 1 µl of forward primer (200 nM), 1 µl of reverse primer (200 
nM), 1 µl nuclease-free water (Thermo Fisher Scientific). Following this, 2 µl of the prepared 
extracted genomic DNA was added to the master mix.  
16s and 18s standards (Integrated DNA Technologies (UK) see Appendix B Table B.3) were 
diluted at 1:20 to form a stock of 5 x 108/µl (top standard), followed by a serial dilution at 
1:10 starting from 5 x 107/µl to 5 x 100/µl (standards). 1 µl of each prepared standard was 
added to 9 µl of master mix in duplicates into reaction wells in order to obtain the number 
of gene copies from unknown samples. Three technical repeats were performed for each 
biological sample.  
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Using CFX384 Real-Time System with C1000 Thermal Cycler (Biorad), the following cycling 
conditions were applied for this experiment: 15 minutes at 95◦C, 40 cycles (and 35 cycles for 
uninfected cells) for 15 seconds at 94◦C, 30 seconds at 55◦C, 15 seconds at 72◦C and a 
melting curve between 50-95◦C. Gene copy numbers were normalised and expressed as a 
16s:18s ratio. 
 
3.3.5 Statistical analysis 
Statistical analysis in this chapter was performed for continuous variables for confocal 
immunofluorescence assay and qPCR using independent sample Student’s t-test. Statistical 
significance was at p ≤ 0.05. For all sections of the statistical analysis in this chapter, we used 
GraphPad Prism version 7. 
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3.4 Results  
3.4.1 Measuring antibiotic-induced autophagy in different cell lines and nematodes 
using western blot 
The results of the expression of two autophagic markers LC3B and p62 using western blot to 
examine autophagic induction of the eight tested antibiotics from diverse classes in 
different cell lines and nematodes are presented in Figures 3.2 to 3.5 (for the full 
immunoblots, please refer to the Appendix A Figure A3-A6).  
For insect cells and mf, LC3B protein was expressed in two distinct bands: LC3B-I (~16 kDa) 
and LC3B-II (~14 kDa). The difference in molecular weight between LC3B-I and LC3B-II and 
its significance in protein expression was previously described in Chapter 2.4.4 in insect 
cells. Whereas for mammalian cells, due to the relatively close molecular weight between 
LC3B-I and LC3B-II, their protein expression is presented as two fused bands, due to the high 
rate of conversion of LC3B-I to LC3B-II, making the latter more intense (131). 
In mammalian cells and mf, p62 protein expression was represented at ~62 kDa by a single 
band. As previously discussed in Chapter 2.4.4 and observed in previous studies on insect 
cells, p62 expression in C6/36 and SF9 cells was observed at ~80 kDa. 
For all tested cells and nematodes, an increase in autophagic influx was indicated by an 
increase of expression of LC3B-II (indicating autophagosome formation) on the 
immunoblots. Conversely, a decrease in expression of p62 (increased autophagic 
degradation) indicated autophagy activation.  
In all immunoblots, DMSO was used as a vehicle control, representing the basal level of 
autophagy for all tested cells and nematodes. Rapamycin, a known autophagic inducer was 
used as a positive control, hence LC3B-II appeared prominent and p62 showed a reduced or 
absent expression. On the other hand, wortmannin and l-asparagine, the autophagy 
inhibitors we have previously tested successfully in Chapter 2, were used as negative 
controls in all immunoblots. These were expressed as a reduced (wortmannin) and 
prominent (l-asparagine) band of LC3B-II and a high intensity of p62 band for both 
inhibitors. Beta-actin (loading control) was represented at molecular size ~40 kDa.  
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3.4.1.1 Insect cells and nematodes  
i) C6/36Wp and C6/36 cells 
In C6/36Wp cells (Figure 3.2 A and B), all four anti-Wolbachia drugs tested at 1 µM 
(doxycycline, rifampicin, moxifloxacin and sparfloxacin), presented with a higher intensity of 
LC3B-II (Figure 3.2 A) and a reduced expression of p62 (Figure 3.2 B) compared to DMSO. 
When these antibiotics were tested at higher concentrations (10 µM), there appeared to be 
a concentration-dependent increase in intensity for rifampicin and moxifloxacin only. All 
four anti-Wolbachia agents appeared to express an increase in intensity of LC3B-II similar to 
that of rapamycin. In contrast, the antibiotics inactive against Wolbachia (levofloxacin, 
ciprofloxacin, amoxicillin and streptomycin) did not activate autophagy.  
Interestingly, the results for C6/36 cells (Figure 3.2 C and D) presented a similar picture to 
C6/36Wp (Figure 3.2 A and B). In the absence of Wolbachia, all anti-Wolbachia agents 
activated autophagy (Figure 3.2 C and D). The absence of Wolbachia in C6/36 cells was 
confirmed using qPCR (this was tested in C6/36 and SF9 cells and is presented in the 
Appendix A Figure A7). Conversely, the other tested antibiotics did not show any evidence 
of autophagic induction compared to DMSO. The ability of antibiotics to activate autophagy 
directly was more clearly observed in uninfected C6/36 cells, as this removes the Wolbachia 
induced autophagy as demonstrated in the DMSO controls.
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Figure 3. 1 Detection of LC3B and p62 expression for antibiotics from diverse classes in C6/36 cells using western blot.  
C6/36 mosquito cells A and B) infected with Wolbachia wAlbB C and D) Wolbachia-free cells were treated with: DMSO – vehicle control (lane 1), 
rapamycin – positive control (lane 2), wortmannin – early autophagy inhibitor (lane 3), l-asparagine – late autophagy inhibitor (lane 4), four anti-
Wolbachia antibiotics: doxycycline (lane 5-6), rifampicin (lane 7-8), moxifloxacin (lane 9-10), sparfloxacin (lane 11-12), and four different 
antibiotics: levofloxacin (lane 13-14), ciprofloxacin (lane 15-16), amoxicillin (lane 17-18), and streptomycin (lane 19-20) for 3 days. Reduced 
protein extracts of cells were loaded at 50 µg/40 ul per lane into 4-12% bis tris SDS-PAGE gels. Separated proteins were transferred into 
nitrocellulose membrane, blocked and incubated with primary and secondary antibodies. Western blot protein expression is presented in A and 
C) for rabbit anti-LC3B (LC3B-I at 16 kDa and LC3B-II at 14 kDa) and B and D) rabbit anti-p62 (at 80 kDa). A reference protein; mouse anti-beta 
actin was used as a control with a size of approximately 40 kDa.
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ii) Pre-clinical candidates and re-purposed antibiotic from the A-WOL consortium in 
C6/36Wp and C6/36 cells 
For all three tested agents, TylAMacTM, fusidic acid and AWZ1066S, LC3B-II expression was 
prominent compared to the DMSO control (Figure 3.3 A). The autophagic inducing 
capabilities of these three agents were further confirmed by the reduced expression of p62, 
especially when compared to DMSO (Figure 3.3 B). These findings for both autophagic 
markers were observed in C6/36Wp, as well as non-infected C6/36 cells.  
 
              
Figure 3. 2 Detection of LC3B and p62 expression for A-WOL selected candidates and 
repurposed anti-Wolbachia agents in C6/36 cells using western blot.  
Wolbachia-free C6/36 (lane 1-6) and infected C6/36Wp cells (lane 7-12) were treated with: 
DMSO – vehicle control (lane 1 and 7), rapamycin – positive control (lane 2 and 8), 
wortmannin – autophagy inhibitor (lane 3 and 9), TylAMacTM (lane 4 and 10), fusidic acid 
(lane 5 and 11), and AWZ1066S (lane 6 and 12) for 3 days. Reduced protein extracts of cells 
were loaded at 50 µg/40 ul per lane into 4-12% bis tris SDS-PAGE gels. Separated proteins 
were transferred into nitrocellulose membrane, blocked and incubated with primary and 
secondary antibodies. Western blot protein expression is presented in A) for rabbit anti-LC3B 
(LC3B-I at 16 kDa and LC3B-II at 14 kDa) and B) rabbit anti-p62 (at 80 kDa). A reference 
protein; mouse anti-beta actin was used as a control with a size of approximately 40 kDa.  
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iii) SF9 cells and B. malayi mf  
For both SF9 cells and B. malayi mf (Figure 3.4), a similar representation as C6/36 cells was 
observed with the induction of autophagy for all anti-Wolbachia drugs and an absence of 
activation for antibiotics that lack activity against Wolbachia.  
In summary, for all the tested insect cells and nematodes, the anti-Wolbachia antibiotics 
showed evidence of autophagy induction, as presented by the higher expression and lower 
intensity of LC3B-II and p62, respectively. This was also observed for Wolbachia-free C6/36 
and SF9 cells. In contrast, the antibiotics, which lack activity against Wolbachia (levofloxacin, 
ciprofloxacin, amoxicillin and streptomycin) did not activate autophagy.   
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Figure 3. 3 Detection of LC3B and p62 expression for antibiotics from diverse classes in SF9 cells and Brugia malayi mf using western blot.  
A and B) SF9 insect cells and C and D) B. malayi mf worms were treated with: DMSO – vehicle control (lane 1), rapamycin – positive control (lane 
2), wortmannin – early autophagy inhibitor (lane 3), l-asparagine – late autophagy inhibitor (lane 4), four anti-Wolbachia agents: doxycycline 
(lane 5), rifampicin (lane 6), moxifloxacin (lane 7), sparfloxacin (lane 8), and four different antibiotics: levofloxacin (lane 9), ciprofloxacin (lane 
10), amoxicillin (lane 11), and streptomycin (lane 12) for 3 days. Reduced protein extracts of cells were loaded at 50 µg/40 ul per lane into 4-12% 
bis tris SDS-PAGE gels. Separated proteins were transferred into nitrocellulose membrane, blocked and incubated with primary and secondary 
antibodies. Western blot protein expression is presented in A and C) for rabbit anti-LC3B (LC3B-I at 16 kDa and LC3B-II at 14 kDa) and B and D) 
rabbit anti-p62 (at 80 kDa for SF9 and 62 kDa for mf). A reference protein; mouse anti-beta actin was used as a control with a size of 
approximately 40 kDa. 
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3.4.1.2 Mammalian cells: THP-1 and MDCK  
In order to test whether the pattern of autophagy activation observed in insect cells and 
microfilariae was also a feature of mammalian cells, THP-1 and MDCK cells were exposed to 
the same antibiotics and autophagy marker expression was assessed at 3 days post-
exposure.  
For both THP-1 (Figure 3.5 A and B) and MDCK cells (Figure 3.5 C and D), LC3B expression 
showed a different pattern to that observed with insect cells and microfilariae. Due to the 
inconsistent pattern, we further tested both mammalian cells at 7 days post-exposure to 
confirm our findings in longer treatment periods.  
For THP-1 cells exposed to doxycycline and rifampicin there was no evidence of autophagy 
activation at either day 3 or 7 post-exposure. THP-1 cells exposed to moxifloxacin and 
sparfloxacin, did appear to show an up-regulation of LC3B-I and LC3B-II at day 3, but this 
upregulation did not continue until day 7, as evident from its similar expression to DMSO. 
Antibiotics without an activity against Wolbachia showed a pattern similar to controls with 
no evidence of autophagy activation. However, the apparent activation of LC3B for 
moxifloxacin and sparfloxacin was not reproduced in the expression of p62, which remained 
similar to control levels for all tested antibiotics, suggesting a lack of autophagy activation. 
With MDCK cells rifampicin, moxifloxacin and sparfloxacin induced the upregulation of LC3B 
at day 3 and 7, which was more intense for the fluroquinolones. Antibiotics lacking activity 
against Wolbachia showed expression levels similar to controls. As for THP-1 cells the 
expression of p62 did not replicate the patterns observed for LC3B and showed similar levels 
to controls for all tested antibiotics. 
101 
 
  
Figure 3. 4 Detection of LC3B and p62 expression for antibiotics from diverse classes in mammalian cells: THP-1 and MDCK using western blot.  
A and B) THP-1 and C and D) MDCK cells were treated with: DMSO – vehicle control (lane 1), rapamycin – positive control (lane 2), wortmannin – 
early autophagy inhibitor (lane 3), l-asparagine – late autophagy inhibitor (lane 4), four anti-Wolbachia agents: doxycycline (lane 5), rifampicin 
(lane 6), moxifloxacin (lane 7), sparfloxacin (lane 8), and four different antibiotics: levofloxacin (lane 9), ciprofloxacin (lane 10), amoxicillin (lane 
11), and streptomycin (lane 12) for 3 and 7 days. Reduced protein extracts of cells were loaded at 50 µg/40 ul per lane into 4-12% bis tris SDS-
PAGE gels. Separated proteins were transferred into nitrocellulose membrane, blocked and incubated with primary and secondary antibodies. 
Western blot protein expression is presented in A and C) for rabbit anti-LC3B (LC3B-I at 15 kDa and LC3B-II at 14 kDa) and B and D) rabbit anti-
p62 (at p62 kDa). A reference protein; mouse anti-beta actin was used as a control with a size of approximately 40 kDa. 
102 
 
3.4.2 Measuring antibiotic-induced autophagy in C6/36Wp and C6/36 cells using 
immunofluorescence staining assay  
To further validate our findings in western blot analysis, we examined autophagic induction 
in the same eight antibiotics using immunofluorescence staining assay in C6/36Wp followed 
by those for Wolbachia-free C6/36 cells. Cell-based images are presented at one selected 
concentration (5 µM, which is the gold standard concentration used by the A-WOL 
consortium for in vitro testing) treated for 3 days. We quantified the percentage of cells 
with positive LC3B-II and p62 puncta for the tested antibiotics to determine their statistical 
significance compared to the DMSO control. Confocal images of cells treated with 
antibiotics presented in this section were performed using the same two autophagy gene 
markers LC3B-II (conjugated with TRITC – red fluorescent puncta) and p62 (conjugated with 
TRITC – yellow fluorescent puncta). Hence, the increase in red fluorescence puncta is 
indicative of autophagic activation (high LC3B-II). On the other hand, the presence of low 
yellow fluorescence puncta represents autophagy induction due to p62 protein degradation. 
Green and blue fluorescence staining represent Wolbachia and cell nuclei, respectively. 
3.4.2.1 C6/36 cells infected with wAlbB  
All four anti-Wolbachia agents: doxycycline, rifampicin, moxifloxacin and sparfloxacin, 
appeared to show an increase in autophagic influx due to the increase in LC3B-II expression 
(Figure 3.6) and decrease in p62 fluorescence (Figure 3.7). This observation was similar to 
that of the positive control (rapamycin treated cells). Conversely, all the remaining antibiotic 
agents without anti-Wolbachia activity: levofloxacin, ciprofloxacin, amoxicillin and 
streptomycin, did not exhibit any observable difference in LC3B-II and p62 fluorescence 
compared to the DMSO control. There appears to be a noticeable difference in the confocal 
images between the tested anti-Wolbachia agents and other antibiotics in terms of 
Wolbachia number (green fluorescence).  
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Figure 3. 5 Immunofluorescence staining in C6/36Wp cells for 
different antibiotics using autophagic marker LC3B-II.  
C6/36 cells infected with wAlbB were treated with DMSO (vehicle 
control representing basal autophagy), rapamycin at 5 µM (positive 
control), wortmannin at 10 µM (negative control), four anti-
Wolbachia agents: doxycycline, rifampicin, moxifloxacin and 
sparfloxacin, and four other antibiotics: levofloxacin, ciprofloxacin, 
amoxicillin and streptomycin, all at 5 µM for 3 days. Cells were fixed, 
permeabilised and incubated with autophagy primary and secondary 
antibodies. Syto11 and DAPI were used to stain Wolbachia and cell 
nuclei (green and blue fluorescence), respectively. Autophagy 
activation is shown by an increase in red puncta (increase in LC3B-II 
due to autophagosomes formation). Bar graph (mean with SD) 
represents % cells with LC3BII positive puncta for each treatment 
group with three different sections were imaged, where each section 
contained ≥50 cells. Scale bars in A are 10 µm. 
Statistical analysis was performed to compare all treatment groups 
to DMSO. Statistical significance tested using Student’s t-test, 
statistical significance was at p ≤ 0.05. For p-value *= 0.01 to 0.05, ** 
= 0.01 to 0.001, *** = 0.001 to 0.0001, and **** ≤ 0.0001. 
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Figure 3. 6 Immunofluorescence staining in C6/36Wp cells for 
different antibiotics using autophagic marker p62.  
C6/36 cells infected with wAlbB were treated with DMSO (vehicle 
control representing basal autophagy), rapamycin at 5 µM (positive 
control), wortmannin at 10 µM (negative control), four anti-
Wolbachia agents: doxycycline, rifampicin, moxifloxacin and 
sparfloxacin, and four other antibiotics: levofloxacin, ciprofloxacin, 
amoxicillin and streptomycin, all at 5 µM for 3 days. Cells were fixed, 
permeabilised and incubated with autophagy primary and secondary 
antibodies. Syto11 and DAPI were used to stain Wolbachia and cell 
nuclei (green and blue fluorescence), respectively. Autophagy 
activation is shown by a decrease in yellow puncta (decrease in p62 
due to autophagic degradation). Bar graph (mean with SD) 
represents % cells with p62 positive puncta for each treatment group 
with three different sections were imaged, where each section 
contained ≥50 cells. Scale bars in A are 10 µm. 
Statistical analysis was performed to compare all treatment groups to 
DMSO. Statistical significance tested using Student’s t-test, statistical 
significance was at p ≤ 0.05. For p-value *= 0.01 to 0.05, ** = 0.01 to 
0.001, *** = 0.001 to 0.0001, and **** ≤ 0.0001. 
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3.4.2.2 Wolbachia-free C6/36 cells 
Interestingly, the visual presentation for Wolbachia-free C6/36 was similar to that of 
C6/36Wp. All four anti-Wolbachia agents: doxycycline, rifampicin, moxifloxacin and 
sparfloxacin, presented with high red fluorescence and low yellow fluorescence 
representing LC3B-II (Figure 3.8) and p62 (Figure 3.9) expression, respectively. This indicated 
the presence of autophagic induction in these drugs. On the contrary, the confocal images 
for the remaining antibiotics, which lack activity against Wolbachia: levofloxacin, 
ciprofloxacin, amoxicillin and streptomycin, did not present any evidence of autophagic 
activation. An interesting observation was that when comparing the DMSO control between 
infected and uninfected C6/36 cells, there was evidence of higher autophagic influx in the 
presence of Wolbachia, indicated by high LC3B-II and low p62 expression. This difference in 
expression was significant for both autophagic markers (this is presented in the Appendix A 
Figure A8). 
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Figure 3. 7 Immunofluorescence staining in C6/36 cells for 
different antibiotics using autophagic marker LC3B-II.  
Wolbachia-free C6/36 cells were treated with DMSO (vehicle 
control representing basal autophagy), rapamycin at 5 µM 
(positive control), wortmannin at 10 µM (negative control), four 
anti-Wolbachia agents: doxycycline, rifampicin, moxifloxacin and 
sparfloxacin, and four other antibiotics: levofloxacin, 
ciprofloxacin, amoxicillin and streptomycin, all at 5 µM for 3 days. 
Cells were fixed, permeabilised and incubated with autophagy 
primary and secondary antibodies. Syto11 and DAPI were used to 
stain Wolbachia and cell nuclei (green and blue fluorescence), 
respectively. Autophagy activation is shown by an increase in red 
puncta (increase in LC3B-II due to autophagosomes formation). 
Bar graph (mean with SD) represents % cells with LC3BII positive 
puncta for each treatment group with three different sections 
were imaged, where each section contained ≥50 cells. Scale bars 
in A are 10 µm. 
Statistical analysis was performed to compare all treatment 
groups to DMSO. Statistical significance tested using Student’s t-
test, statistical significance was at p ≤ 0.05. For p-value * = 0.01 
to 0.05, ** = 0.01 to 0.001, *** = 0.001 to 0.0001, and **** ≤ 
0.0001. 
 
110 
 
 
111 
 
 
 
Figure 3. 8 Immunofluorescence staining in C6/36 cells for different 
antibiotics using autophagic marker p62.  
Wolbachia-free C6/36 cells were treated with DMSO (vehicle control 
representing basal autophagy), rapamycin at 5 µM (positive control), 
wortmannin at 10 µM (negative control), four anti-Wolbachia agents: 
doxycycline, rifampicin, moxifloxacin and sparfloxacin, and four other 
antibiotics: levofloxacin, ciprofloxacin, amoxicillin and streptomycin, 
all at 5 µM for 3 days. Cells were fixed, permeabilised and incubated 
with autophagy primary and secondary antibodies. Syto11 and DAPI 
were used to stain Wolbachia and cell nuclei (green and blue 
fluorescence), respectively. Autophagy activation is shown by a 
decrease in yellow puncta (decrease in p62 due to autophagic 
degradation). Bar graph (mean with SD) represents % cells with p62 
positive puncta for each treatment group with three different 
sections were imaged, where each section contained ≥50 cells. Scale 
bars in A are 10 µm. 
Statistical analysis was performed to compare all treatment groups to 
DMSO. Statistical significance tested using Student’s t-test, statistical 
significance was at p ≤ 0.05. For p-value * = 0.01 to 0.05, ** = 0.01 to 
0.001, *** = 0.001 to 0.0001, and **** ≤ 0.0001. 
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3.4.3 Measuring concentration-dependency for autophagic induction by antibiotics 
and the effect on Wolbachia load in C6/36Wp and C6/36 cells 
In this experiment, a range of concentrations from the eight previously tested antibiotics 
(doxycycline, rifampicin, moxifloxacin, sparfloxacin, levofloxacin, ciprofloxacin, amoxicillin 
and streptomycin) were examined for their anti-Wolbachia activity, as well as their 
capability to activate autophagy. The rationale for this is to evaluate whether effective 
antibiotic concentrations against Wolbachia also activate autophagy for each tested drug 
and whether modifying these concentrations would have an impact on the bacteria or the 
autophagy pathway. This was tested in both Wolbachia infected and uninfected C6/36 cells, 
to examine the effect of antibiotics on activating autophagy in the absence of the bacteria 
within the same range of concentrations.  
As in Section 3.4.2, we quantified the immunofluorescence staining findings based on the 
percentage of cells with positive LC3B-II and p62 puncta for all tested concentrations of the 
eight antibiotics to examine their statistical significance compared to the DMSO control. 
Additionally, Wolbachia activity of the tested antibiotics was measured using qPCR to 
quantify the presence of Wolbachia gene copies. 
 
3.4.3.1 Concentration-dependency of antibiotics on autophagy induction - C6/36Wp 
i) Anti-Wolbachia antibiotics 
Both doxycycline and rifampicin (Figure 3.10 A and B) presented with a significantly higher 
and lower percentage of LC3B-II and p62, respectively, indicating their autophagic inducing 
capabilities. This was observed for all tested concentrations of both these antibiotics. 
Moreover, all tested concentrations of doxycycline and rifampicin significantly reduced 
Wolbachia load irrespective of the concentration (Figure 3.10 C and D). 
Conversely, the two anti-Wolbachia fluoroquinolone agents (moxifloxacin and sparfloxacin), 
showed a significant difference in terms of autophagic induction in higher concentrations 
only (between 5-20 µM) in a concentration-dependent manner (Figure 3.11 A and B). 
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Interestingly, there also appeared to be a concentration-dependent pattern in terms of anti-
Wolbachia effect for both moxifloxacin and sparfloxacin. This was observed by the 
significantly lower Wolbachia titre at higher concentrations of cells treated with 
moxifloxacin and sparfloxacin (Figure 3.11 C and D). Although moxifloxacin at 0.5 µM and 
sparfloxacin at 1 µM reduced Wolbachia significantly, with a 71% and 62% reduction 
respectively, compared to DMSO, these concentrations did not activate autophagy. On the 
other hand, the higher concentrations (5-20 µM) of both these fluoroquinolones 
significantly reduced >90% of Wolbachia in cells compared to DMSO and activated 
autophagy.  
A point worth mentioning is that rapamycin at 5 µM (an autophagy inducer), reduced 
Wolbachia titre significantly compared to DMSO control (Figure 3.10-3.12). On the other 
hand, wortmannin at 10 µM (an autophagy inhibitor) significantly increased Wolbachia load 
compared to control. These findings were also observed in the confocal images of C6/36Wp 
(Figure 3.6 and 7), in which Wolbachia stained with syto11 (green fluorescence puncta) 
were expressed higher and lower in cells treated with wortmannin and rapamycin, 
respectively, compared to DMSO.  
ii) Other tested antibiotics 
Quantifying the percentage of positive LC3B-II and p62 puncta confirmed our observations 
of the visual analysis of confocal images for cells treated with levofloxacin, ciprofloxacin, 
amoxicillin and streptomycin (Figure 3.12 A-D).  
For these four antibiotics, all tested concentrations (between 0.125-20 µM) have shown no 
significant difference in terms of autophagic activity compared to DMSO control. 
Furthermore, the same concentrations have not influenced any significant change in 
Wolbachia load for all four agents (Figure 3.12 E-H).  
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Figure 3. 9 Quantifying antibiotic-induced autophagy and Wolbachia load in C6/36Wp cells 
treated with doxycycline and rifampicin. 
C6/36 cells infected with wAlbB were treated with DMSO (vehicle control representing basal 
autophagy), rapamycin at 5 µM (positive control), wortmannin at 10 µM (negative control), 
two anti-Wolbachia agents: A and C) doxycycline (between 0.125-10 µM) and B and D) 
rifampicin (between 0.125-20 µM) for 3 days. For immunofluorescence, A and B) cells were 
fixed, permeabilised and incubated with autophagy primary and secondary antibodies. For 
autophagy activation, autophagic markers: LC3B-II and p62 expression increased and 
decreased, respectively. Graphs (mean with SD) represent % cells with LC3BII or p62 positive 
puncta for each treatment group with three different sections were imaged, where each 
section contained ≥50 cells. 
In the same treatment groups, qPCR was used to quantify Wolbachia C and D) DNA extracted 
from cells were amplified using Wolbachia 16s rRNA gene normalised to Aedes albopictus 18s 
rRNA gene. Graphs (mean with SD) represent 16s:18s gene copies (log10) in three biological 
repeats per treatment group. 
Statistical analysis was performed to compare all treatment groups to DMSO. Statistical 
significance tested using Student’s t-test, statistical significance was at p ≤ 0.05. For p-value * 
= 0.01 to 0.05, ** = 0.01 to 0.001, *** = 0.001 to 0.0001, and **** ≤ 0.0001. 
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Figure 3. 10 Quantifying antibiotic-induced autophagy and Wolbachia load in C6/36Wp cells 
treated with moxifloxacin and sparfloxacin.  
C6/36 cells infected with wAlbB were treated with DMSO (vehicle control representing basal 
autophagy), rapamycin at 5 µM (positive control), wortmannin at 10 µM (negative control), 
two anti-Wolbachia agents: A and C) moxifloxacin and B and D) sparfloxacin (both between 
0.125-20 µM) for 3 days. For immunofluorescence, A and B) cells were fixed, permeabilised 
and incubated with autophagy primary and secondary antibodies. For autophagy activation, 
autophagic markers: LC3B-II and p62 expression increased and decreased, respectively. 
Graphs (mean with SD) represent % cells with LC3BII or p62 positive puncta for each 
treatment group with three different sections were imaged, where each section contained 
≥50 cells. 
In the same treatment groups, qPCR was used to quantify Wolbachia C and D) DNA extracted 
from cells were amplified using Wolbachia 16s rRNA gene normalised to Aedes albopictus 18s 
rRNA gene. Graphs (mean with SD) represent 16s:18s gene copies (log10) in three biological 
repeats per treatment group. 
Statistical analysis was performed to compare all treatment groups to DMSO. Statistical 
significance tested using Student’s t-test, statistical significance was at p ≤ 0.05. For p-value * 
= 0.01 to 0.05, ** = 0.01 to 0.001, *** = 0.001 to 0.0001, and **** ≤ 0.0001. 
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Figure 3. 11 Quantifying antibiotic-induced autophagy and Wolbachia load in C6/36Wp cells 
treated with levofloxacin, ciprofloxacin, amoxicillin and streptomycin.  
C6/36 cells infected with wAlbB were treated with DMSO (vehicle control representing basal 
autophagy), rapamycin at 5 µM (positive control), wortmannin at 10 µM (negative control), 
and four antibiotics A and E) levofloxacin, B and F) ciprofloxacin, C and G) amoxicillin and D 
and H) streptomycin all between 0.125-20 µM for 3 days. For immunofluorescence, A, B, C 
and D) cells were fixed, permeabilised and incubated with autophagy primary and secondary 
antibodies. For autophagy activation, autophagic markers: LC3B-II and p62 expression 
increased and decreased, respectively. Graphs (mean with SD) represent % cells with LC3BII 
or p62 positive puncta for each treatment group with three different sections were imaged, 
where each section contained ≥50 cells. 
In the same treatment groups, qPCR was used to quantify Wolbachia E, F, G and H) DNA 
extracted from cells were amplified using Wolbachia 16s rRNA gene normalised to Aedes 
albopictus 18s rRNA gene. Graphs (mean with SD) represent 16s:18s gene copies (log10) in 
three biological repeats per treatment group. 
Statistical analysis was performed to compare all treatment groups to DMSO. Statistical 
significance tested using Student’s t-test, statistical significance was at p ≤ 0.05. For p-value * 
= 0.01 to 0.05, ** = 0.01 to 0.001, *** = 0.001 to 0.0001, and **** ≤ 0.0001. 
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3.4.3.2 Concentration-dependency of antibiotics on autophagy induction – Wolbachia-free 
C6/36 
i) Anti-Wolbachia antibiotics 
As in C6/36Wp, all four anti-Wolbachia agents significantly induced autophagy as expressed 
by both autophagic markers (Figure 3.13). All tested concentrations showed a significant 
increase and decrease in LC3B and p62 expression, respectively, compared to DMSO.  
ii) Other tested antibiotics 
C6/36 cells exposed to levofloxacin, ciprofloxacin, amoxicillin and streptomycin 
demonstrated similar results to those obtained for C6/36Wp with the same antibiotics 
(Figure 3.14). Even at higher concentrations, none of these agents significantly induced 
autophagy.  
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Figure 3. 12 Quantifying antibiotic-induced autophagy in C6/36 cells treated with anti-
Wolbachia agents.  
Wolbachia-free C6/36 cells were treated with DMSO (vehicle control representing basal 
autophagy), rapamycin at 5 µM (positive control), wortmannin at 10 µM (negative control), 
four anti-Wolbachia agents: A) doxycycline (between 1-10 µM) and B) rifampicin C) 
moxifloxacin and D) sparfloxacin (all between 1-20 µM) for 3 days. Cells were fixed, 
permeabilised and incubated with autophagy primary and secondary antibodies. For 
autophagy activation, autophagic markers: LC3B-II and p62 expression increased and 
decreased, respectively. Graphs (mean with SD) represent % cells with LC3BII or p62 positive 
puncta for each treatment group with three different sections were imaged, where each 
section contained ≥50 cells. 
Statistical analysis was performed to compare all treatment groups to DMSO. Statistical 
significance tested using Student’s t-test, statistical significance was at p ≤ 0.05. For p-value * 
= 0.01 to 0.05, ** = 0.01 to 0.001, *** = 0.001 to 0.0001, and **** ≤ 0.0001. 
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Figure 3. 13 Quantifying antibiotic-induced autophagy in C6/36 cells treated with different 
antibiotics.  
Wolbachia-free C6/36 cells were treated with DMSO (vehicle control representing basal 
autophagy), rapamycin at 5 µM (positive control), wortmannin at 10 µM (negative control), 
and four antibiotics: A) levofloxacin and B) ciprofloxacin C) amoxicillin and D) streptomycin 
(all between 1-20 µM) for 3 days. Cells were fixed, permeabilised and incubated with 
autophagy primary and secondary antibodies. For autophagy activation, autophagic markers: 
LC3B-II and p62 expression increased and decreased, respectively. Graphs (mean with SD) 
represent % cells with LC3BII or p62 positive puncta for each treatment group with three 
different sections were imaged, where each section contained ≥50 cells. 
Statistical analysis was performed to compare all treatment groups to DMSO. Statistical 
significance tested using Student’s t-test, statistical significance was at p ≤ 0.05. For p-value * 
= 0.01 to 0.05, ** = 0.01 to 0.001, *** = 0.001 to 0.0001, and **** ≤ 0.0001. 
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3.4.4 Time-course assessment of autophagy induction by antibiotics –C6/36Wp 
The final part of the results section presents our assessment of different time-points (at day 
0, 1, 3, 5 and 7) in C6/36 cells infected with wAlbB and treated with the eight pre-selected 
antibiotics: doxycycline, rifampicin, moxifloxacin, sparfloxacin, levofloxacin, ciprofloxacin, 
amoxicillin and streptomycin at a fixed concentration (5 µM).  
We will first present the results for LC3B and p62 immunoblotting expression in C6/36Wp to 
determine autophagic influx at the selected time-points for all tested antibiotics. This will be 
followed by qPCR analysis to quantify Wolbachia elimination at the same time-points.  
3.4.4.1 Immunoblotting analysis for autophagy induction at different time-points 
The findings for autophagy activation using western blot in the eight pre-selected antibiotics 
are presented in Figure 3.15 A (for LC3B expression) and Figure 3.15 B (for p62) at different 
time-points (day 0, 1, 3 ,5 and 7). Autophagic activation was considered present by the 
expression of two bands for LC3B and the absence of the single band for p62 (as seen for 
the positive control, rapamycin). As with the previous immunoblotting experiments, DMSO 
was used to represent basal level of autophagy in C6/36Wp.  
All four tested anti-Wolbachia agents (doxycycline, rifampicin, moxifloxacin, and 
sparfloxacin) presented evidence of autophagic induction for all treatment periods (day 1, 3, 
5 and 7) compared to DMSO, as expressed in the high and low band intensity of LC3B-II and 
p62, respectively. However, their appeared to be a difference between the anti-Wolbachia 
agents in longer duration of treatment. In the case of doxycycline and rifampicin, expression 
of a high band intensity of LC3B-II was observed for all treatment periods (from day 1 to day 
7). Conversely, both moxifloxacin and sparfloxacin showed a reduced protein expression of 
LC3B-II after day 1, indicating a possibly lower autophagic influx. The differences in 
treatment duration between the four anti-Wolbachia agents were not observed in terms of 
p62 expression, where all agents expressed a reduced intensity compared to the DMSO 
control, and similar to rapamycin.  
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With regards to other tested antibiotics that lack anti-Wolbachia activity (levofloxacin, 
ciprofloxacin, amoxicillin and streptomycin), a general observation is that different time-
points did not appear to impact autophagic induction compared to DMSO, by the low 
expression and prominent band of LC3B and p62, respectively. Interestingly, an exception of 
this was observed with two fluoroquinolone agents (levofloxacin and ciprofloxacin) at the 
beginning of treatment (day1). In the first day of antibiotic treatment, levofloxacin and 
ciprofloxacin expressed both LC3B bands (indicating possible autophagic activation), 
however this was not maintained in subsequent treatment days or expressed in p62 
immunoblotting interpretation.  
3.4.4.2 qPCR analysis of Wolbachia load at different time-points 
The results for the qPCR analysis to quantify Wolbachia load in C6/36Wp treated with the 
eight antibiotics at different time-points are presented in Figure 3.16. A graph presenting 
the full treatment period (from day 0 to day 7) including all treatment groups in the 
Appendix A Figure A9. 
As seen in Section 3.4.3, rapamycin treated cells reduced Wolbachia titre significantly 
compared to DMSO. The reduction increased with time reaching approximately 50% 
clearance, compared to the control. Whereas in the case of wortmannin, a significant 
increase in Wolbachia number was recorded at day 3 onwards compared to DMSO. 
For all anti-Wolbachia agents, there was a significant reduction in Wolbachia titre compared 
to DMSO from day 1 (Figure 3.16). This significant reduction on day 1 (of ˂ 50%) continued 
in subsequent treatment days for all four agents, reaching over 95% reduction compared to 
DMSO control at day 7. This reduction was observed earlier for sparfloxacin followed by 
moxifloxacin, although this was only noticeable for day 1 and 3 of treatment.  
Compared to the DMSO control, the remaining four agents (levofloxacin, ciprofloxacin, 
amoxicillin and streptomycin) did not reduce Wolbachia number and this observation 
remained for the duration of the treatment period (Figure 3.16).  
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Figure 3. 14 Immunoblotting analysis for autophagy induction at different time-points using 
diverse antibiotics in C6/36Wp cells.  
C6/36 mosquito cells infected with Wolbachia (wAlbB) treated with: DMSO – vehicle control, 
rapamycin – positive control, wortmannin -autophagy inhibitor, four anti-Wolbachia agents: 
doxycycline, rifampicin, moxifloxacin, sparfloxacin, and four different antibiotics: levofloxacin, 
ciprofloxacin, amoxicillin, and streptomycin at different time-points: day 0, 1, 3, 5 and 7. 
Reduced protein extracts of cells were loaded at 50µg/40ul per lane into 4-12% bis tris SDS-
PAGE gels. Separated proteins were transferred into nitrocellulose membrane, blocked and 
incubated with primary and secondary antibodies. Western blot protein expression is 
presented in A) for rabbit anti-LC3B (LC3B-I at 16 kDa and LC3B-II at 14 kDa) and B) rabbit 
anti-p62 (at 80 kDa). Ponceau s staining was used as a loading control. 
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Figure 3. 15 qPCR analysis of Wolbachia load in antibiotics at different time-points.  
C6/36Wp cells were treated at different time-points: A) day 1, B) day 3, C) day 5 and D) day 7 
with DMSO (vehicle control), rapamycin at 5 µM (autophagy inducer), wortmannin at 10µM 
(autophagy inhibitor), four anti-Wolbachia agents at 5 µM: doxycycline, rifampicin, 
moxifloxacin and sparfloxacin and four other antibiotics at 5 µM: levofloxacin, ciprofloxacin, 
amoxicillin and streptomycin. DNA extracted from cells were amplified using Wolbachia 16s 
rRNA gene normalised to Aedes albopictus 18s rRNA gene. Graphs (mean with SD) represent 
16s:18s gene copies in three biological repeats per treatment group. 
Statistical analysis was performed to compare all treatment groups to DMSO. Statistical 
significance tested using Student’s t-test, statistical significance was at p ≤ 0.05. For p-value * 
= 0.01 to 0.05, ** = 0.01 to 0.001, *** = 0.001 to 0.0001, and **** ≤ 0.0001. 
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3.5 Discussion: 
Initial experimentation focused on the primary in vitro cell-based assay used by the A-WOL 
consortium of C6/36 infected with Wolbachia (wAlbB), where all four anti-Wolbachia 
antibiotics (doxycycline, rifampicin, moxifloxacin and sparfloxacin) reduced Wolbachia load 
and induced autophagy. Furthermore, two pre-clinical candidates (TylAMacTM and 
AWZ1066S) and a re-purposed antibiotic (fusidic acid) from the A-WOL consortium 
produced similar results to established anti-Wolbachia agents, indicating the potential role 
of autophagy in the efficacy of anti-Wolbachia drugs. This observation raised the hypothesis 
that inhibition of protein synthesis by these antibiotics leads to an inhibition of putative 
proteins involved in autophagy evasion by Wolbachia (87). However, this hypothesis was 
not supported by experiments on uninfected cells, which also showed a similar pattern of 
induction of autophagy in the absence of Wolbachia infection. To determine if this ability of 
antibiotics to induce autophagy was restricted to C6/36 cells, another insect cell line that 
lack Wolbachia (SF9 cells) was tested and produced similar results for autophagic activation 
when treated with the same antibiotics. Importantly this pattern of autophagy induction 
was replicated in the target organism, B. malayi where drugs with efficacy against 
Wolbachia induced autophagy, whereas those lacking efficacy against Wolbachia failed to 
induce autophagy. Next, we screened two mammalian cells lines (THP-1 and MDCK) with 
the same set of antibiotics, which did not present evidence of autophagic activation, 
indicating that our observation of antibiotic-induced autophagy was restricted to insect cells 
and nematodes and not replicated in mammalian cells at the concentrations tested in this 
research. 
Concentration-dependency testing of the antibiotics revealed a close correlation between 
concentrations of drug that induce autophagy with the elimination of Wolbachia. This was 
particularly apparent with the fluoroquinolones, moxifloxacin and sparfloxacin, where 
autophagy was only induced by drug concentrations that reduce Wolbachia by >90%. This 
level of Wolbachia reduction is the empirical threshold, which has to be achieved to deliver 
macrofilaricidal activity (65). While all tested concentrations of doxycycline and rifampicin 
achieved >90% Wolbachia reduction, the concentration-dependent manner of reduction 
was not observed. However, more research is needed in lower concentrations (lower than 
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0.125 µM) for these two agents to confirm this particular finding. Furthermore, antibiotics 
without efficacy against Wolbachia failed to induce autophagy at any of the concentrations 
tested. While we have examined different classes of antibiotics in the same concentration it 
is important to note that differences occur between their EC50 and hence caution is needed 
when drawing broad conclusions between these drugs. 
When examining the effect of antibiotics at different time-points, we observed that 
induction of autophagy occurs within the first day of exposure and is maintained throughout 
the seven-day period of culture for all tested anti-Wolbachia drugs. This early autophagic 
activity occurs with only low levels of Wolbachia reduction, supporting the notion that 
autophagy is not only involved in the clearance of dead bacteria, but closely linked with 
antibacterial activity.   
Previous studies have not examined antibiotics of this range of chemical diversity 
(tetracycline, rifamycin and fluoroquinolone) in insects and nematodes against intracellular 
bacteria in terms of autophagy activation. However, there is evidence that autophagy is 
implicated in the efficacy of antimycobacterial drugs. Kim et al. (235) examined 
macrophages infected with Mycobacterium tuberculosis (Mtb) treated with anti-
tuberculosis (anti-TB) drugs: isoniazid and pyrazinamide, which resulted in autophagy 
activation only at effective antibacterial concentrations. In the same study, no autophagic 
activation was observed in the absence of Mtb treated with the same drugs. This 
observation corresponds with our findings in mammalian cells (lacking Wolbachia), where 
no autophagic activation was observed. Kim et al. (235) proposed that autophagy activation 
in macrophages infected with Mtb was initiated through ROS production, leading to 
oxidative stress following antimycobacterial treatment. Other researchers have also 
observed that certain antibiotics may alter cell organelles (such as mitochondria), increase 
formation of ROS and lower intracellular pH, all of which are factors that may influence 
autophagic induction (199, 211, 259, 260). 
In conclusion, an increase in autophagic activation was consistently observed for all four 
tested anti-Wolbachia drugs (doxycycline, rifampicin, moxifloxacin and sparfloxacin) when 
exposed to insect cells and B. malayi mf, but not for antibiotics without activity against 
Wolbachia. Furthermore, we have successfully observed an increase in autophagic activity 
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in two pre-clinical candidates and one re-purposed antibiotic from the A-WOL consortium 
(TylAMacTM, AWZ1066S and fusidic acid). Exposure of antibiotics to mammalian cells did not 
replicate the pattern observed in insect cells and mf, with antibiotics showing no clear 
evidence of autophagy activation. Through concentration-dependency experimentation on 
anti-Wolbachia antibiotics, we have observed that their anti-Wolbachia activity is closely 
correlates with activating autophagy, which we will examine further in the presence of 
autophagy inhibitors in Chapter 4 of this thesis.  
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Chapter 4 Examining the contribution of autophagy in the activity of 
anti-Wolbachia drugs 
4.1 Chapter overview 
In this third and final results section of this thesis I will present and discuss the experiments 
performed to examine whether autophagy may play a role in the anti-Wolbachia activity of 
drugs in mosquito cells C6/36Wp, microfilariae (mf) and female adult worms of Brugia 
malayi. This was examined using two anti-Wolbachia antibiotics, doxycycline and rifampicin, 
as well as the newly identified drug AWZ1066S, which has been candidate-selected by the A-
WOL consortium. These drugs were selected based on known macrofilaricidal properties 
and their use in clinical trials and pre-clinical development. Furthermore, we have selected 
these three diverse antibiotics based on their potential different modes of action against 
Wolbachia. 
Two sets of experiments were performed in this chapter. In the first group, the impact of 
autophagy suppression was monitored on doxycycline and rifampicin treated in mosquito 
cell line C6/36 infected with wAlbB (C6/36Wp), B. malayi mf and female adult worms. In the 
second set of experiments, the role of autophagy suppression was assessed in B. malayi mf 
and female worms in doxycycline and AWZ1066S induced Wolbachia decline after the 
removal of drugs, in addition to rifampicin in mf. For both sets of experiments, wortmannin 
and/or l-asparagine, two autophagy inhibitors previously validated in these experimental 
systems in Chapter 2, were used to suppress autophagy.  
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4.2 Background 
4.2.1 Brugia malayi and Wolbachia: a symbiotic relationship  
As this chapter will focus on examining anti-Wolbachia drugs in the presence of autophagy 
inhibitors in B. malayi mf and female adult worms, this section will briefly discuss the 
nematode life cycle, including several important biological and structural differences in 
different developmental stages of B. malayi, as well as the symbiotic relationship between it 
and the intracellular bacteria, Wolbachia pipientis. For the full detailed life cycle, the 
symbiotic relationship as well as the epidemiological relevance of filarial nematodes that 
cause lymphatic filariasis, please refer to Chapter 1 of this study.  
From a general perspective, the life cycle of B. malayi is divided into an extrinsic (in the 
mosquito vector of Aedes and Mansonia species) and intrinsic life cycle (in the human host). 
After feeding on an infected human host, mf within the mosquito vector mature into the 
infective larval stage (L3 larvae) and make their way towards the head and proboscis of the 
mosquito. Thereafter, a blood meal will transfer the L3 larvae from the mosquito and into a 
new human host, where it would develop to L4 larvae, and later into the female and male 
adult stage of the parasite. Adult worms may survive for over ten years in the lymphatic 
system of humans and female adult worms continue to release mf into the blood stream of 
the host, thereby continuing the life cycle in subsequent blood meals by mosquito vectors 
(2, 26, 261). 
While the life cycle for B. malayi is generally similar to that of W. bancrofti, there are several 
important differences between the two nematode species. First, from a morphological 
perspective, both the mf and adult stages of W. bancrofti are larger in length and diameter 
than B. malayi. In terms of mf, B. malayi have distinct lateral indentations of their caudal 
nuclei, which are not present in W. bancrofti (2). Additionally, the cephalic space is larger in 
Brugia species compared to W. bancrofti mf (2). The nocturnal periodicity of mf in the blood 
of human host is observed for both W. bancrofti and B. malayi, however this periodicity is 
reversed in W. bancrofti in the South Pacific region where the vector is the day biting Aedes 
polynesiensis (2, 9, 10). Finally, it is important to note that the mosquito vectors differ 
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between B. malayi and W. bancrofti, with the former transmitted via mosquitoes principally 
from the Mansonia genera only (10, 261). 
The symbiotic relationship between filarial nematodes of B. malayi and Wolbachia has long 
been documented in the literature and we have previously discussed this issue in Chapter 1 
of this thesis. Due to the inability of filarial nematodes to mature, reproduce, and obtain 
essential nutrients for survival without the presence of Wolbachia, their relationship has 
been described as obligate mutualism (2, 26, 262). While Wolbachia can naturally occur in 
mosquito vectors of filarial nematodes and many other different types of arthropods 
(including Aedes albopictus cell line C6/36Wp cells tested in this chapter), their interaction 
has generally been described as reproductive parasites. On the other hand, Experiments 
performed on Aedes albopictus have also shown that Wolbachia infection can increase 
fecundity, as well as increase the life expectancy of female mosquitoes (26, 263).  
For both female and male adult worms, Wolbachia are located in the lateral cords of the 
organism. While Wolbachia may occur in certain parts of the reproductive system of female 
adult worms, such as oocytes, ovaries and the developing embryos of the uterus, the adult 
male reproductive system of filarial nematodes is devoid of Wolbachia (26). Distinct 
morphological features are present between male and female adult worms of B. malayi. 
Female adult worms are larger in length than their male counterparts, ranging in length 
between 43-55 mm and 13-23 mm, respectively. Furthermore, female adult worms are on 
average wider than male worms, generally between 130-170 µm and 70-80 µm, respectively 
(261). 
As previously discussed in Chapter 1, Wolbachia are present in all stages of B. malayi, 
however, the population density varies between different worms and life cycle stages (23, 
30, 264). Female worms will generally present with a higher number of Wolbachia than 
males due to their larger size and the presence of Wolbachia in embryonic stages within the 
uterus. Mf have the lowest number of Wolbachia compared to other developmental stages, 
which is maintained throughout development to third-stage larvae in the vector, before 
rapidly expanding during the first week of infection of the mammalian host and throughout 
development of the fourth-stage larvae (49, 264).  
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Autophagy (discussed in detail in previous chapters) plays an important role in the 
regulation of Wolbachia populations. Voronin et al. (87) observed that autophagy was 
activated in life stages of B. malayi that contain replicating Wolbachia. In the same study, 
the effect of autophagy was assessed, by chemical and genetic manipulation in B. malayi, 
where activation and inhibition of autophagy, decreased and increased Wolbachia titres, 
respectively. Similar results were also observed when inducing or inhibiting autophagy in 
Aedes albopictus cells C6/36 cells and Drosophila infected with Wolbachia. Moreover, in 
vivo studies performed on jirds infected with B. malayi treated with two different autophagy 
activators (spermidine and rapamycin), decreased Wolbachia load compared to non-treated 
animals (87).  
4.2.2 Doxycycline, rifampicin and AWZ1066S as anti-Wolbachia agents 
Due to the documented disadvantages of antiparasitic drugs (for example ivermectin, 
albendazole, and diethylcarbamazine), which include their ineffectiveness against adult 
worms (described previously in Chapter 1), as well as the emerging issue of drug resistance, 
there is a need to consider the possibility of a role for anti-Wolbachia agents (26). In light of 
the obligate symbiotic relationship between filarial nematodes (in all their stages) and 
Wolbachia, the A-WOL consortium has proposed novel approaches in the treatment of 
filarial infection by targeting Wolbachia through anti-Wolbachia drugs, including 
doxycycline, high dose rifampicin and newly developed agent AWZ1066S (52, 64, 82, 265). 
Details on each of these compounds and their mechanism of action, as well as in vitro, in 
vivo and human clinical studies performed using these agents were previously mentioned in 
Chapter 1. 
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4.2.3 Experimental justification  
In the experiments of this chapter, three anti-Wolbachia drugs were used: doxycycline, 
rifampicin and AWZ1066S. The tested drugs were selected based on their proven potency 
against Wolbachia, and potential different modes of action (26, 82), which were described 
in detail in Chapter 1. Validated in vitro assays of B. malayi nematodes developed by A-WOL 
consortium focused on mf and adult worms were used in this chapter.  
The first set of experiments were performed to determine whether the pre-selected anti-
Wolbachia drugs can reduce Wolbachia titre when autophagy was inhibited chemically, 
using wortmannin or l-asparagine during exposure to each antibiotic. This was tested with 
C6/36Wp, B. malayi mf and female adult worms. This group of experiments were performed 
by quantifying Wolbachia load (using qPCR).  
In the second group of experiments, a post-drug exposure washout assay was conducted to 
determine whether the continued reduction or rebound in Wolbachia load post-exposure to 
the drug during washout periods were dependent on the autophagy pathway. In this set of 
experiments, Wolbachia load was quantified using qPCR technique in tested B. malayi mf 
and female worms.  
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4.3 Materials and methods: 
For more details on the materials used in the experiments conducted in this chapter please 
refer to the Appendix B Table B.1 section of this thesis.  
4.3.1 In vitro culture of cell lines and worms 
i) Mosquito cell line C6/36Wp cells with wAlbB:  
The materials and preparation used for mosquito cell line C6/36Wp infected with wAlbB 
were the same as those previously described in Chapter 2.3.1. 
ii) Brugia malayi microfilariae (mf) and female adult worms: 
The mf and adult stages of the parasite were extracted from the peritoneal cavity of gerbils. 
This was performed by members of the filariasis laboratory, Mr Andrew Steven and Mr John 
Archer, Department of Tropical Disease Biology at LSTM, UK, following the same protocol 
and procedure as described by Griffiths et al. (258).  
B. malayi mf were filtered and cultured following the same steps described in Section 3.3.1.  
With regards to adult worms, they were first washed using fresh RPMI media (Gibco, 
Thermo Fisher Scientific) and later prepared in a similar manner to that of mf culture, 
described in Section 3.3.1. RPMI 1640 culture media supplemented with 2 mM L-glutamine, 
25 mM HEPES, 100 U/ml penicillin-streptomycin, 2.5 mg/ml amphotericin B (Thermo Fisher 
Scientific) and 10% FBS (Thermo Fisher Scientific), which will be referred to as RPMI media 
in the rest of this chapter.  
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4.3.2 Analysis of Wolbachia load using quantitative polymerase chain reaction (qPCR): 
4.3.2.1 C6/36Wp cells 
C6/36Wp cells were seeded in a 96-well plate (Thermo Fisher Scientific) at 10,000 cells/ml in 
a total volume of 200 µl Leibovits-15 (L-15) media (Gibco, Thermo Fisher Scientific), 
prepared as described in Section 2.3.1. Cells were treated for 7 and 14 days in the following 
groups: doxycycline at 5 µM (alone or combined with wortmannin or l-asparagine), 
rifampicin at 5 µM (alone or combined with wortmannin or l-asparagine), and autophagy 
inhibitors: wortmannin and l-asparagine, at 10 µM and 10 mM, respectively. DMSO was 
used as a vehicle control. 
Following the preparation of treatment groups, the subsequent steps of DNA extraction and 
qPCR analysis were performed as previously described in Section 3.3.4. All qPCR findings for 
this section are presented as a (log10) ratio of 16s:18s genes, to normalise the results in 
relation to DNA quantity. 
4.3.2.2 Brugia malayi mf and female adult worms: 
Mf and female adult worms were treated for 6 days in the following groups: doxycycline at 5 
µM (alone or combined with wortmannin or l-asparagine), rifampicin at 5 µM (alone or 
combined with wortmannin or l-asparagine), and autophagy inhibitors: wortmannin and l-
asparagine at 10 µM and 10 mM, respectively. DMSO was used as a vehicle control. 
8000 mf were cultured in 100 µl RPMI media per well of a 96-well plate. 100 µl of media 
containing the prepared treatment groups were added to mf suspension in wells for a total 
volume of 200 µl. 
For adult worms, two adult females were cultured into 6-well plates (Thermo Fisher 
Scientific) in a total of 3 ml RPMI media containing the prepared treatment groups. 
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DNA lysis and extraction: 
Genomic DNA was extracted from B. malayi worms (mf and adult worms) using QIAmp mini 
DNA kit from Qiagen. Mf and adult females were transferred from well plates and into 
microtubes. 35 µl (for mf) and 20 µl (for females) of Proteinase K and 100 µl (for mf) and 
180 µl (for females) of ATL tissue lysis buffer (both supplemented with kit) were added to all 
microtubes and incubated overnight in a water bath set at 56◦C. For female adult worms 
only, prior to the overnight incubation, tubes were incubated for 30 minutes at 56◦C and 
mixed using vortex mixer.  
After 20 hours, 200 µl of AL buffer (supplemented with kit) was added and returned to the 
water bath at 70◦C for 10 minutes, to allow adequate cell lysis. 200 µl of absolute ethanol 
(Sigma Aldrich) was added to tubes and incubated for 5 minutes at room temperature for 
DNA precipitation. All cell lysates were transferred to mini-spin columns (provided by the 
DNA kit) and centrifuged at 5000 g for 1 minute. Following centrifugation, two washing 
steps were performed by adding 500 µl of AW1 followed by 500 µl of AW2 washing buffer 
(both supplemented with the kit). 100 µl (for mf) and 62 µl (for females) of AE elution buffer 
(supplemented with kit) was added into each mini-spin column. Columns were centrifuged 
at 13,000 g for 5 minutes and purified eluted DNA was collected and stored at -20◦C for 
qPCR analysis. 
qPCR analysis: 
The protocol reported by McGarry et al. (49) was followed with slight modification, as 
detailed below. Extracted genomic DNA of B. malayi mf and female adults were amplified 
using Wolbachia Surface Protein (wBm wsp) and glutathione S-transferase (Bm gst) genes 
(designed by Integrated DNA Technologies, UK), and gene copy numbers were quantified by 
qPCR, using CFX384 Real-Time System with C1000 Thermal Cycler (Biorad). The final volume 
of all reaction wells was 20 µl of SYBR green master mix containing a pair of primers specific 
for wBm wsp and Bm gst (the exact nucleotide sequence of each primer provided in the 
Appendix B Table B.3). 
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For wsp and gst, 2 µl and 1 µl of DNA were added to the reaction mix, respectively. A 
standard curve of wBm wsp and gst plasmid stock serial dilution was performed in 
duplicates. The following cycling conditions were applied for qPCR: 15 minutes at 95◦C, 40 
cycles for 15 seconds at 94◦C, 30 seconds at 60◦C (for wsp) and at 55◦C (for gst), 30 seconds 
at 72◦C, and a melting curve between 60-97◦C. Gene copy numbers were normalised and 
expressed as wsp:gst ratio. Five and eight biological replicates were performed for mf and 
female adult worms, accordingly. Three qPCR reaction technical repeats were performed for 
each biological sample. All qPCR findings for this section are presented as a (log10) ratio of 
wsp:gst genes to normalise the results in relation to DNA quantity. 
 
4.3.3 Viability of Brugia malayi microfilariae and adult worms: 
Three different methods were used to assess mf and adult worms to determine if the added 
chemical compounds (anti-Wolbachia and/or autophagy inhibitors) previously mentioned in 
Section 4.3.2 had a negative impact on their viability during the experimental period. These 
methods are described below. 
i) Motility scoring  
The motility of B. malayi mf and female adult worms in all treatment groups was scored 
daily during the treatment period of 6 days (or 12 days). Following the methodology 
described by Rao et al. (58) , mf and adults were graded from 4 (highly motile) to 0 
(stationary), using a light microscope. 
ii) MTT assay 
A colourimetric assay used to quantify the metabolic activity of B. malayi mf and adult 
worms through the detection of formazan colour transformation (blue to purple). This 
colour change occurred only in live mf and adult worms through the reduction of the 
tetrazolium salt MTT (3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide). Heat-
killed worms, DMSO treated worms, and blank wells (DMSO only) were used as controls.  
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A protocol used by Johnston et al. (266) for mf, with slight modification for adult worms was 
followed for MTT assay, these are described below (60, 267, 268).  
MTT assay for microfilariae (mf): At day 6, mf were transferred into 1.5 ml microtubes and 
centrifuged at 1300 g for 5 minutes at 4◦C. Supernatants were removed and pellets were 
resuspended in 400 µl RPMI media. 100 µl MTT (0.5 mg/ml in PBS, Sigma Aldrich) was added 
to all tubes and incubated for 90 minutes at 37◦C in 5% CO2 in the dark. Tubes were 
centrifuged at 400 g for 5 minutes and pellets were washed with PBS, centrifuged and 
pellets were resuspended in 200 µl DMSO. The contents were then transferred into 96-well 
plate and incubated for 1 hour at room temperature to allow formazan crystal solubilisation. 
All plates were measured at 490 nm using Varioskan plate reader (Thermo Fisher Scientific) 
and the absorbance readings were subtracted from blank values (DMSO only). Dead mf 
(heat killed at 56◦C followed by freezing ≥ 1 hour) were used as a negative control. 
MTT assay for female adult worms: For female adult worms, slight modifications were made 
for their MTT assay. Adult worms were washed by full immersion of worms into PBS and 
placed in a 96-well plate, containing 200 µl MTT solution (0.5 mg/ml in PBS). This was 
followed by an incubation of 2 hours at 37◦C in 5% CO2 in the dark. After incubation, all 
worms were transferred into wells containing 200 µl DMSO for 1 hour at room temperature. 
Following this procedure, all plates were measured at 490 nm using Varioskan plate reader 
(Thermo Fisher Scientific) and the absorbance reading were subtracted from blank values 
(DMSO only). Dead adult worms (heat killed at 56◦C followed by freezing ≥ 1 hour) were 
used as a negative control. 
iii) Mf release count from Brugia malayi female adult worms  
Mf release was assessed in female adult worms cultured in 6-well plates with the same 
treatment groups mentioned in Section 4.3.2.2 (prepared for qPCR analysis) using 
microscopy. This assessment was performed every two days in the 6-day period of 
treatment. 
10 µl of RMPI media containing two worms in each well was placed onto a slide (in 
triplicate) and assessed using light microscopy to count the number of mf/10 µl. The 
estimated total number of mf was calculated in a final volume of 2 ml/well.  
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4.3.4 RNA gene expression of Wolbachia – in B. malayi mf  
Following the preparation described in Section 4.3.2.2 for mf in the same treatment groups, 
Wolbachia viability of B. malayi mf was assessed using RNA gene expression analysis.  
RNA extraction 
At day 6 for the treatment groups mentioned above, total RNA was isolated from all 
samples using MiRCURY RNA Isolation kit (Exiqon). Following the instructions provided by 
the kit, mf samples were centrifuged at 300 g for 5 minutes to pellet them. 600 µl lysis 
solution (provided by the kit) was added to all tubes containing mf pellets and resuspended. 
Samples were homogenised using Pellet Pestle Motor (Kimble) with sterilised RNase and 
DNase free disposable pellet pestles (Thermo Scientific Fisher) twice for 30 seconds, keeping 
samples on ice after each rotation. Samples were centrifuged again at 13,000 g for 1 minute 
to remove cell debris. All sample supernatants were collected, and an equal amount of 70% 
ethanol was added to each tube.  
Mf lysates were transferred into columns (at a maximum of 600 µl/column) and centrifuged 
at 1300 g for 1 minute. The remaining lysates were added to columns and centrifuged again 
until all samples were eluted. A volume of 400 µl wash solution (provided by the kit) was 
added to columns and centrifuged at 13,000 g for 2 minutes. All lysates at this point were 
treated with 100 µl 0.25 Kunitz unit/µl RNAse-free DNAse I (Qiagen), in order to remove any 
genomic DNA contamination from samples. Following this, columns were centrifuged at 300 
g for 2 minutes and incubated for 15 minutes at room temperature. A second 400 µl of wash 
solution was added to columns and centrifuged at 13,000 g for 2 minutes. Eluted samples 
were later transferred into microtubes and 50 µl of elution buffer (provided with the kit) 
was added and incubated for 3 minutes at room temperature. RNA integrity and purity were 
recorded using Nanodrop 1000 (Thermo Fisher Scientific). 
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Reverse transcription RT-PCR 
After the RNA extraction steps, ~0.25 µg of purified RNA samples were used in reverse 
transcriptase polymerase chain reaction (RT-PCR) to synthesise complementary DNA (cDNA) 
using Superscript III RT (Invitrogen, Thermo Fisher scientific). RT-PCR steps in this 
experiment were optimised by Dr Louise Ford and Mr Shannon Quek, Department of 
Tropical Disease Biology, LSTM (UK). 
Purified RNA samples were added to 1.4 µl (50 ng/µl) random hexamers and 1.4 µl (10 mM) 
dNTP mix (provided by the kit). This mixture was incubated at 65◦C for 5 minutes and placed 
on ice for 1 minute. The following compounds (all provided by the kit) were added to the 
mixture: 2.76 µl 10x buffer, 5.52 µl (25 mM) Mgcl2, 2.76 µl (0.1 M) DTT, 1.38 µl (40 U/µl) 
RNAse OUT and 1.38 µl (200 U/µl) superscript II. Under the following PCR conditions: 10 
minutes at 25°C, 50 minutes at 50°C and 5 min at 85°C, cDNA was synthesised.  
 
qPCR 
In the qPCR reaction, cycle threshold (Ct) values of the targeted and reference genes were 
quantified using primers targeting Brugia malayi Wolbachia wsp gene and nematode gst 
(reference gene). The specificity of primers to target the mRNA of the selected genes was 
determined using Primer Blast software (National Center for Biotechnology Information -
NCBI). These forward and reverse primers were diluted at a final concentration of 0.5 µM. 
1.2 µl of each primer was added to 10 µl SYBR green mix with 1 µl of amplified cDNA and 0.4 
µl MgCl2 diluted in RNAse-free water (Thermo Fisher Scientific) to provide a total volume of 
20 µl in each reaction well. The PCR cycles were set as follows: at 95◦C for 15 minutes, 40 
cycles at 94◦C for 30 seconds, 62◦C for 30 seconds and at last 72◦C for 1 minute per kb. ∆∆Ct 
values were calculated against a reference gene (gst), following the formula used by Ghedin 
et al. (87, 269, 270). This was achieved by comparative quantification of the obtained Ct 
values through qPCR. ∆Ct values were calculated by subtracting the gst gene from the wsp 
gene and ∆∆Ct values were measured by subtracting treated groups from untreated mf. 
Using the 2- ∆∆ Ct analysis, the fold changes of gene expression were obtained. 
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4.3.5 Post-drug exposure washout assay in B. malayi mf and female adult worms 
This experiment was designed to determine the effect of autophagy inhibition (using 
autophagy inhibitor wortmannin) on Wolbachia clearance dynamics post-drug exposure 
during a washout period without drug, when autophagy was inhibited in B. malayi mf and 
female adult worms. This was designed to test the role of autophagy in either the continued 
decline in Wolbachia loads during washout or the rebound in Wolbachia populations. 
Hence, an increase in Wolbachia load following the addition of an autophagy inhibitor after 
the washout process would indicate a possible role of autophagy.  
B. malayi mf and female adult worms were incubated with the following treatment groups: 
DMSO (as a vehicle control), anti-Wolbachia agents at 10x EC50 (previously determined by A-
WOL) (82, 271): doxycycline (1.2 µM) and AWZ1066S (2.4 µM) for two different time-points 
(6 and 12 days). In addition, rifampicin (0.2 µM) was used for mf only. Mf and adult worms 
were assessed for their motility throughout the treatment period to monitor viability.  
Washout was performed at two different set points for mf (at day 2, sub-optimal exposure 
or day 6, optimal exposure) and once for adult worms (at day 6, optimal exposure) in a total 
experimental period of 6 (for mf only) or 12 days (for both life stages). qPCR was done at 
different pre-set time-points to quantify Wolbachia load.  
Figure 4.1 and 4.2 present the treatment period (in days) for the availability of tested drugs, 
their washout, addition of wortmannin and performing qPCR for mf and adult worms.
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Figure 4. 1 Plan for the post-drug exposure washout experiment with B. malayi mf.  
To assess the dynamics of Wolbachia decline or rebound following the removal of anti-Wolbachia drugs with the addition of wortmannin at 
different set time points. Three different treatment groups were used in Brugia malayi mf for a treatment duration of A) 6 days and B) 12 days. 
In A and B) mf were treated with anti-Wolbachia antibiotics: doxycycline, rifampicin and AWZ1066S for different duration (in days) depending on 
group. In selected treatment groups (group 3), wortmannin was added following washout on A) day 2 and B) day 6 onwards. qPCR of Wolbachia 
wsp normalised to the nematode gst was performed at the end of every treatment cycle for each group in A and B. 
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Figure 4. 2 Plan for the post-drug exposure washout experiment with B. malayi female adult 
worms. 
To assess the dynamics of Wolbachia decline or rebound following the removal of anti-
Wolbachia drugs with the addition of wortmannin at different set time points. Two different 
treatment groups were used in Brugia malayi adult worms for a treatment duration of 12 
days. 
Adult worms were treated with anti-Wolbachia agents: doxycycline and AWZ1066S for 
different duration (in days) depending on group. In selected treatment groups (group 2), 
wortmannin was added following washout on day 6 onwards. qPCR of Wolbachia wsp 
normalised to the nematode gst was performed at day 12 for all groups. 
 
B. malayi mf washout technique 
Mf were maintained and cultured as described in Section 4.3.2.2 in the previously 
mentioned treatment groups. The washout technique was performed as described in Hong 
et al. and Clare et al. (82, 271).  
The washout procedure was performed by transferring all mf content into sterile 96-deep 
well plates (Abgene, Thermo Fisher Scientific). 550 µl RPMI media was added to all wells and 
plates were centrifuged at 200 g for 5 minutes. After centrifugation, 150 µl of supernatant 
was removed and discarded, and the same amount was taken from the bottom of the wells 
containing mf pellets and transferred into a new 96-deep well plate, and the same amount 
of RPMI media was added again to make a total of 700 µl per well. This washing step was 
repeated 5 times to remove treatment compounds from samples (see Table 4.1 below for 
further details of the achieved dilution per washout).  
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For experimental groups with washout of treatment compounds, no anti-Wolbachia drugs 
were added after the pre-selected washout day (at day 2 or 6). Wortmannin was added 
after washout (for selective groups) at 10 µM. 
Following washout, qPCR was performed to quantify Wolbachia load in mf, as previously 
described in Section 4.3.2.2. 
 
Wash Mf stock 
Diluent 
(Media) 
Dilution factor 
Final dilution concentration 
Doxycycline 
(1.2 µM)* 
Rifampicin 
(0.2 µM)* 
AWZ1066S 
(2.4 µM)* 
1 200 µl 550 µl 1: 3.75 322.7 nM 53.3 nM 637.3 nM 
2 150 µl 550 µl 1: 4.67 69.1 nM 11.4 nM 136.5 nM 
3 150 µl 550 µl 1: 4.67 14.8 nM 2.4 nM 29.2 nM 
4 150µl 550 µl 1: 4.67 3.2 nM 0.52 nM 6.3 nM 
5 150 µl 550 µl 1: 4.67 0.68 nM 0.11 nM 1.3 nM 
Table 4. 1 Post-drug exposure washout experimental procedure.  
This protocol was designed and optimised by Clare et al. (271). * Starting from the original 
concentrations added for anti-Wolbachia drugs: doxycycline 1.2 µM, rifampicin 0.2 µM and 
AWZ1066S 2.4 µM, the following 5 steps of washout were performed to reach 0.68 nM, 0.11 nM and 
1.3 nM, respectively. These final concentrations after the washout steps have been previously shown 
to exhibit no effect in reducing Wolbachia titre in B. malayi mf by A-WOL team at LSTM, UK. 
 
B. malayi female adult worms washout technique 
Adult worms were maintained and cultured as described in Section 4.3.2.2 in the previously 
mentioned treatment groups with modifications as described below.  
Worms were co-cultured with monolayered primary human lymphatic endothelial cells 
(LECs) to maintain their viability and survival during the 2 weeks treatment. LECs (ECACC) 
were provided by Miss Amy Marriott and Dr Stephen Cross at Department of Tropical 
Disease Biology, LSTM, UK. The methodology of co-culturing female adult worms with LECs 
was developed by Marriott et al. (unpublished methodology) (272). 
Two adult female worms were placed per well on monolayers of LECs and a total number of 
12 worms were cultured for each treatment group. The media used to co-culture B. malayi 
worms and LECs was supplemented with the following, all from Microvascular Endothelial 
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Cell Growth Medium SingleQuotsTM kit (EGM-2 MV singleQuots kit): 25 ml heat-inactivated 
FBS, 0.2 ml hydrocortisone, 2 ml hF-GF-B, 0.5 ml VEGF, 0.5 ml R3-IGF-1, 0.5 ml ascorbic acid, 
0.5 ml hEGF, and 0.5 ml GA-1000.  
LECs were pre-attached to the 6-well plate surfaces a day prior to the addition of worms. 
Transwell plate (6-well plate with inserts) were used for the co-culture of LECs and worms. 
In each well, a total of 6 ml EGM-2 MV media was added: 4 ml at the bottom of the well 
(containing LECs and worms with treatment compounds) and 2 ml of EGM-2 MV media 
(without treatment compounds) in the inserts.  
Media in all wells were changed every 2 days during the 12-day treatment. For treatment 
groups with washout of compounds, no anti-Wolbachia drugs were added after the pre-
selected washout day (at day 6). Wortmannin was added after washout (for selective 
groups) with the fresh media (every 2 days).  
Following washout, qPCR was performed to quantify Wolbachia load in adult worms as 
previously described in section 4.3.2.2. All qPCR findings for this section are presented as a 
(log10) ratio of wsp:gst genes to normalise the results in relation to DNA quantity. 
 
4.3.6 Statistical analysis 
In this chapter, statistical analysis was performed using GraphPad Prism version 7. 
Continuous variables for MTT assay and qPCR were analysed using independent sample for 
Student’s t-test. One-way analysis of variance (ANOVA) was used for continuous variables 
with two or more independent variables, also analysed using GraphPad Prism version 7. 
Statistical significance was at p ≤ 0.05 for all the statistical analysis performed in this 
chapter.  
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4.4 Results 
In the first group of experiments, we explore the effect of autophagy inhibition during drug 
exposure, using chemical autophagy inhibitors (wortmannin: an early autophagy inhibitor 
and l-asparagine: late autophagy inhibitor) on the activity of anti-Wolbachia drugs 
(doxycycline and rifampicin, both at 5 µM) in mosquito cell line C6/36Wp infected with 
Wolbachia wAlbB and Brugia malayi mf and female adult worms. The second set of 
experiments will examine the effect of autophagy inhibition on the decline or rebound of 
Wolbachia post-exposure to anti-Wolbachia drugs. 
 
4.4.1 Examining autophagy inhibition in anti-Wolbachia activity of drugs during drug 
exposure – in C6/36Wp, B. malayi mf and adult female worms  
i) Mosquito cell line C6/36Wp 
C6/36Wp cells exposed to anti-Wolbachia drugs (doxycycline and rifampicin) for 7 days in 
the presence of autophagy inhibitors failed to increase Wolbachia titre (Figure 4.3 A). As in 
shorter treatment periods (7 days), cells exposed to the same anti-Wolbachia antibiotics for 
a longer treatment period of 14 days significantly reduced Wolbachia titre by approximately 
99% compared to the vehicle control (DMSO) for both antibiotics (Figure 4.3 A and B). The 
addition of autophagy inhibitors for 14 days significantly reduced the anti-Wolbachia 
properties of doxycycline and rifampicin, but only partially and not to the same extent 
observed in B. malayi, which will be discussed in the following section.  
An observation worth mentioning is that when both autophagy inhibitors were tested in the 
absence of anti-Wolbachia drugs, they significantly increased Wolbachia titre by 
approximately 2-fold and 3.5-fold following 7 and 14 days of treatment, respectively, 
compared to the DMSO. Due to this observation, we compared the percentage in reduction 
of Wolbachia between anti-Wolbachia drugs and DMSO with autophagy inhibitors alone 
and combined with antibiotics, where all comparisons showed an approximate 99% 
reduction in Wolbachia indicating no difference between the groups.  
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Figure 4. 3 qPCR analysis of Wolbachia load of autophagy inhibition during drug exposure in 
C6/36Wp cells.  
C6/36 cells Infected with wAlbB were treated with doxycycline or rifampicin at 5 µM alone or 
combined with wortmannin (at 10 µM) or l-asparagine (at 10 mM) for A) 7 and B) 14 days. In 
addition, treatment groups containing only wortmannin or l-asparagine were included. DMSO 
was used as vehicle control. DNA extracted from cells were amplified using Wolbachia 16s 
rRNA gene normalised to the A. albopictus 18s rRNA gene, expressed as ratios 16s:18s (for 
actual values: please refer to the Appendix A Figure A10). Graphs (mean with SD) represent 
16s:18s gene copies (log10). 
Statistical analysis to compare all treatment groups to DMSO was tested using Student’s t-
test. One-way ANOVA was used to determine the significant difference in percentage 
reduction of Wolbachia when comparing antibiotics alone and DMSO with autophagy 
inhibitors combined with antibiotics and autophagy inhibitors alone. Statistical significance 
was at p ≤ 0.05. For p-value * = 0.01 to 0.05, ** = 0.01 to 0.001, *** = 0.001 to 0.0001, and 
**** ≤ 0.0001. 
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ii) B. malayi mf and female adult worms 
Using either wortmannin or l-asparagine to suppress autophagy in worms exposed to 
doxycycline or rifampicin (both at 5 µM) significantly reduced the ability of these anti-
Wolbachia drugs to eliminate the bacteria, compared to worms treated with only anti-
Wolbachia drugs. This reduction in anti-Wolbachia activity was not significant when 
compared to DMSO control. Similar findings were observed for both mf (Figure 4.4 A) and 
female adult worms (Figure 4.4 B). 
As observed in C6/36Wp cells, both autophagy inhibitors in the absence of anti-Wolbachia 
drugs significantly increased Wolbachia titre compared to the DMSO in mf (wortmannin 
20%, l-asparagine 23% increase) and female adult worms (wortmannin 53%, l-asparagine 
58% increase). To further examine the effect of autophagy inhibitors on doxycycline and 
rifampicin activity against Wolbachia, the percentage (%) reduction of Wolbachia was 
calculated between control groups. In mf, the % reduction in Wolbachia compared to DMSO 
for doxycycline (84%) and rifampicin (82%) was significantly higher than the reduction 
measured for the combination of antibiotics and wortmannin compared with wortmannin 
alone (for doxycycline + wortmannin= 26%, for rifampicin + wortmannin= 30%). This 
significant % reduction in Wolbachia was also observed for doxycycline and rifampicin 
combined with l-asparagine in mf. 
As in mf, the significant reduction in % of Wolbachia load was also seen in female adult 
worms. The reduction in Wolbachia load achieved by doxycycline (71%) and rifampicin 
(67%) alone compared to DMSO was significantly higher than the reduction observed when 
comparing the combination of autophagy inhibitors with both anti-Wolbachia agents 
(doxycycline + wortmannin/l-asparagine= 28-43%; rifampicin + wortmannin/l-asparagine= 
35-42%). Based on these observations in mf and adult worms, inhibiting autophagy using 
either wortmannin or l-asparagine during antibiotic exposure reduced the ability of these 
antibiotics to eliminate Wolbachia.  
With regards to the viability assessment, the results of the MTT assay have indicated that 
tested chemicals in all treatment groups did not hinder the metabolic activity of mf (Figure 
4.4 C) and female adult worms (Figure 4.4 D). Similar observations were also seen in 
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visualising worms for motility scoring (Figure 4.4), with the highest motility score (4) 
recorded in all treatment groups. For female adult worms only, our findings for manual 
counting mf release reached similar levels for treatment groups compared to DMSO control 
at day 6, indicating their viability at all tested concentrations.  
 
 
Figure 4. 4 Microscopic images of B. malayi adult worms and microfilariae in RPMI media 
during motility scoring (taken from video feed). 
 
 
 
 
 
 
 
149 
 
  
  
  
 
 
 
 
150 
 
 
Figure 4. 5 qPCR analysis of Wolbachia load of autophagy inhibition during drug exposure in 
B. malayi mf and female adult worms.   
Brugia malayi A) mf and B) female worms were treated with doxycycline (dox) or rifampicin 
(Rif) at 5 µM alone or combined with wortmannin (wort) (at 10 µM) or l-asparagine (Asp) (at 
10 mM) for 6 days. In addition, treatment groups containing only wortmannin or l-asparagine 
were included. DMSO was used as vehicle control. DNA extracted from worms were amplified 
using Wolbachia wsp gene normalised to the nematode gst gene. Graphs (mean with SD) 
represent wsp:gst gene copies (log10) in five and eight biological repeats per treatment 
group, for mf and female worms, respectively.  
MTT assay for C) mf and D) female worms: Formazan colour transformation of viable worms 
treated with the same treatment groups mentioned above were measured at an optical 
density of 490 nm using VarioSkan plate reader. Graphs (mean with SD) represent optical 
density at 490 nm in five biological repeats per treatment group for MTT assay. 
Statistical analysis to compare all treatment groups to DMSO was tested using Student’s t-
test. One-way ANOVA was used to determine the significant difference in percentage 
reduction of Wolbachia when comparing antibiotics alone and DMSO with autophagy 
inhibitors combined with antibiotics and autophagy inhibitors alone. Statistical significance 
was at p ≤ 0.05. For p-value * = 0.01 to 0.05, ** = 0.01 to 0.001, *** = 0.001 to 0.0001, and 
**** ≤ 0.0001. 
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4.4.2 Wolbachia RNA gene expression in B. malayi mf 
In order to determine the viability of Wolbachia following exposure to anti-Wolbachia drugs 
alone or with the inhibition of autophagy, I measured the RNA expression of wsp in the 
different experimental groups (Figure 4.5). Our rationale of quantifying mRNA is that its 
expression indicates viable bacteria only, whereas genomic DNA expression may detect both 
viable and dead bacteria. Hence, mRNA expression was taken as a confirmatory step for 
viable Wolbachia to further solidify our findings (58, 74). 
Wolbachia RNA expression in mf after exposure to doxycycline and rifampicin indicated no 
expression of wsp in the treated groups, suggesting the absence of any viable bacteria 
remaining.  In the groups exposed to drug and inhibitors of autophagy, wsp expression was 
observed at levels similar to DMSO controls. However, as in mf gDNA qPCR analysis, it is 
important to note that exposure to autophagy inhibitors in DMSO controls lead to 
significant elevation in wsp expression. Further analysis comparing these groups to drug-
exposed mf with autophagy inhibitors showed a 51-56% reduction in the level of gene 
expression compared to autophagy inhibitors alone. This reduction in gene expression was 
significantly lower than the ≥ 98% reduction for drug-exposed mf compared to DMSO in the 
absence of autophagy inhibitors.  
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Figure 4. 6 Wolbachia RNA gene expression of autophagy inhibition during drug exposure in 
B. malayi mf.  
The relative change in B. malayi Wolbachia wsp gene expression levels between untreated mf 
and different mf groups exposed to the following treatment for 6 days: doxycycline (dox) or 
rifampicin (Rif) at 5 µM alone or combined with wortmannin (wort) (at 10 µM) or l-
asparagine (Asp) (at 10 mM). In addition, treatment groups containing only wortmannin or l-
asparagine were included. Graph (mean with SD) represents fold change of gene expression 
in six biological repeats per treatment group. 
Statistical analysis to compare all treatment groups to DMSO was tested using Student’s t-
test. One-way ANOVA was used to determine the significant difference in percentage 
reduction of Wolbachia when comparing antibiotics alone and DMSO with autophagy 
inhibitors combined with antibiotics and autophagy inhibitors alone. Statistical significance 
was at p ≤ 0.05. For p-value * = 0.01 to 0.05, ** = 0.01 to 0.001, *** = 0.001 to 0.0001, and 
**** ≤ 0.0001. 
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4.4.3 Post-drug exposure washout assay in B. malayi mf and female adult worms 
As we have observed a reduction in anti-Wolbachia activity through inhibiting autophagy in 
drug-exposed mf and adult worms, we examined whether autophagy plays a role in the 
continued decline or rebound of Wolbachia post-drug washout. As previously discussed in 
the method section, antibiotics at the concentration of 10x EC50 were tested in this 
experiment: for doxycycline (1.2 µM), AWZ1066S (2.4 µM) and rifampicin (0.2 µM). 
In this section, I will first present the results for the post-drug exposure washout experiment 
in B. malayi mf in two different treatment durations (2 day exposure and 4 day washout 
[sub-optimal exposure] and 6 day exposure and 6 day washout [optimal exposure]) (Figure 
4.6 and 4.7), followed by 6 day exposure and 6 day washout [optimal exposure] in female 
adult worms (Figure 4.8). For all treatment groups, mf and female adult worms were 
confirmed to be highly motile (with a motility score of 4), indicating their viability 
throughout the 6-day or 12-day treatment period. 
 
i) B. malayi mf – 2-day exposure with 4-day washout period (sub-optimal exposure) 
After only two days of anti-Wolbachia treatment (group 1), all three drugs: doxycycline, 
rifampicin and AWZ1066S, significantly reduced Wolbachia by 39% compared to control 
(DMSO) in mf. Washout of drugs (at day 2) with a quantification measurement of Wolbachia 
genes performed on day 6, appeared to record a higher clearance of the bacteria achieved 
by AWZ1066S (88%) compared to the other two tested antibiotics (doxycycline 64%, 
rifampicin 54%). Following sub-optimal exposure with day 4 washout (group 2), a continued 
significant reduction of Wolbachia titre was recorded for all three drugs with the highest 
reduction observed for AWZ1066S. When autophagy was inhibited by wortmannin (group 3) 
in the washout period, a significant rebound in Wolbachia load was observed for all anti-
Wolbachia drugs.  
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ii) B. malayi mf – 6-day exposure and 6-day washout period (optimal exposure) 
Following optimal drug exposure (group 1), the three antibiotics achieved > 90% reduction 
in Wolbachia. A continued reduction in Wolbachia load was observed for the tested anti-
Wolbachia drugs in optimal drug exposure with day 6 washout (group 2) compared to 
optimal exposure without washout (group 1). However, autophagy inhibition (group 3) 
resulted in a slight rebound in doxycycline treatment only.  
155 
 
 
 
 
Figure 4. 7 Post-drug exposure washout assay in B. malayi mf for 2-day sub-optimal exposure with 4-day washout period.  
Mf were treated as shown in A) with anti-Wolbachia agents: doxycycline (1.2 µM), rifampicin (0.2 µM) and AWZ1066S (2.4 µM) for 2 days. 
Washout of drugs was performed at day 2, followed by the addition of wortmannin in group 3 only. qPCR was performed at day 2 for group 1 
and day 6 for all other groups. DNA extracted from mf were amplified using Wolbachia wsp gene normalised to the nematode gst gene as a ratio 
representing Wolbachia load for each treatment group. Graph (mean with SD) represents wsp:gst gene copies (log10) in five biological repeats 
per treatment group. 
Statistical analysis was performed to compare all treatment groups to DMSO and other selected subgroups. Statistical significance tested using 
Student’s t-test, statistical significance was at p ≤ 0.05. For p-value * = 0.01 to 0.05, ** = 0.01 to 0.001, *** = 0.001 to 0.0001, and **** ≤ 
0.0001. 
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Figure 4. 8 Post-drug exposure washout assay in B. malayi mf for 6-day optimal exposure with 6-day washout period.  
Mf were treated as shown in A) with anti-Wolbachia agents: doxycycline (1.2 µM), rifampicin (0.2 µM) and AWZ1066S (2.4 µM) for 6 days. 
Washout of drugs was performed at day 6 in group 2 and 3, followed by the addition of wortmannin in group 3 only. qPCR was performed at day 
6 for group 1 and day 12 for all other groups. DNA extracted from mf were amplified using Wolbachia wsp gene normalised to the nematode gst 
gene as a ratio representing Wolbachia load for each treatment group. Graph (mean with SD) represents wsp:gst gene copies (log10) in five 
biological repeats per treatment group.  
Statistical analysis was performed to compare all treatment groups to DMSO and other selected subgroups. Statistical significance tested using 
Student’s t-test, statistical significance was at p ≤ 0.05. For p-value * = 0.01 to 0.05, ** = 0.01 to 0.001, *** = 0.001 to 0.0001, and **** ≤ 
0.0001.
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iii) B. malayi female adult worms – 6-day exposure and 6-day washout (optimal exposure) 
The results for the post-drug exposure washout assay in female adult worms are presented 
in Figure 4.8. When quantifying Wolbachia gene ratio at day 12, optimal exposure of worms 
with both doxycycline and AWZ1066S has shown significantly higher Wolbachia clearance 
with a 67% and 86% reduction of Wolbachia respectively, compared to worms treated with 
DMSO (control), following the washout of drugs at day 6 (group 1). The anti-Wolbachia 
properties post-washout appeared to be higher in AWZ1066S, compared to doxycycline. As 
we previously observed in B. malayi mf, inhibiting autophagy with wortmannin (group 2) 
following optimal exposure with day 6 washout resulted in a significant Wolbachia rebound 
for both antibiotics.  
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Figure 4. 9 Post-drug exposure washout assay in B. malayi female adult worms for 6-day optimal exposure with 6-day washout period.   
Female adult worms were treated as shown in A) with anti-Wolbachia agents: doxycycline (1.2 µM) and AWZ1066S (2.4 µM) for 6 days. Washout 
of drugs was performed at day 6, followed by the addition of wortmannin in group 2 only. qPCR was performed at day 12 for all groups. DNA 
extracted from adult worms were amplified using Wolbachia wsp gene normalised to the nematode gst gene as a ratio, representing Wolbachia 
load for each treatment group. Graph (mean with SD) represents wsp:gst gene copies (log10) in twelve biological repeats per treatment group.  
Statistical analysis was performed to compare all treatment groups to DMSO and other selected subgroups. Statistical significance tested using 
Student’s t-test, statistical significance was at p ≤ 0.05. For p-value * = 0.01 to 0.05, ** = 0.01 to 0.001, *** = 0.001 to 0.0001, and **** ≤ 
0.0001.
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4.5 Discussion  
In the experiments of this chapter, we have used validated in vitro screening assays 
developed by the A-WOL consortium to examine the role of autophagy in the depletion of 
Wolbachia in B. malayi mf and female adult worms. The rationale for our approach is to 
determine whether autophagy has a role that is dependent or independent of different 
classes of anti-Wolbachia antibiotics with different modes of action. Hence, we chose 
doxycycline and rifampicin for their known and established anti-Wolbachia properties, as 
well as AWZ1066S, a candidate-selected by the A-WOL consortium.  
In insect cells (C6/36Wp) exposed to anti-Wolbachia antibiotics, inhibition of autophagy 
using two different inhibitors (wortmannin: an early autophagy inhibitor and l-asparagine: 
late inhibitor) over a 7 and 14 day period did not present a significant difference in terms of 
percentage Wolbachia reduction compared to antibiotics alone. Even though these 
antibiotics can induce autophagy in this cell line (as observed in Chapter 3), this induction 
did not appear to be linked to the efficacy of these drugs in this experiment design. 
Conversely, clear evidence was observed in mf that inhibiting autophagy during drug 
exposure decreases the antibiotics’ ability to reduce the bacterial population and loss of 
Wolbachia viability. Furthermore, drug exposure to female adult worms while inhibiting 
autophagy presented similar findings to mf in terms of reducing the ability of drugs to 
eliminate Wolbachia.  
Due to the observed reduction in anti-Wolbachia activity in drug-exposed nematodes when 
autophagy is inhibited, we have examined whether autophagy plays a role in the continued 
decline or rebound of Wolbachia following drug washout. In both mf and female adult 
worms, the inhibition of autophagy post-drug washout resulted in a rebound of Wolbachia, 
despite the continued decline in Wolbachia following drug washout. Therefore, the decline 
of Wolbachia following washout is dependent on autophagy. In contrast to sub-optimal drug 
exposure, autophagy inhibition in optimal exposure in mf did not show a rebound of 
Wolbachia post-washout. This finding raises the possibility that beyond 90% Wolbachia 
reduction recorded following optimal drug exposure in mf, autophagy does not appear to 
have a role in the anti-Wolbachia activity of drugs.  
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The apparent difference between the requirement for autophagy in elimination of 
Wolbachia between C6/36 cells and B. malayi may relate to the differences in Wolbachia in 
both systems, being parasitic and mutualistic respectively, or may relate to a differential 
potency of autophagy inhibition between insect cells and B. malayi. Further experiments are 
needed to monitor the inhibition of autophagy under these experimental conditions in 
C6/36Wp cells. For example, shorter treatment periods (of less than 7 days) using the same 
antibiotics combined with autophagy inhibitors have to be assessed. Furthermore, future 
work will benefit from examining lower concentrations of doxycycline and rifampicin as 
these might yield different results in terms of Wolbachia load in insect cells compared to 
nematodes in the presence of autophagy inhibitors. With regards to anti-Wolbachia drug 
susceptibility, Johnston et al. (251) have proposed that the penetration of antibiotics into 
the nematode cuticle differs from cell membrane of insects. Moreover, differences between 
Wolbachia in insects and nematodes have to be considered and whether this also impacts 
drug susceptibility (32, 251, 262). 
In B. malayi, inhibiting autophagy during the period of drug exposure lead to a complete 
inhibition of Wolbachia elimination, with bacterial numbers in inhibited groups showing no 
significant difference to controls. This complete inhibition was not observed in the 
experiments testing the role of autophagy following drug wash-out, where although a 
significant rebound was observed following inhibition of autophagy, this was only a partial 
rebound. This observation suggests a more profound role for autophagy in the early mode-
of-action/efficacy against Wolbachia and argues against it simply being a mechanism 
required for the removal of the bacteria from the cell. This was further supported by an 
analysis of the viability of the bacteria, which significantly increased in the presence of 
autophagy inhibition. Together these results support a role for autophagy in the direct 
killing of Wolbachia during drug treatment and independent of the mode-of-action of 
different antibiotic classes. 
Further experiments are required to test whether AWZ1066S with a more rapid clearance of 
Wolbachia, compared to existing anti-Wolbachia drugs (82) is dependent on autophagy in B. 
malayi mf and adult females. This can be examined further by directly measuring autophagic 
activity (through autophagic markers, including LC3B and p62) or factors associated with 
autophagy activation, such as ROS formation. Other researchers have found AWZ1066S to 
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be a fast-acting drug in terms of Wolbachia elimination (82), and this could potentially play a 
future role in further improving the efficacy and macrofilaricidal properties, as well as 
shorten the duration (≤ 7 days) of current treatment modalities against LF and 
onchocerciasis. 
The challenges of in vitro culturing adult worms for longer treatment periods are well 
documented (60, 262, 273, 274). However, in the methodology performed in this chapter of 
co-culturing female adult worms with LECs supplemented with specific growth factors and 
nutrients, developed at LSTM, UK (unpublished methodology) (272), we have successfully 
prolonged the duration of culturing adult worms for 12 days. An important limitation was 
faced with regards to adult worms. Due to the time constraints of this project and the 
efforts required to obtain large numbers of adult worms from animal hosts, the decision 
was made to limit the number of treatment groups. Therefore, certain anti-Wolbachia drugs 
were prioritised over others in our assessment of adult worms compared to mf, where all 
the desired groups were analysed. This limitation was also considered in testing of female 
adult worms in optimal drug exposure (longer treatment duration) as opposed to both 
optimal and suboptimal drug exposure in mf. 
Finally, it is worth noting that while we have examined the possible role of autophagy 
inhibition using two chemical inhibitors acting on different stages of the autophagic 
pathway, we have not assessed the pathway through genetic inhibition due to time 
limitations of this project. While there are currently no efforts of successfully inhibiting 
autophagy in C6/36 cells through gene silencing, this method of autophagic suppression has 
been examined in previous work in nematodes (B. malayi female adult worms) and insect 
cells (Drosophila cells) (87). 
In conclusion, we have demonstrated the importance of autophagy as a pathway 
responsible for delivering the efficacy of anti-Wolbachia antibiotics and their reduction of 
bacterial viability in B. malayi mf and adult worms. Furthermore, the decline of Wolbachia 
population during the washout period post-drug exposure is partially dependent on 
autophagy in nematodes.  
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Chapter 5 Summary and Conclusions 
Through the series of experiments we have performed in this research, we were able to 
determine a role for autophagy in the activity of antibiotics against Wolbachia in the target 
organism, B. malayi. This role could potentially be used to improve the efficacy and shorten 
current treatment regimens, of new anti-wolbachial macrofilaricidal drugs. In this final 
chapter, we will summarise our main findings and provide recommendations for future 
experimental work. 
Wortmannin and l-asparagine: safe and effective autophagy inhibitors 
In the experiments in Chapter 2, we were able to identify two autophagy inhibitors, 
wortmannin and l-asparagine, that suppressed autophagy and did not negatively impact cell 
growth, viability and toxicity in mosquito C6/36 cells. This was successfully achieved 
between the concentrations of 5-20µM and 10-20mM for wortmannin and l-asparagine, 
respectively. Furthermore, we have detected the range of their autophagic inhibitory 
capabilities using two methods, immunoblotting and immunofluorescence staining (IF) 
assays. Our results will aid future research as we have examined both an early (wortmannin) 
and late (l-asparagine) autophagy inhibitor.  
Although we have observed the safety and effectiveness of l-asparagine as an autophagy 
inhibitor between 10 and 20 mM, there are considerable gaps in understanding how amino 
acids inhibit the autophagic pathway. Future experimental work is needed to understand 
whether amino acids, used as chemical autophagy inhibitors, may interfere with other 
pathways not associated with autophagy in insect cells and other cell lines, such as in 
protein synthesis and cell proliferation (275, 276). This has to be taken into consideration 
given the high concentration of l-asparagine needed in our experiments to successfully 
inhibit autophagy in C6/36 cells. Moreover, high amino acid supplementation can activate 
AKT phosphorylation through mTORC2 activation, which in turn can affect autophagy and 
other cellular process (129, 275). 
In our experimentation using 3-ma and ly294002, both inhibitors were not suitable to 
chemically suppress autophagy in C6/36 cells, due to their toxicity when used in autophagic 
inhibiting concentrations. Furthermore, the conditions set in our experiments, such as the 
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long treatment duration and full nutrient culture media, must also be considered in future 
assessments of determining suitable autophagy inhibitors. Despite only testing four 
chemical autophagy inhibitors in our experiments, two of which were deemed suitable in 
C6/36 cells, several widely used agents have not been fully examined in insect cells, for 
example bafilomycin A1 and chloroquine, and could be considered in the future research 
(118, 124). 
Antibiotic-induced autophagy: A restricted role in insect cells and nematodes, 
independent of Wolbachia 
In Chapter 3, we have successfully demonstrated an increase in autophagic activation, which 
was consistently observed in four broad-spectrum anti-Wolbachia antibiotics from different 
classes (doxycycline, rifampicin, moxifloxacin and sparfloxacin) exposed to two different 
insect cell lines (C6/36 and SF9 cells), as well as in B. malayi mf. Moreover, this autophagic 
activation was also observed for selected-candidates from the A-WOL consortium 
(TylAMacTM, AWZ1066S and fusidic acid). The chemical structures of antibiotics and 
compounds examined in the series of experiments performed in this thesis for their activity 
against Wolbachia and autophagy are presented in Figure 5.1. Interestingly, the antibiotic-
induced autophagy was observed both in the presence and absence of Wolbachia in insect 
cells, indicating a direct effect of anti-Wolbachia antibiotics on autophagy that is 
independent of the bacteria. With regards to mammalian cells (THP-1 and MDCK), it is 
important to note that all tested anti-Wolbachia drugs did not activate autophagy, 
highlighting their restricted role in insect cells and nematodes in activating the pathway. 
This particular observation is of importance due to that fact that if an activation of 
autophagy by these antibiotics occurred in mammalian cells, it could lead to adverse events. 
Through concentration-dependency testing of anti-Wolbachia antibiotics, we have 
demonstrated that only concentrations that induced autophagy resulted in effective 
Wolbachia depletion (of >90%), the empirical threshold of delivering the desired 
macrofilaricidal activity (65). This observation was more apparent for the two anti-
Wolbachia fluoroquinolones (moxifloxacin and sparfloxacin). Hence, the efficacy of anti-
Wolbachia drugs against the bacteria is closely linked with their ability to induce autophagy. 
Additionally, we have found evidence that this autophagic induction starts early (within the 
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first day of drug exposure), even before the effective clearance of Wolbachia. This 
observation supports the notion that the role of autophagy is not limited to the clearance of 
dead bacteria but plays an important part in the activity of these antibiotics. In contrast, the 
four tested antibiotics that lack anti-Wolbachia properties (ciprofloxacin, levofloxacin, 
amoxicillin and streptomycin) (Figure 5.1) did not activate autophagy or deplete Wolbachia, 
in different cell lines and when changing experimental variables, including concentrations 
and time.  
Future research can examine the four diverse anti-Wolbachia drugs used in this thesis, or 
antibiotic-induced autophagy as a concept, in other insect cell lines in the presence and 
absence of Wolbachia. Examples of these include Anopheles, as well as other Aedes and 
insect cell lines. Also, there is potential for examining our observations in Drosophila and 
Caenorhabditis elegans due to their widespread use in autophagic evaluation and genetic 
and experimental tractability. It would be worth extending our observations to other 
intracellular bacteria, as well as in parasitic organisms such as Plasmodium species (95, 277-
282). Moreover, more research is needed to assess other types of mammalian cells from the 
ones examined in Chapter 3 or mammalian cells transfected with Wolbachia, in order to 
further confirm our findings in terms of autophagic induction (283). Although as a 
cautionary note, due to the inconsistency observed when using the autophagic marker LC3B 
in mammalian cells, alternative autophagic markers should be considered (131, 284). These 
include p62 (which provided consistent findings in this research irrespective of tested 
antibiotics, cell line and experimental approach), as well as potential candidates that have 
gained recent prominence as selective autophagic markers, for example NBR1, NDP52 and 
OPTN (131, 143, 145, 146). 
As we only tested B. malayi mf that was naturally infected with Wolbachia, future work is 
needed to examine autophagic induction in similar experimental settings on other 
nematodes lacking Wolbachia, for example Loa loa and Acanthocheilonema viteae. 
Examining drug exposed Wolbachia-free nematodes will confirm our findings in uninfected 
insect cells, where autophagy was independently activated in the absence of Wolbachia.  
Further studies are needed to evaluate our observations with regards to the tested 
fluoroquinolones, where two drugs showed anti-Wolbachia activity and autophagy 
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induction (moxifloxacin and sparfloxacin) in a concentration-dependent pattern, while 
ciprofloxacin and levofloxacin presented with neither of these properties. This class of 
antibiotics could be examined in similar experimental settings in other insect and 
mammalian cell lines, using IF assay as it provided more robust results compared to western 
blot in this research. The differential induction of autophagy by fluoroquinolones may be 
useful to determine any molecular structures associated with the induction of autophagy 
and efficacy against Wolbachia.  
Future work can benefit from implementing other imaging techniques not assessed in this 
thesis, including electron and confocal microscopy. Through these methods, Wolbachia can 
be located within the tested cells and in situations where autophagy is inhibited or 
activated, autophagy associated structures such as autophagosomes and 
autophagolysosomes or cellular structures, including mitochondria, can be visualised (285, 
286).  
It is important to note that while we have monitored an increase in autophagic influx for the 
four tested anti-Wolbachia drugs, we have not examined other factors associated with 
these antibiotics that may influence autophagy. Examples of these factors include, oxidative 
stress (ROS production), pH and mitochondrial damage (199, 211, 235, 244, 259, 260). 
Moreover, research is needed to assess the autophagic activity of anti-Wolbachia drugs, 
through autophagy-related gene expression.  
As recent studies have presented the superior efficacy and potency of AWZ1066S (82), 
TylAMacTM (81) and fusidic acid (86) as anti-Wolbachia drugs compared to established 
antibiotics (doxycycline, rifampicin and moxifloxacin), there is a need to examine if the A-
WOL selected candidates have higher autophagic inducing capabilities. This will aid in our 
understanding of whether the potency of drugs against Wolbachia is linked to their 
autophagic promoting activity. 
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Figure 5. 1 Chemical structures of selected compounds of diverse classes.  
Data source: (81, 82, 287). 
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The contribution of autophagy in the efficacy of anti-Wolbachia antibiotics  
Using validated in vitro screening assays developed by the A-WOL consortium in Chapter 4, 
we have successfully demonstrated the contribution of autophagy in the efficacy of anti-
Wolbachia drugs and their ability to reduce bacterial viability in B. malayi mf and adult 
worms. This was examined by inhibiting autophagy using wortmannin and l-asparagine 
during anti-Wolbachia drug exposure in nematodes, resulting in an inhibition of Wolbachia 
reduction when compared to antibiotic exposure alone. Furthermore, we have 
demonstrated in both mf and female adult worms, a continued decline in Wolbachia load 
post-exposure washout of antibiotics, which was reversed following autophagy suppression 
during the washout period. This indicate that bacterial decline is dependent on autophagy in 
nematodes both during exposure to anti-wolbachial drugs and post drug exposure.  
In contrast to our observations in B. malayi, the inhibition of autophagy in insect cells 
(C6/36Wp) during drug exposure did not impact the ability of these antibiotics to reduce 
Wolbachia. Future work is required to confirm whether this observation in insect cells is due 
to experimental conditions or if it demonstrates that autophagy is not linked to the efficacy 
of these drugs in insect cells. As we have examined drug exposure in C6/36Wp cells in a 7 
and 14-day period, with an over 90% reduction in Wolbachia for both periods, future studies 
can examine these cells in shorter periods or with sub-optimal concentrations of antibiotics. 
Several recommendations could be made for future experimentation in investigating anti-
Wolbachia antibiotic-induced autophagy. To complement our chemical induced suppression 
we could use genetic suppression of autophagy-related genes using gene silencing (RNA 
interference). Additionally, it is worth examining anti-Wolbachia antibiotics and autophagy 
inhibition in Onchocerca species, in order to confirm our findings in other filarial nematodes 
that are relevant to human filariasis. In the future, in vivo studies are needed to determine if 
they will yield similar findings to my thesis when examining anti-Wolbachia activity during 
autophagic inhibition. An example of how this can be performed is through generating 
transgenic mice with autophagy-related genes and locating autophagic markers (such as LC3 
with green fluorescent protein GFP, monomeric red fluorescent protein mFRP or mCHERRY)  
using immunofluorescence microscopy (288-291). From these in vivo experiments, future 
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studies can evaluate the role of antibiotic-induced autophagy in mf, as well as different life 
stages of B. malayi within infected transgenic mice. 
The promising results of my thesis highlight the role of autophagy in the anti-Wolbachia 
properties of antibiotics. While there are considerable gaps with regards to our 
understanding of autophagy as a target for anti-Wolbachia drug therapy, we have to 
consider the role it may play when selecting future macrofilaricidal drugs for the treatment 
of lymphatic filariasis, as well as onchocerciasis. In particular the induction of autophagy 
could be used in developing high-throughput screening of additional drug libraries and in 
the lead optimisation of existing 'hits' identified by the A-WOL consortium (271). Despite 
only evaluating autophagy in anti-Wolbachia drugs in my thesis, the findings we have 
obtained may help future work in improving the understanding of selective autophagy, 
particularly in developing treatments for other intracellular microorganisms, including 
Mycobacterium tuberculosis (292, 293) and Chlamydia trachomatis (294, 295). Moreover, 
research has highlighted the role of modulating autophagy in future treatment of 
intracellular parasites, for example Intrahepatic stages of Plasmodium spp. (281, 296, 297), 
Toxoplasma gondii (222, 297-299) and Leishmania (297, 300, 301). Recently, significant 
breakthroughs have been made with the discovery of new potent anti-Wolbachia agents, 
such as TylAMacTM and AWZ1066S, and chemically inducing autophagy can potentially play a 
future role in further improving their efficacy and macrofilaricidal properties.  
There is future potential of combining the anti-Wolbachia drugs used in this research with 
other drugs that form part of the current MDA treatment in endemic areas against filarial 
diseases. While several examples have successfully been implemented by combining MDA 
agents, such as albendazole or DEC with doxycycline in clinical trials (70, 73, 75) (and 
rifampicin in pre-clinical models (61)), there is potential of examining this further using 
autophagy inducers. As current trends of effective treatment modalities against LF and 
onchocerciasis aim for shorter oral treatment periods (of ≤ 7 days) with macrofilaricidal 
properties of over 90% (empirical threshold), autophagy can become an important target 
for anti-Wolbachia drug research and provide future solutions in drug therapy. Autophagy 
as a concept and its induction may play a future role by shortening treatment periods, 
thereby reducing the cost and burden of filarial diseases in order to reach the targets of 
global MDA treatments.  
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Appendix A 
 
Table A 1 Impact of selected autophagy inhibitors on C6/36Wp cell growth inhibition. C6/36 
mosquito cell line infected with Wolbachia (wAlbB) dynamic growth profile after treatment 
with chemical autophagy inhibitors at selected concentrations for set-time points (at day 0, 2, 
4, 6 and 8) expressed as percentages in reduction of cell growth to DMSO treated cells. An 
upward arrow indicates an increase in percentage. For cell growth effect, green represents 
compounds with no measurable effect on cell growth and red indicates compounds with an 
effect of more than 50% reduction of cell growth compared to DMSO control. 
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Figure A 1 Rapamycin safety profile testing on C6/36Wp cell line. Infected C6/36 cells with 
wAlbB were treated with rapamycin at different concentrations (1-20 µM) for 8 days. A) Total 
number of cells/well were measured every two days (at day 0, 2, 4, 6 and 8) using Operetta. 
Suitability of rapamycin concentration was considered if its effect on cell proliferation was 
less than 50% reduction compared to control (DMSO treated cells). Rapamycin between 1-10 
µM did not affect cell growth and were found to be suitable. B) Total number of viable cells 
were stained with calcein AM and measured at day 8 using Operetta. Saponin was used as a 
control, expressing the presence of dead cells. Rapamycin between 1-10 µM were found to 
be viable and no difference was observed compared to the control.  
Graphs (mean with SD) represent A) total number of cells and B) total viable cell count in four 
biological repeats for every treatment group. Cell viability/cytotoxicity was assessed by 
comparing with DMSO control using Student’s t-test, where statistical significance was p ≤ 
0.05. For p-value * = 0.01 to 0.05, ** = 0.01 to 0.001, *** = 0.001 to 0.0001, and **** ≤ 
0.0001. 
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Figure A 2 Full membrane blots for C6/36Wp against LC3B and p62 markers of autophagy. 
C6/36 cells infected with wAlbB treated with selected autophagy inhibitors at different 
concentrations alone or combined with rapamycin. Lane 1: DMSO, lane 2: ly294002 at 1 µM, 
lane 3-6: wortmannin from 1-20 µM, lane 7-10: l-asparagine from 1-20 mM, a combination of 
rapamycin and lane 11: ly294002 at 1 µM, lane 12-15: wortmannin from 1-20 µM, lane 16-
19: l-asparagine from 1-20 mM, and lane 20: rapamycin alone. 
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Figure A 3 Full membrane blots for C6/36Wp against LC3B and p62 markers of autophagy in 
different antibiotics. C6/36 A) infected with wAlbB and B) Wolbachia-free cells treated with 
DMSO – vehicle control (lane 1), rapamycin – positive control (lane 2), wortmannin – early 
autophagy inhibitor (lane 3), l-asparagine – late autophagy inhibitor (lane 4), four anti-
Wolbachia agents: doxycycline (lane 5-6), rifampicin (lane 7-8), moxifloxacin (lane 9-10), 
sparfloxacin (lane 11-12), and four different antibiotics: levofloxacin (lane 13-14), 
ciprofloxacin (lane 15-16), amoxicillin (lane 17-18), and streptomycin (lane 19-20) for 3 days. 
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Figure A 4 Full membrane blots for C6/36 cells against LC3B and p62 markers of autophagy in 
pre-clinical candidates and re-purposed antibiotic from the A-WOL consortium. Wolbachia-
free C6/36 (lane 1-6) and infected C6/36Wp cells (lane 7-12) were treated with: DMSO – 
vehicle control (lane 1 and 7), rapamycin – positive control (lane 2 and 8), wortmannin – 
autophagy inhibitor (lane 3 and 9), TylAMacTM (lane 4 and 10), fusidic acid (lane 5 and 11), 
and AWZ1066S (lane 6 and 12) for 3 days. 
 
 
 
 
Figure A 5 Full membrane blots for SF9 and B.malayi worms against LC3B and p62 markers of 
autophagy in different antibiotics. A) SF9 insect cells and B) B. malayi mf worms were treated 
with: DMSO – vehicle control (lane 1), rapamycin – positive control (lane 2), wortmannin – 
early autophagy inhibitor (lane 3), l-asparagine – late autophagy inhibitor (lane 4), four anti-
Wolbachia agents: doxycycline (lane 5), rifampicin (lane 6), moxifloxacin (lane 7), sparfloxacin 
(lane 8), and four different antibiotics: levofloxacin (lane 9), ciprofloxacin (lane 10), 
amoxicillin (lane 11), and streptomycin (lane 12) for 3 days. 
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Figure A 6 Full membrane blots for THP-1 and MDCK cells against LC3B and p62/SQSTM-1 
markers of autophagy in different antibiotics. A) THP-1 and B) MDCK cells were treated with: 
DMSO – vehicle control (lane 1), rapamycin – positive control (lane 2), wortmannin – early 
autophagy inhibitor (lane 3), l-asparagine – late autophagy inhibitor (lane 4), four anti-
Wolbachia agents: doxycycline (lane 5), rifampicin (lane 6), moxifloxacin (lane 7), sparfloxacin 
(lane 8), and four different antibiotics: levofloxacin (lane 9), ciprofloxacin (lane 10), 
amoxicillin (lane 11), and streptomycin (lane 12) for 3 and 7 days. 
 
198 
 
 
 
Figure A 7 Detection of Wolbachia in insect cells. A) using qPCR analysis, DNA extracted from 
C6/36 (infected and uninfected with wAlbB) and SF9 cells were amplified using Wolbachia 
16s rRNA gene using the following thermal cycling conditions: 15 minutes at 95◦C, 35 cycles, 
for 15 seconds at 94◦C, 30 seconds at 55◦C, 15 seconds at 72◦C and a melting curve between 
50-95◦C. Four biological repeats per treatment group were analysed. Statistical significance 
tested using Student’s t-test, statistical significance was at p ≤ 0.05. For p-value * = 0.01 to 
0.05, ** = 0.01 to 0.001, *** = 0.001 to 0.0001, and **** ≤ 0.0001. 
B) Confocal images of C6/36 cells (infected and uninfected with wAlbB) stained with syto11 
(green fluorescence puncta) to detect Wolbachia infection. 
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Figure A 8 Comparison in autophagic induction of C6/36 cells uninfected and infected with 
wAlbB using two autophagic markers LC3B-II and p62. Using immunofluorescence staining 
assay A) confocal images of LC3B-II and p62 expression in cells treated with DMSO. B) 
Quantification analysis of the two autophagic markers expressed in percentages of LC3B-II 
and p62 puncta/cell. For each treatment group, three different sections were imaged, where 
each section contained ≥50 cells. 
Statistical significance tested using Student’s t-test, statistical significance was at p ≤ 0.05. For 
p-value * = 0.01 to 0.05, ** = 0.01 to 0.001, *** = 0.001 to 0.0001, and **** ≤ 0.0001. 
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Figure A 9 qPCR analysis of Wolbachia load in antibiotics at different time-points. C6/36Wp 
cells were treated at different time-points: day 0, 1, 3, 5 and 7 with DMSO (vehicle control), 
rapamycin at 5 µM (autophagy inducer), wortmannin at 10 µM (autophagy inhibitor), four anti-
Wolbachia agents at 5 µM: doxycycline, rifampicin, moxifloxacin and sparfloxacin and four 
other antibiotics at 5 µM: levofloxacin, ciprofloxacin, amoxicillin and streptomycin. Wolbachia 
load is expressed as a ratio of 16s:18s rRNA gene in log10. Three biological repeats per 
treatment group were analysed. 
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Figure A 10 qPCR analysis of 16s and 18s rRNA genes of autophagy inhibition during drug 
exposure in C6/36Wp cells. Infected C6/36 cells with wAlbB were treated with doxycycline 
(Dox) or rifampicin (Rif) at 5 µM alone or combined with wortmannin (Wort) at 10 µM or l-
asparagine (Asp) at 10 mM for A and B) 7 days and C and D) for 14 days. In addition, 
treatment groups containing only wortmannin or l-asparagine were included. DMSO was 
used as vehicle control. DNA extracted from cells were amplified using A and C) Wolbachia 
16s rRNA gene and the B and D) Aedes albopictus 18s rRNA gene.  
Statistical analysis was performed to compare all treatment groups to DMSO and other 
selected subgroups. Statistical significance tested using Student’s t-test, statistical 
significance was at p ≤ 0.05. For p-value *= 0.01 to 0.05, ** = 0.01 to 0.001, *** = 0.001 to 
0.0001, and **** ≤ 0.0001. 
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Appendix B: list of materials  
Product type Product name Supplier 
Solution/Liquid Amphotericin B Gibco, Thermo Fisher Scientific 
 DAPI mounting medium Vectashield, Vector laboratories 
 Dimethyl sulfoxide (DMSO) Hybri-
Max™, sterile-filtered (ampules) 
Sigma Aldrich 
 Eagle’s Minimum Essential 
Medium (EMEM) 
 Endothelial cell basal medium-2 
(EBM-2) 
Lonza-Clonetics 
 Ethanol Sigma Aldrich 
 Foetal bovine serum FBS Thermo Fisher Scientific 
 Formaldehyde solution 16% Pierce, Thermo Fisher Scientific 
 Leibovitz’s 15 (L-15) medium Gibco, Thermo Fisher Scientific 
 MEM non-essential amino acids 
Sigma Aldrich 
 Methanol 
 Nuclease free water 
Thermo Fisher Scientific 
 NuPAGE MES SDS Running Buffer 
(20x) 
 NuPAGE antioxidant  
 NuPAGE sample reducing agent 
 NuPAGE LDS sample buffer (4x) 
 PageRuler™ Prestained Protein 
Ladder, 10 to 180 kDa 
 Penicillin-Streptomycin (10,000 
U/ml) 
 Phosphate-buffered saline PBS Sigma Aldrich 
 Protease inhibitor mix GE Healthcare 
 Rapamycin ready-made solution 
2.47mM 
Sigma Aldrich 
 Restore™ Plus Western Blot 
Stripping Buffer Thermo Fisher Scientific 
 RIPA lysis buffer 
 RPMI 1640 culture media  
Gibco, Thermo Fisher Scientific 
 SF-900 II Serum free medium 
 Ssofast EvaGreen Supermix Biorad 
 Syto 11 stain Life Technologies, Thermo Fisher 
Scientific 
 Tissue Extraction Reagent Invitrogen, Thermo Fisher 
Scientific 
 TRITC goat anti-rabbit (whole 
molecule) 
Sigma Aldrich 
 Trypan blue solution 0.4% Thermo Fisher Scientific 
 Trypsin/EDTA solution 0.25% 
Sigma Aldrich 
 Tryptone phosphate broth 
 Triton x100 
 Tween 20 
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 Wortmannin ready-made solution 
10mM 
Antibodies Beta actin antibody (mouse)  Cell signaling 
 FITC Ds grade, goat anti-rabbit Invitrogen, Thermo Fisher 
Scientific 
 Goat anti-rabbit HRP conjugated 
secondary antibody 
New England Bio Labs, Cell 
Signaling 
 Hoechst 34442 Life Technologies, Thermo Fisher 
Scientific 
 LC3B antibody, rabbit Invitrogen, Thermo Fisher 
Scientific 
 LC3B antibody, rabbit Cell signaling 
 LC3B antibody, rabbit Novus 
 Monkey anti-rabbit HRP IgG 
secondary antibody 
GE Healthcare 
 P62/Sequestosome 1, rabbit Cell signaling 
 Rabbit anti-mouse HRP linked 
secondary antibody 
Sigma Aldrich 
 
Powder Amoxicillin 
 Bovine serum albumin BSA 
 Ciprofloxacin  
 Doxycycline hyclate 
 Rifampicin 
 Glycine 
 L-asparagine  
 Ly294002 
 MTT formazan 
 Moxifloxacin hydrochloride 
 Saponin 
 Sparfloxacin 
 Streptomycin sulfate salt 
 Sodium Chloride NaCl 
 Thiazolyl Blue Tetrazolium 
Bromide 
 Trizma base 
 3-Methyladenine (3-MA) 
Kits Baseline-ZERO™ DNase Epicentre 
 Bicinchoninic acid protein assay 
BCA kit 
Pierce, Thermo Fisher Scientific 
 Chemilluminscent substrate super 
signal system 
 EGM-2 MV singleQuots Lonza-Clonetics 
 Live/Dead Viability/Cytotoxicity 
kit 
Life Technologies, Thermo Fisher 
Scientific 
 MiRCURY RNA Isolation kit Exiqon 
 QIAmp mini DNA kit Qiagen 
 SuperScript™ III Reverse 
Transcriptase 
Invitrogen, Thermo Fisher scientific 
Miscellaneous  Bis Tris Bolt plus 6-12% gel Thermo Fisher Scientific 
 CORDLESS PELLET PESTLE Kimble 
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 Corning™ Disposable Vacuum 
Filter/Storage Systems 
Thermo Fisher Scientific 
 Nitrocellulose Membrane Hybond 
ECL (pore size 0.22µM) 
Amersham, GE Healthcare 
 Nunc cell scrapers 
Thermo Fisher Scientific  RNase free disposable pellet 
pestles 
 Sephadex G-25 in PD-10 Desalting 
Columns 
GE Healthcare 
 Sterilin™ 7mL Polystyrene Bijou 
Containers with cover slips Thermo Fisher Scientific 
 X-ray films CL xsposure 
 384 well PCR plate Biorad 
 96 Well 0.8mL Polypropylene 
Deepwell Storage Plate 
Abgene, Thermo Fisher Scientific 
Table B. 1 Materials and products used throughout the thesis. 
 
Buffer/solution Components 
NuPAGE MES SDS Running 
Buffer (1x) 
50 ml of MES running buffer 
950 ml distilled water  
Tris Buffered Saline TBS 
washing buffer (10x) 
2 M Tris base (pH 8.5) – 12.1 g 
in 50 ml 
5 M Sodium Chloride NaCl (pH 
7.6 with HCl) – 87.8 g in 300 ml 
640 ml distilled water  
10 ml Tween 20 
Tris Glycin transfer buffer (10x) Tris Base 30.3 g (pH 8.3) 
Glycine 144 g 
distilled water to adjust 
volume to 1 L 
Diluted to 1x by adding 700 
distilled water, 100 ml of the 
10x prepared buffer and 200 
ml methanol (20%)  
Ponceau S staining 0.2% (w/v) Ponceau S 
5% glacial acetic acid 
Table B. 2 Buffers/solutions and components  
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Primers Sequences 
16s forward 5’-TTGCTATTAGATGAGCCTATATTAG-3’ 
16s reversed 5’-GTGTGGCTGATCATCCTCT-3’ 
18s forward 5’-CCGTGATGCCCTTAGATGTT-3’ 
16s reversed 5’-ATGCGCATTTAAGCGATTTC-3’ 
BMWSP forward 5’ CCC TGC AAA GGC ACA AGT TAT TG 3’ 
BMWSP Reversed 5’ CGA GCT CCA GCA AAG AGT TTA ATT 3’ 
GST 1368 5’ GAG ACA TCT TGC TCG CAA AC 3’ 
GST 1632 5’ ATC ACG GAC GCC TTC ACA G 3’ 
Table B. 3 Complete List of primer pairs used. The table represents a complete list of all 
primers and their sequences used in qPCR reactions of this thesis. All were designed and 
purchased by Integrated DNA Technologies (UK). 
 
 
 
 
 
 
 
 
 
 
 
 
